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Abstract 
 
 
Nanomedicine, the application of nanotechnology for medical purposes, has been widely 
identified as a potential solution for today‟s healthcare problems. Nanomedicine uses the 
„bottom-up‟ principles of nanoscale engineering to improve areas of medicine which have 
previously been considered undevelopable.  
 
One of the enduring challenges for medicine is the design of innovative devices able to 
overcome biological barriers, allowing drugs and therapeutics to effectively reach their correct 
location of action. Biological barriers are a defence mechanism of the body which are 
extremely well-evolved to protect the body from foreign and harmful particles. Therapeutic 
drugs and devices, which are not harmful, are often identified by the body as dangerous 
because their composition differs from native and accepted entities. The traversal of these 
biological barriers, such as mucus, remains a bottleneck in the progress of drug delivery and 
gene therapy. The mucus barrier physically limits the motion of particles due to its 
complicated mesh structure which obstructs the particles‟ traversal path. Mucus fibres can 
also adhere to the particles, entrapping them and restricting their motion.  
 
Particle traversal of mucus is carried out by passive diffusion. As diffusion has traditionally 
been defined by the Stokes-Einstein equation as inversely proportional to particle radius, it 
follows that reducing particle sizes into the nanoscale would result in increased diffusive 
ability. These predictions, however, do not consider the obstructive effects of the complicated 
mesh structure for the case of mucus. The exact effect of reducing particle size into the 
nanoscale for diffusion through mucus is therefore unknown.  
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Multiple Particle Tracking was used to obtain real-time movies of the diffusion of 
nanoparticles, ranging from 12nm – 220nm in diameter, through mucus samples. The 
experimental data generated was used to systematically correlate the relationship between 
particle size and diffusivity through mucus. This study reveals that nanoparticles, smaller than 
the average pore size in the mucus mesh structure, can diffuse through lower viscosity pores 
which pose less resistance to diffusive motion, allowing nanoparticles to travel at up to four 
times the speed expected from the bulk viscosity of the mucus. This type of information can 
help researchers understand the importance of size for therapeutic nanoparticles, allowing 
researchers to decide whether attempts to decrease nanoparticle size at the expense of other 
functionality are worthwhile.  
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Abbreviations 
 
AFM Atomic Force Microscopy 
CF Cystic Fibrosis 
CFTR Cystic Fibrosis Transmembrane Regulator 
DLS Dynamic Light Scattering 
EM Electron Microscopy 
FRAP Fluorescence Recovery After Photobleaching 
HSA Human Serum Albumin 
MPT Multiple Particle Tracking 
MSD Mean Squared Displacement 
PBS Phosphate Buffer Solution 
PEG Polyethylene Glycol 
PS-NP-COOH Fluorescent, carboxylate-modified polystyrene nanoparticles 
PS-NP-PEG(x) PEGylated carboxylate-modified polystyrene nanoparticle, x nm in diameter 
QD-NP-COOH Fluorescent, carboxylate-modified quantum dot nanoparticles 
QD-NP-NH2 Fluorecent, amino-modified quantum dot nanoparticles 
QD-NP-PEG PEGylated amino-modified quantum dot nanoparticles 
QD-NP-PEG5000 Amino-modified quantum dot nanoparticles PEGylated with PEG5000 chains 
QD-NP-PEG750 Amino-modified quantum dot nanoparticles PEGylated with PEG750 chains 
SEM Scanning Electron Microscopy 
TEM Transition Electron Microscopy 
TRITC Tetramethyl Rhodamine Isothiocyanate 
VDC Vertical Diffusion Chambers 
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1.1  Nanomedicine 
 
Nanomedicine is the application of nanotechnology for medical purposes 
1
. The concept joins 
the fields of nanotechnology and medicine in an effort to revolutionise the way in which 
medical care is delivered. Nanomedicine has been widely identified as a potential solution for 
today‟s healthcare problems 1-3, offering improved treatment for diseases of increasing 
prevalence; such as cancer, cardiovascular disease and lung disease 
4
. The novel chemical, 
physical and optical properties of nanoscale materials have the potential to enable innovative, 
more sophisticated approaches for resolving existing problems in medicine. An improved 
understanding of how the human body functions at the molecular and nanometre scale is of 
the utmost importance to meet these expectations 
2
. It is necessary to comprehensively 
determine how nanomedicines behave within the body to be able to optimise and govern their 
use.  
 
The manipulation of matter locally and deliberately on the atomic scale is an old dream of 
natural science, as expressed by Richard Feynman in 1959 during his talk at the American 
Physical Society entitled „There‟s Plenty of Room at the Bottom‟ 5. Feynman discussed the 
idea of building structures more precisely from the „bottom up‟ by manipulating individual 
atoms. „Bottom-up‟ differs from the more commonly used „top-down‟ approach in which 
structures are manufactured by selectively removing areas at the bulk level to sculpt the final 
product 
6. The degree of precision in „top-down‟ fabrication therefore depends upon the 
dimensions of the tools available. In comparison, „bottom-up‟ fabrication attempts to align 
individual atoms exactly where they are needed, enabling structures to be built out of efficient 
assemblies of functional components. This leads to the ability to streamline, producing light 
and compact structures 
7
.  During his talk, Feynman also commented that progress in biology 
could be accelerated if biologists had the tools to visualise and manipulate complex nanoscale 
entities of interest, such as proteins and antibodies 
8
.  
  14 
 
Figure 1.1: A scale showing the relative sizes of man-made and naturally occurring nanostructures. Although the 
size boundaries of nanomedicine remain ambiguous, the range that holds the most interest is typically from 0.2 nm 
– 100 nm, shown in blue 9.   
 
Many nanoscale machines and entities already function and exist in nature, often leading to 
nature being used as a template for nanotechnology 
10
. Advances in nanotechnology, have 
enabled new opportunities in virtually all branches of technology, ranging from optical, 
electronic and chemical sciences, to environmental engineering and medicine 
5
. Although still 
in its infancy, these first practical applications of nanotechnology clearly demonstrate its 
enormous potential 
5
. Many products using nanotechnology are already commercially 
available; including sunscreens enhanced with nanoparticles and self-cleaning windows that 
use nano-engineering to prevent dirt sticking to the surface 
6
. Nanoparticles have physical 
properties that often dramatically differ from those exhibited by the same bulk material. The 
most prominent examples of this are quantum dots, which are semiconductor nanocrystals 
ranging from 2 nm-10 nm in diameter. Due to their small size, their excitons are confined in 
all three spatial dimensions. Quantum dots have novel optical properties due to this quantum 
confinement effect which means they have broad absorption spectra and narrow emission 
spectra, resulting in an emission wavelength dependent on their chemical composition and 
size 
6, 11
. The colour of their fluorescence can be tuned by altering the size of the quantum dot. 
Their fluorescence is brighter and less susceptible to photobleaching than naturally occurring 
fluorophores 
12
. The field of nanomedicine aims to improve the understanding and use of 
novel characteristics of this kind to optimise medical procedures and devices. 
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Medicine is a field currently faced with complex societal and ethical challenges due to the 
increasing life expectancy of the population and the demand for a high quality of life which 
grows with it 
1, 5, 13
. Healthcare services are being put under increasing pressure with higher 
expectations and tightening budgets 
5
. Mass applications of screening, diagnostic and 
therapeutic tools therefore have to be fast, convenient and inexpensive 
5
. There is increasing 
optimism that the application of nanotechnology to medicine, will bring significant advances 
in the diagnosis and treatment of diseases 
14
. In contrast to conventional therapies, such as 
surgery, radiation and chemotherapy, where the basic approach is to remove diseased cells 
faster than healthy cells, nanomedicine attempts to use sophisticated approaches to either kill 
specific cells or repair them one at a time 
5
; a „bottom up‟ rather than „top down‟ approach. 
The common basis between nanotechnology and medicine evolves from the molecular-scale 
properties relevant to both fields 
5
. This is because physiological and pathological processes at 
the cell level occur on the nanoscale 
15
. The two fields are therefore largely interlinked with 
feedback from one providing improvements in the other, which in turn provides greater 
functionality in the first.  
 
„Nanomedicine‟, as a term, can be traced back to the 1990s. According to the Science Citation 
Index (Institute for Scientific Information, Thompson, Philadelphia, PA, USA) the first 
research publication using the term nanomedicine appeared in 2000 
16
. A bibliometric analysis 
of documents in the Science Citation Index 
16
, shows that nanomedicine has since seen a 
dramatic surge in research and patent activity, as shown Figure 1.2 
13, 16
. Drug delivery is the 
dominant research field, within nanomedicine, with a 76% share of scientific papers and 59% 
of all patents 
16
.  
 
Drug delivery has been identified as a field in which the use of nanoscale systems could lead 
to improvements in the bioavailability and pharmacokinetics of therapeutics. Bioavailability is 
the extent to which a drug can be used within the body. Pharmacokinetics is the process by 
which a drug is absorbed, distributed, metabolised and eliminated by the body.  
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Figure 1.2: A timeline showing nanomedicine publications and patents worldwide. Nanomedicine has seen a 
dramatic surge in the number of publications and patents since 2000. Data from the Science Citation Index 17. 
 
One of the reasons for the lack of efficacy of some currently available medicines is poor 
delivery to the desired site of action 
15
. Using nanomedicine, it may be possible to achieve 
17
: 
 Improved delivery of poorly water-soluble therapeutics 
 Targeted delivery of therapeutics in a cell or tissue-specific manner 
 Transport of therapeutics across intracellular and extracellular barriers 
 Delivery of large molecule therapeutics to intracellular sites of action 
 Co-delivery of two or more drugs/therapeutics for combined therapy 
 Visualisation of target sites by combining therapeutics with imaging modalities 
 
Nanoparticles show promise for improving the efficacy of drugs with a narrow therapeutic 
window or low bioavailability, such as anti-cancer drugs and nucleic acid-based therapeutics 
18
. The pharmacokinetics and tissue distribution of nanoparticles largely define their 
therapeutic effect. This is determined by the chemical and physical properties of the 
nanoparticles, including size, surface charge and surface chemistry 
18
. Many nanoscale 
therapeutic products have been approved for clinical use to date 
16, 17
. Examples of nanoscale 
therapeutic solutions include: liposomes, nanosuspensions, polymeric nanoparticles, 
dendrimers, fullerenes, carbon nanotubes, and inorganic nanoparticles 
19
, many of which have 
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already been approved for routine use as medicines 
13, 16
. The majority of these therapeutic 
products improve the pharmaceutical efficacy or dosing of existing, clinically approved drugs 
17
. Nanoparticles are attractive for medical purposes due to their unique features, such as a 
large surface area to mass ratio and their ability to diffuse, adsorb and carry other compounds 
14
. With nanoscale therapeutics now validated through the improvement of previously 
approved drugs, interest is growing in revisiting pharmaceutically suboptimal but biologically 
active molecular entities that were previously considered unusable 
17
.  
 
One vision is that nanoparticles will carry therapeutic payloads or genetic content into 
diseased cells, minimising side effects by only becoming active upon reaching their ultimate 
destination. They might even check for over-dosage before becoming active, thus preventing 
drug-related poisoning 
2
. Localised therapy of the target organ generally requires smaller total 
doses to achieve clinically effective results 
20
. To reach this goal, nanoparticles can be tailored 
to slowly degrade, react to stimuli such as changes in pH, and be site specific 
20
. 
Nanomedicines currently available on the market are shown in Table 1.1, which includes 
some structures up to 1000 nm in size because the control of materials at this size range 
requires the use of novel nanotechnology techniques 
16
.  
 
The size boundaries of nanomedicines remain ambiguous. The definition proposed by the 
National Nanotechnology Initiative of nanotechnology refers to structures with at least one 
dimension 1 nm – 100 nm in size 3, 17, 21. In practice however, nanotechnology commonly 
refers to structures that are up to 1000 nm as they frequently involve the use of novel 
nanotechnology techniques 
16, 17
. The size range that holds most interest is typically from 100 
nm down to the atomic level, approximately 0.2 nm, as shown in Figure 1.1 
3
. It is in this 
range that materials can display novel physical, chemical and biological properties 
22
 and 
quantum confinement effects can significantly affect optical, magnetic or electrical properties 
3
.  
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Healthcare 
Application 
Composition/ 
Nanotech component 
Indication Company 
Drug Delivery 
Abelecet 
Amphotericin B/ 
Lipid colloidal dispersion 
Fungal Infections Enzon (Bridgewater, NJ, USA) 
Amphotec 
Amphotericin B/ 
Lipid colloidal dispersion 
Fungal Infections InterMune (Brisbane, CA, USA) 
Ambisome Liposomal Amphotericin B Fungal Infections 
Gilead (Foster City, CA, USA), 
Fujisawa (Osaka, Japan) 
DaunoXome Liposomal daunurubicin Kaposi Sarcoma Gilead 
Doxil/Caelyx Liposomal doxorubicin Cancer, Kaposi Sarcoma 
Orth Biotech (Bridgewater, NJ, USA); 
Schering-Plough (Kenilworth, NJ, USA) 
Depocyt Liposomal cytarabine Cancer SkyePharma (London), Enzon 
Epaxal Berna Virosomal Hepatits Vaccine Hepatits A Berna Biotech (Bern, Switzerland) 
Inflexal V Berna Virosomal Influenza Vaccine Influenza Berna Biotech 
Myocet Liposomal Doxorubicin Breast Cancer Zeneus Pharma (Oxford, UK) 
Visudyne Liposomal Verteporfin 
Age-related macular 
degeneration 
QLT (Vancouver, Canada), 
Novartis (Basel) 
Estrasorb Estradiol in Micellar Nanoparticles Menopausal Therapy Novavax (Malvern, PA, USA) 
Adagen PEG-adenosine Deaminase Immunodeficiency Disease Enzon 
Neulasta PEG-G-CSF Febrile Neutrpenia Amgen (Thousand Oaks, CA, USA) 
Oncaspar PEG-asparaginase Leukemia Enzon 
Pegasys PEG-α-interferon 2a Hepatitis C 
Nektar (San Carlos, CA, USA), 
Hoffman-La Roche (Basel) 
PEG-Intron PEG-α-interferon 2b Hepatitis C Enzon, Schering-Plough 
Macugen Peglated anti-VEGF Aptamer 
Age-related macular 
degeneration 
OSI Pharmaceuticals (Melville, NY, USA), 
Pfizer (New York) 
Somavert PEG-HGH Acromegaly Nektar, Pfizer 
Copaxone 
Copolymer of Alanine, lysine, glutamic 
acid and tyrosine 
Multiple Sclerosis 
TEVA Pharmaceuticals (Petach Tikva, 
Israel) 
Renagel Crosslinked poly(allylamine) resin Chronic kidney disease Genyzyme (Cambridge, MA, USA) 
Emend Nanocrystalline aprepitant Antiemetic 
Elan Drug Delivery (King of Prussia, PA, 
USA), Merck & Co. (Whitehouse Station, 
NJ, USA) 
MegaceES Nanocrystalline megesterol acetate Eating disorders 
Elan Drug Delivery, Par Pharmaceutical 
Companies (Woodcliff Lake, NJ, USA) 
Rapamune Nanocrystalline sirolimus Immunosuppressant 
Elan Drug Delivery, Wyeth Pharmaceuticals 
(Collegeville, PA, USA) 
Tricor Nanocrystalline fenofibrate Lipid regulation 
Elan Drug Delivery, 
Abbott (Abbot Park, IL, USA) 
Triglide Nanocrystalline fenofibrate Lipid regulation 
SkyePharma, First Horizon Pharmaceuticals 
(Alpharetta, GA, USA) 
Abraxane Paclitaxel protein bound nanoparticles Cancer 
Abraxis BioScience (Schaumburg, IL, 
USA), AstraZeneca (London) 
In vivo imaging 
Resovist Iron nanoparticles Liver tumours Schering (Berlin) 
Feridex/Endorem Iron nanoparticles Liver tumours 
Advance Magnetics (Cambridge, MA, 
USA), Guerbet (Roissy, France) 
Gastromark/Lumirem Iron nanoparticles 
Imaging of abdominal 
structures 
Advanced Magnetics, Guerbet 
In vitro diagnostics 
Lateral flow tests Colloidal gold 
Pregnancy, ovulation, HIV, 
among others 
British Biocell (Cardiff, UK), 
Amersham/GE (Little Chalfont, UK), 
Nymox (Hasbrouck Heights, NJ, USA) 
Clinical cell separation Magnetic nanoparticles Immunodiagnostics 
Dynal/Invitrogen (Oslo, Norway), Miltenyi 
Biotec (Bergisch Gladbach, Germany), 
Immunicon (Huntington Valley, PA, USA) 
 
Table 1.1: A table showing some nanomedicines available on the market, including some structures up to 1000 nm 
in size because manipulation of materials at this size range requires novel nanotechnology techniques 16. 
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Although the introduction of nanotechnology has improved the bioavailability of drugs and 
enabled numerous problems to be overcome, unresolved delivery problems still remain 
20
. 
One of the current remaining challenges for nanomedicine is to design innovative materials, 
techniques and devices able to guide therapeutic payloads to their desired location of action 
23
. 
The global message from the literature is that smaller particles have an enhanced ability to 
reach targets which are difficult to access 
24
. However, the body has evolved effective 
biological barriers to protect itself from the harmful effects of foreign materials, such as 
bacteria, viruses and other unfamiliar entities, ~50 nm – 1000 nm in diameter 23. Biological 
barriers include cell membranes, epithelia, mucus, collagen, blood, surfactants, polymer gels 
and blood vessels 
23, 25
. Traversal of biological barriers has remained a bottleneck in the 
progress of drug delivery and gene therapy 
26, 27
, preventing a therapeutic from navigating 
itself to the target cells when it has not been administered directly. The aim for nanomedicine 
is to understand if novel nanoscale phenomena can be used to improve biological barrier 
traversal and hence delivery.   
 
 
1.2  Therapeutic Delivery to the Lung 
 
The most commonly used drug and therapeutic delivery route is peroral delivery; the 
swallowing of medicine with absorption into the bloodstream via the gastrointestinal tract 
2
. A 
swallowed therapeutic, must be absorbed through the cell membrane wall of the 
gastrointestinal tract to gain access into the bloodstream. The blood then distributes the 
therapeutic around the body transporting it (non-specifically) to the target cells. Obstacles to 
transport posed by the gastrointestinal tract are severe and varied. They include the cell 
membrane itself, mucus lining the walls of the gastrointestinal tract, acid-induced hydrolysis 
in the stomach, and enzymatic degradation throughout the gastrointestinal tract 
2
.  
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For many targets in the body, digestion of medicine provides the only method for drug 
delivery without the use of intravenous methods (which are largely unpopular due to the 
discomfort caused). However, another important therapeutic delivery route is pulmonary 
delivery; the inhalation of medicine into the lung. Pulmonary delivery offers local targeting 
for the treatment of respiratory diseases 
2, 20, 28
, such as: 
 Asthma 
 Bronchitis 
 Chronic obstructive pulmonary disorder (COPD) 
 Cystic Fibrosis (CF) 
 Lung Cancer 
 Pneumonia 
 Pulmonary hypertension 
 
Local targeting enables the therapeutic to be inhaled into the lung near the target cells, 
avoiding many of the barriers posed by the gastrointestinal tract and those associated with 
having to cross from the bloodstream into the lung. The delivery of locally-acting medicine 
directly to the site of action means that the dose needed to produce a pharmacological effect 
can be reduced; avoiding side-effects. It also enables the rapid onset of action and avoidance 
of intestinal metabolism 
28
. Functionally, the respiratory system works with the circulatory 
system to deliver oxygen from the lungs to the cells and remove carbon dioxide. The 
respiratory tract is divided into two main parts, as shown in Figure 1.3; the upper respiratory 
tract, consisting of the nose, nasal cavity and the pharynx; and the lower respiratory tract 
consisting of the larynx, trachea, bronchi and the lungs. The trachea, which begins at the end 
of the larynx, divides into two bronchi and continues into the lungs. The trachea allows air to 
pass from the larynx into the bronchi and then into the lungs. The bronchi divide into smaller 
bronchioles, which then branch in the lungs to form passageways for air. The terminal parts of 
the bronchi are the alveoli 
20
. This intricate fractal-like structure of air passageways provides a 
large surface area for the absorption of therapeutics. 
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Pulmonary delivery can be carried out in a number of ways; via aerosols, metered dose inhaler 
systems, dry powder inhalers and nebulizers, which may contain micelles, liposomes, 
nanoparticles and microemulsions 
20
. Aerosols are suspensions of solid or liquid particles in a 
gas; usually air 
20
. Modern asthma therapy has promoted the benefits of aerosol drug delivery 
to the lung 
29, 30
.  Well designed aerosol systems can rapidly deliver therapeutics to a high 
proportion of the lung‟s large surface area, whereas orally delivered therapeutics will have 
limited access to the absorptive part of the small intestine due to intestinal motility and gastric 
emptying 
28
. Research into pulmonary delivery is driven by the potential for successful protein 
and peptide delivery and the promise of an effective delivery mechanism for gene therapy 
20, 
31
. This is largely because the bioavailability of peptides and proteins has been shown to be 
10-200 times greater by pulmonary administration as compared with other non-invasive routes 
20, 32
. Inhalation does not cause as much discomfort as injections and is therefore preferred, 
which improves compliance 
32
. For other small molecules, inhalation is also a fast way of 
getting into the body because metabolising enzymes are present in the lung at much lower 
levels than in the gastrointestinal tract 
33
.  The pulmonary membrane is naturally permeable to 
small molecule drugs and many therapeutics.  
 
 
Figure 1.3: Diagrams illustrating the structure of the lungs and the epithelial cells lining the inside of the airway 
passages. The diagrams show the position of the mucus and the aqueous periciliary layers; careful regulation of the 
composition of both these layers is critical for mucociliary clearance. The target cells for cystic fibrosis gene 
therapy are highlighted in red 34, 35. 
a) b) 
  22 
The epithelium of the lung; i.e the cells lining the inside airway passages, is thick (50-60 μm) 
in the trachea, but diminishes in thickness to an extremely thin 0.2 μm in the alveoli 32. The 
change in cell types and morphology going from the trachea, bronchi and bronchioles to the 
alveoli is very dramatic 
20, 32
. The lungs are far more permeable to macromolecules than any 
other portal of entry into the body.  
 
One barrier common to oral, nasal and pulmonary delivery is the mucus layer that adheres to 
the inside surface of these passageways, Figure 1.3.b. If therapeutics are to be administered 
via any of these routes, this mucus barrier must be effectively traversed 
25
. The structure and 
composition of mucus varies depending on the site of action, the function of the host organ 
and the nature of the underlying epithelia. For the focus of this study, the barrier properties of 
lung mucus occurring in the diseased state of cystic fibrosis are investigated. Cystic fibrosis is 
a genetic disease for which the development of aerosol administered therapeutics has seen 
considerable success in vitro, but slow progress in vivo 
36
. One symptom of cystic fibrosis is 
an amassing of highly viscoelastic, debris-filled mucus in the lungs, resulting in a more 
pronounced barrier effect 
37-39
. Cystic fibrosis is the most frequent lethal genetic disorder in 
children and is also the most common fatal autosomal recessive disease of Caucasians 
40
. 
Delivery of therapeutics to the target cells in the lung, Figure 1.3, remains a bottleneck for the 
genetic therapy of cystic fibrosis 
26, 27
.  
 
 
1.3  The Mucus Barrier 
 
The first hurdle any pulmonary-administered nanoparticles will encounter is the mucus barrier 
of the lungs, which has specifically evolved to trap and inhibit foreign particles and can be an 
insurmountable obstacle 
26
. Mucus is a viscoelastic gel layer that protects tissues that would 
otherwise be exposed to the external environment 
41
. It is a protective medium used by the 
immune system to prohibit the movement of dangerous pathogens to the underlying epithelial 
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cells of organs. At the macroscopic level, mucus is a non-Newtonian, pseudo-plastic gel. 
Under low shear, it behaves like an elastic solid and regains shape over time; under high 
shear, it behaves like a viscous liquid eventually deforming irreversibly 
34, 42
. The dynamic 
viscoelastic properties of mucus are closely regulated biochemically to ensure efficient 
clearance, whilst also maintaining sufficient adhesive and elastic strength to be retained on the 
epithelial surface despite the shearing forces of swallowing, coughing and gravity 
42
. The 
biochemical regulation of the various constituents in mucus is complex and highly 
interdependent, and failure in any one component can adversely affect the physical properties 
of mucus and greatly contribute to disease conditions 
42
, such as cystic fibrosis and chronic 
obstructive pulmonary disease.    
 
1.3.1  Rheological Properties of Mucus 
The thickness of the mucus blanket is determined by the balance between the rate of secretion 
and the rate of degradation and shedding. Toxic and irritating substances can greatly stimulate 
mucus secretion and slightly decrease the thickness of the mucus blanket, efficiently and 
rapidly moving the irritants away from the epithelium 
35
. A second and often underappreciated 
dynamic property of mucus is its ability to maintain an unstirred layer of mucus adjacent to 
epithelial surfaces despite the shearing actions of swallowing and coughing. This is indicated 
by the thicker mucus gel immediately adjacent to the epithelial surfaces. Mucus does this by 
being a shear-thinning gel that forms a lubricating slippage plane between sliding surfaces. 
The shear-thinning property of mucus is characterised by a decrease in viscosity with 
increasing shear rates, the force causes it to go from being thick like honey to flowing like 
water; this is characteristic of pseudo-plastics. In contrast the viscosity of a Newtonian fluid, 
such as water or glycerol, does not change with the shear rate and remains constant at all shear 
rates. When a mucus gel is displaced only a short distance, mucin fibres stretch rather than 
disentangle and hence tend to spring back when the displacing force is released, giving mucus 
its elastic characteristics. This elastic property of mucus is critical for mucociliary clearance.  
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Figure 1.4: A schematic model of mucociliary clearance. Left; In a healthy lung, a thin mucus layer resides above 
the periciliary layer allowing the cilia to beat effectively. Right; In the diseased state of cystic fibrosis, abnormal 
ion transport removes the periciliary layer, mucus becomes thicker and adheres to the epithelial surface, therefore 
mucociliary clearance cannot be performed by the cilia 34, 35. 
 
1.3.2  Mucociliary Clearance 
Cilia on the epithelial surfaces of the respiratory tract continuously sweep mucus shed from 
the lungs towards the pharynx. Any particles, bacteria and pathogens trapped within the 
mucus are delivered to the stomach where they are rapidly inactivated by acid. Respiratory 
mucus is transported out of the lungs at rates of ~60 μm/s, clearing the lungs from within 
minutes to hours 
34, 35
. When the tip of a cilium sweeps the surface of the mucus blanket, it 
sweeps with a shearing motion that is small and fast enough for the mucus gel to act primarily 
by elastic rather than viscous forces. This enhances the efficiency of this transport mechanism 
35, 43
. The cilia are immersed in a dilute „watery‟ mucus layer, the periciliary layer (PCL) 
which has a lower viscosity than the mucus blanket above it, see Figure 1.4. The volume and 
height of this layer is carefully regulated in normal lungs by ion regulation. The height of the 
periciliary layer is such that most of the ciliary motion occurs within the low viscosity of the 
periciliary layer and only the tips of the cilia sweep against the viscoelasic gel layer.  
 
Cilia can only transport mucus if it has the appropriate viscoelasticity. If respiratory mucus 
loses viscoselasticity, gravity can overcome ciliary transport, causing the mucus to run out of 
the nose and into the lungs 
44
. Conversely, if mucus becomes too viscoelastic, as in cystic 
healthy lung cystic fibrosis 
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fibrosis; it cannot be transported by the cilia, leading to the amassing of mucus in the lungs. A 
rather modest increase in viscoelasticity can markedly inhibit the ability of cilia to clear 
respiratory mucus and a small decrease in viscoelasticity can cause fluid to collect in the lungs 
35
. Therefore the viscoelasticity of mucus must be closely regulated to ensure optimal 
functionality 
35
. Under normal conditions, respiratory mucus is of a consistency that somewhat 
slows mucus transport. When irritants are then encountered, more dilute mucin is secreted, 
decreasing the mucus viscoelasticity into the optimal range for maximising mucociliary 
clearance 
45
. In the diseased state of cystic fibrosis, however, the ability to regulate mucus 
concentration to this precision is lost, contributing to the symptomatic highly viscous mucus 
of the disease 
34
.   
 
1.3.3  Mucus Regulation 
The viscoelasticity of mucus depends primarily on mucin concentration 
35, 46
. For reasons 
aforementioned, it is imperative for mucosal epithelia to accurately regulate the viscoelasticity 
of the secreted mucus gels. Most mucosal epithelia do this in part by regulating the ionic 
environment, which in turn regulates mucus hydration and hence viscoelasticity 
35, 47
. Normal 
airway mucus hydration is regulated by at least two signalling systems, both are present in 
cystic fibrosis, but one is non-functional. This is because its effecter component, the cystic 
fibrosis transmembrane conductance regulator protein (CFTR) is either missing or non-
functional 
35
. Normal CFTR acts as a Cl
-
 channel and also helps to regulate Na
+
 re-absorption 
through the epithelial Na
+
 channel. To hydrate airway mucus, CFTR is normally regulated to 
stop Na
+
 re-absorption and initiate Cl
-
 secretion. Dysfunctional CFTR cannot perform these 
functions, therefore Na
+
 re-absorption continues which leads to mucus dehydration. Mucus 
then absorbs water from the PCL reducing its height and flattening the cilia. The flattened 
cilia cannot clear the mucus which becomes increasingly dehydrated and viscous. This causes 
the amassing of the tenacious mucus characteristic to cystic fibrosis.   
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Many other factors also contribute to the regulation of mucus viscoelasticity, including 
secreted lipids, pH, Ca
2+
 and non-mucin glycoproteins such as albumin 
35
. In cystic fibrosis, 
mucus secretions throughout the body become too viscoelastic to be cleared efficiently. This 
causes stasis and greatly increases the chances of bacterial infections from pathogens, 
particles and bacteria embedded in the mucus layer. Even the normal shedding of epithelial 
cells, whose debris is normally swept away, begins to collect and further increases the 
viscoelasticity of mucus 
35
. 
       
1.3.4  Mucus Composition 
Mucus is primarily composed of cross-linked and entangled mucin fibres, which are secreted 
by the globlet cells and submucosal glands of the epithelial layer 
37, 41, 48, 49
. Mucin is a high 
molecular weight glycoprotein with a long chain structure, typically 0.5-40 MDa in size 
34, 35
, 
which gives mucus its viscous, gel-forming characteristics 
37
. Mucins are formed by the 
linking of numerous mucin monomers, each of ~0.3-0.5 MDa 
50, 51
. Mucins are coated by a 
complex and highly diverse array of proteins 
34, 41
. The mucin fibers that form mucus gel are 
like long flexible strings, most of which are tipped with a negative charge (carboxyl or 
sulphate groups) 
35
. Previous biochemical and electron microscopy studies 
52, 53
 have 
characterised individual mucin fibres to be highly flexible molecules ~3-10 nm in diameter, 
and ~15 nm in length 
34, 52, 53
. The flexibility of mucin fibres enables mucus gel to stick to any 
surface with which mucin fibres can form low affinity bonds 
35
. The mucus of a healthy lung 
is composed of 2 %-5 % mucin by weight and is 90 %-98 % water 
41, 54-58
. In addition to 
mucin and water, a large number of other constituents, such as protein, DNA (0.02 % 
42, 59, 60
), 
lipids (upto 1-2 % 
59, 60
), salts (1 % 
59, 60
) , cellular and serum molecules, secreted 
immunoglobins, alginate, hyaluronan, electrolytes, microorganisms, plasma proteins and other 
debris of inflammatory response and sloughed cells are present in lung mucus, although at 
very low concentrations 
25, 61, 62
. Mucus viscoelasticity is tightly regulated in healthy subjects 
by controlling the mucin to water secretion ratio 
41, 63
, as well as by varying lipid 
64
, protein 
65
 
and ion concentration 
66
. Lung mucus is pH neutral in general 
67
 and is continually secreted, 
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then shed and discarded or digested and recycled. It has a short lifetime, ranging from a few 
minutes to hours 
41
. Recent studies based on confocal microscopy suggest that airway mucus 
ranges between 5 μm-55 μm in thickness 68-71. The mucus layer thickness in cystic fibrosis 
patients varies substantially between 5 µm to 500 µm 
40
. Cystic fibrosis mucus acquires an 
increased viscoelasticity, because the mucin gel is denser, has an increased level of 
carbohydrate content and contains an increased concentration of sugars. The increased 
carbohydrate content results in highly branched oligosaccharide structures 
37
. These 
modifications of the mucin structures give them a higher tendency to interact, gel and obstruct 
transport of particles in vivo 
36
.  
 
All therapeutic nanoparticles targeting cells in the lung epithelia must successfully diffuse 
through this mucus layer. Although, overall, diffusivity has been observed to increase with 
decreasing particle size, previous studies of particle diffusion through various mucus samples 
25, 40, 61, 72-81
, have recorded mixed observations regarding the exact relationship between 
diffusivity and size. It is therefore difficult to generalise the effect of particle size on 
diffusivity through mucus. The exact effects of the complicated mucus mesh structure on 
particle diffusivity require further investigation. 
 
 
1.4  Nanoparticle Traversal of Biological Barriers 
 
Although biopharmaceutical projects are ongoing to further understand the cellular barriers 
for nanoparticles 
25
, less attention has been given to the influence of biogels (such as mucus) 
and extracellular matrices (e.g collagen within tumours) on the bioavailability of therapeutics 
25
. Traversal of extracellular barriers is carried out primarily by passive diffusion 
82
.  
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Figure 1.5: A schematic diagram of the process of diffusion. A high concentration of particles on the left hand side 
of the barrier acts as a driving force to push particles through the barrier to the side with a lower particle 
concentration.  
 
In the process of diffusion, a high concentration of particles on one side of a barrier acts as the 
driving force to push particles through to the other side with a lower particle concentration, 
Figure 1.5. The effect of size on diffusion through biological barriers is quantitatively 
unknown and requires investigation. The effects of complex, often non-Newtonian biogel 
environments on particle diffusivity are not understood adequately enough to predict whether 
a therapeutic will traverse the barrier effectively. Even less is known about the diffusion of 
nanoparticles through these biological barriers and whether novel physical characteristics can 
enhance their diffusivity.  
 
Diffusion has traditionally been found to be inversely proportional to particle radius, it 
therefore follows that reducing sizes into the nanoscale would result in increased diffusivity. 
The diffusion coefficient (D) is a measure of how efficiently a particle diffuses through a 
solvent 
83
, measured in m
2
s
-1
. The Stokes-Einstein equation, Equation 1, states that the 
diffusion coefficient (D) is proportional to the temperature (T) and inversely proportional to 
the viscosity of the solvent (η) and the particle radius (r). 
 
r
kT
D
6
                                                  (Equation 1) 
Barrier High Concentration Low Concentration 
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The Stokes-Einstein equation is derived from Stokes‟ Law, which describes the frictional 
force exerted on a very small particle in a continuous viscous fluid: 
                                                       (Equation 2) 
and the Einstein relation: 
                                                      (Equation 3) 
where µ is the „mobility‟ constant which relates the small particle‟s terminal drift velocity, v, 
to an applied force, F. 
                                                       (Equation 4) 
 
A formal derivation of Stokes‟ Law requires use of the Navier-Stokes equation, which is a 
lengthy process. Stokes‟ law can be obtained to within a proportionality constant by 
dimensional analysis, as follows: 
 
Stoke observed that the viscous drag force, F, depends on: 
- the coefficient of viscosity,   
- the velocity of the spherical mass, v 
- the radius of the spherical body, r 
 
If the dimensional formula of the coefficient of viscosity is [ML
-1
T
-1
] (= kgm
-1
s
-1) for Stokes‟ 
Law for the viscous force on a small spherical body in motion through a static fluid medium, 
then: 
F α ηa ; F α vb ; F α rc 
 
By combining this we have: 
          
where „K‟ is the constant of proportionality and is dimensionless. Applying the principle of 
homogeneity of dimensions, the dimensions on the left and right side of the equation should 
be the same. Hence: 
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Considering „K‟ as dimensionless and putting the dimensional formulas of each quantity, we 
have: 
                              
applying the indices law and rearranging, we have: 
                         
For dimensional consistency as required by the principle, the powers of individual basic 
quantities should be equal. Hence: 
      
            
           
By combining the first and second equations, we have: 
            
        
By combining the first and third equations, we have: 
        
    
Hence, a = 1, c = 1. Putting these values in the equation for the force gives: 
       
Where „K‟is found experimentally to be 4π for motion in 2 dimensions. Hence the Stokes‟ 
Law for viscous drag is written as: 
        
 
From Equation 3 and Equation 4, it follows that:  
  
 
 
 
 
 
   
 
   
 
                                        (Equation 5) 
From Equation 2 and Equation 5, it follows that: 
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: The Stokes-Einstein equation 
 
The Stokes-Einstein equation assumes that the diffusing particle is charge neutral, that the 
solution through which diffusion is occurring is homogeneous and also charge neutral and that 
there is no interaction between the diffusing particle and the solution. These assumptions do 
not hold in the case of nanoparticle transport through biological barriers. Most barriers have a 
complicated structure, often with charged components, such as proteins, and a large degree of 
heterogeneity. Therapeutic particles also carry a surface charge and may therefore interact 
with the biological barrier and with each other. These deviations from the assumptions must 
be taken into account when using the Stokes-Einstein equation to predict the diffusion of 
therapeutics through complex environments such as mucus.   
 
Questions about the suitability of the Stokes-Einstein equation at the nanoscale have been 
previously raised 
84
. A study by Tuteja et al. 
85
 has demonstrated the breakdown of the 
continuum Stokes-Einstein relation for the diffusion of cadmium selenide particles ~10 nm in 
diameter through a polystyrene melt. They report diffusion coefficients of up to 200 times 
faster than Stokes-Einstein predictions 
85
. Unfortunately, with only one experimental particle 
size it is difficult to distinguish if the Stokes-Einstein relation breaks down gradually with 
decreasing size, or if this is an isolated observation for the specific case of 10 nm cadmium 
selenide particles diffusing through a polystyrene melt. 
 
A comprehensive study into the effects of decreasing nanoparticle size, by systematically 
investigating the diffusion of a range of nanoparticle sizes, is therefore required. It is 
important to understand how closely the size dependent diffusion of nanoparticles conforms to 
traditional hypotheses in order to validate their suitability as predictive models for 
nanoparticle diffusion. There is a need for concise models that can be used to predict the 
effects of nanoparticle size, surface charge and hydrophobicity on diffusion through biological 
  32 
barriers. These models would then allow researchers to understand the optimal characteristics 
required of nanoparticle therapeutics for effective diffusion through a given environment.        
 
1.5  Experimental Procedures for the Measurement of Nanoparticle Diffusion 
 
Techniques for measuring nanoparticle diffusion generally build on existing techniques used 
to understand the diffusion of microscale particles. Some can be applied quite easily to 
nanoparticles, whilst others require some modification. Three techniques have been widely 
used in the literature; vertical diffusion chambers 
25, 36, 40, 75
, fluorescence recovery after 
photobleaching 
72, 76
 and multiple particle tracking 
77, 79, 86-88
.  
 
1.5.1  Vertical Diffusion Chambers 
Diffusion studies of particles through mucus by Sanders et al. 
36
 and Norris et al. 
73
 were 
carried out using vertical diffusion chambers (VDC). This technique is an old, yet frequently 
used experimental procedure for understanding particle diffusion through membranes. 
Vertical diffusion chambers have been used for many studies of diffusion through mucus 
25, 40, 
73, 89, 90
.  
 
The system consists of a donor compartment which is separated from an acceptor 
compartment by the membrane through which diffusion is to be measured. The experimental 
apparatus is shown in Figure. 1.6. A fixed volume of a known concentration of particles is 
placed in the donor compartment and the same volume of a buffer solution is placed in the 
acceptor compartment to maintain the hydraulic pressure across the membrane. The diffusion 
chambers can then be used in a variety of modes to obtain the diffusion rate for the motion of 
the particles from the donor compartment, through the membrane, into the acceptor 
compartment.  
 
  33 
In the case of mucus samples, the experimental setup must be modified as proposed by Norris 
et al. 
73
. As mucus is a liquid, a packet must be constructed to contain the mucus and hold it in 
place between the donor and acceptor compartments. This packet is constructed using two 
polycarbonate membranes (0.4 μm pore size) and a plastic ring which provides the depth of 
the container. The packet is then filled with the mucus sample and placed between the donor 
and acceptor compartments in order to study the transport properties of particles across the 
mucus gel. The diffusion coefficient of the particle motion through the mucus membrane is 
determined by measuring the particle concentration in the acceptor compartment after a given 
time, t.  
 
Although vertical diffusion chambers have in the past been widely used for studying particle 
diffusion through mucus, the technique only provides information regarding the bulk transport 
of particles. This information can provide generalized observations about particle transport, 
but cannot be used to understand particle interactions with the environment. To obtain an 
understanding of the exact nature of nanoparticle diffusion through mucus and the effects of 
particle characteristics, a technique which can provide information about particle interaction 
with the environment is required. 
 
 
Figure 1.6: An image of the vertical diffusion chamber system. The schematic on the right shows the placement of 
the snapwell holder for samples (green), the donor (pink) and acceptor (white) compartments 73. 
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1.5.2  Fluorescence Recovery after Photobleaching 
Fluorescence recovery after photobleaching (FRAP) experiments have previously been 
conducted by Saltzmann et al. 
72
 and Olmsted et al. 
76
. In FRAP, the diffusion of fluorescently 
labelled particles through various biological fluids is measured using fluorescence 
microscopy. An attenuated laser beam is focused through a modified epifluorescence 
microscope to a small point, ~4 µm in diameter, in a sample containing the fluorescent 
particles of interest 
76
. The attenuator is momentarily removed to increase the intensity of the 
beam approximately 10
3
 - 10
4
 fold, which rapidly and irreversibly bleaches typically 20 % - 
50 % of the fluorescent particles in this part of the sample. After a bleach exposure lasting 10-
40 µs, the attenuator is replaced in the laser beam and the residual fluorescence from the same 
area is monitored 
76
. As unbleached particles diffuse into the partially bleached area, the 
fluorescent signal returns to a new steady state value. The rate at which the fluorescence 
signal recovers reveals the rate of diffusion of the fluorescent particles 
76
. 
 
Unfortunately, there are many disadvantages associated with the FRAP technique. Firstly, no 
individual particle motion information can be derived, as offered by multiple particle tracking. 
The technique is prone to error if particle aggregates move into the sample area. Aggregates 
have a higher fluorescent intensity than individual particles, but move much slower. This will 
obscure the calculated diffusion rate as the high intensity will be interpreted as a large number 
of particles moving at a slower rate. Fluorescent particles also have inherently different 
fluorescent intensities, depending on the amount of fluorophore encapsulated into the particle. 
It is therefore difficult to understand if an increase in intensity is due to single or multiple 
particles.  Olmsted et al.  
76
 used multiple particle tracking as well as FRAP for their 
experiments, multiple particle tracking was used when the fluorescent signals of the probes 
were not sufficiently uniform or bright for FRAP 
76
. Overall multiple particle tracking has a 
larger scope for different experimental conditions, and provides more insight into the diffusive 
motion of the particles.      
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Figure 1.7: A diagram showing particle trajectories of particles moving by Brownian motion, this random motion 
is the basis for the Random Walk Model 91. 
 
1.5.3  Multiple Particle Tracking 
Multiple particle tracking (MPT) has been used by Dawson et al. 
77
, Suh et al. 
79
, and Lai et al. 
81
 as a method for understanding the diffusion of micro- and nanoparticles, 100nm-500nm in 
diameter, through biological environments 
79, 86, 92, 93
. Multiple particle tracking uses high-
speed, high-resolution, fluorescence, video microscopy to capture the motion of a number of 
individual fluorescent particles in a real-time movie clip 
78, 86-88, 94
. The movies simultaneously 
track the trajectories of a number of particles. Frame-by-frame analysis of particle positions 
then enables the determination of the particle displacements between frames. This method has 
had some success in applications to study drug and gene carrier diffusion through biological 
environments 
77, 78, 94
, live cells 
87, 95
, and protein networks 
86, 96
.   
 
Multiple particle tracking was developed by Valentine et al. 
86
 for making precise, localised 
measurements of the microenvironments of inhomogeneous environments, such as F-Actin 
and Agarose 
86
. The idea is to track and calculate the diffusivity of each individual particle in 
order to understand how the particles behave as a population in a given environment. This 
allows examination of the proportion of particles that undergo simple Brownian motion as 
opposed to hindered motion. This technique can additionally indicate if the environment is 
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built up of areas of differing viscosities in which particles diffuse differently. Previous 
techniques only enabled calculation of the bulk averaged diffusivity, which cannot provide the 
same degree of insight. 
 
Multiple particle tracking is based on the principles of the Random-Walk model 
91
. This 
model describes particle motion as discrete in both space and time, yet random in direction. In 
a short time, τ, each particle moves a short distance, λ, in any direction with equal probability. 
The direction chosen for each time-step is independent of the direction chosen for the previous 
time-step. Examples of four trajectories, shown in 2D can be seen in Figure 1.7. The diffusion 
coefficient is derived by dividing the ensemble average mean squared displacement (MSD) of 
the distance moved by a particle in a given time step by the duration of the time step.  
 
The mean squared displacement is determined by averaging the displacement of each 
individual particle between time points of increasing size, Figure 1.8. The distance a particle 
moves between subsequent frames is measured and then averaged. MPT using video 
microscopy tracks particles in two dimensions. The displacement in the third dimension is 
calculated based on the assumption that the environment is isotropic, but not necessarily 
homogeneous 
77
. In this instance, particle displacement along the x, y and z axis are 
uncorrelated and hence the MSD in the x and y directions is simply two-thirds of the MSD in 
three dimensions. The calculations are adapted to factor in this assumption using d, the 
dimension of space. The diffusion coefficient is calculated by fitting the ensemble MSD, 
<∆r2(τ)>, data to Equation. 6, where α characterises the extent of impediment by random 
point obstacles 
93
. α tends to 1 when particles are diffusing by Brownian motion, α tends to 0 
as the extent of obstruction increases.   
 
 


d
r
D
2
2
                       (Equation 6) 
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Multiple particle tracking has previously been used to understand both the behaviour of 
particles and also determine various characteristics of the environment. Work by Ritchie et al. 
97
 and Murase et al. 
98
 uses particle tracking techniques to probe the cell membrane to identify 
structural characteristics. They show that particle tracking is a powerful technique and can be 
used effectively to distinguish the exact nature and type of diffusive motion that particles 
undergo. From this, conclusions can be drawn about the obstructions faced by the particles to 
gain insight into the actual structure of the environment itself. A review by Suh et al. 
79
 
describes the potential uses of multiple particle tracking for understanding the nature of 
different biological environments, such as the cell cytoplasm, the plasma membrane and 
mucus 
79
. Multiple particle tracking studies of particle diffusion, down to 100 nm in diameter, 
through mucus have previously been carried out by Hanes‟ group, who have demonstrated the 
efficacy of the multiple particle tracking technique in several studies 
77-79
. Multiple particle 
tracking is extremely versatile and the technique can be used for many different particle and 
environment types, provided that individual particles can be visualized and their motion can 
be tracked over a long enough period for accurate analysis.  
 
          
 
Figure 1.8: A schematic showing the calculation of the mean squared displacement from the frames of a multiple 
particle tracking movie. The calculation required the co-ordinate values of the nanoparticle in each frame of the 
movie. 
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) 
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1.6  Previous Studies 
 
There have been a number of studies to date which have investigated the effects of particle 
size, surface charge and hydrophobicity on particle traversal through the mucus barrier 
25, 40, 72, 
75-77, 79, 81, 99, 100
. One of the main motivations of these studies has been for the development of 
gene delivery particles for the treatment of cystic fibrosis. For gene delivery to the airways of 
cystic fibrosis patients to be effective, the mucus covering the target cells must be successfully 
penetrated 
36
.  
 
1.6.1  The Effect of Mucus Structure 
One of the first series of studies investigating particle diffusion through cystic fibrosis mucus 
was carried out by Sanders et al. 
25, 36
. The authors investigated the diffusion, through human 
cystic fibrosis mucus, of 124 nm, 270 nm and 560 nm diameter fluorescent, carboxylate-
modified polystyrene particles using vertical diffusion chambers. Previous studies had 
involved investigations into the diffusion of drugs of undefined sizes through cystic fibrosis 
mucus samples 
40
, assessing the barrier effect of cystic fibrosis mucus without correlation to 
particle size. The particles chosen by Sanders et al. 
36
, were of sizes comparable to that of 
lipoplexes and other transfection systems being clinically evaluated for cystic fibrosis gene 
therapy at the time of publication 
36
. The percentage of the particles transported, after 150 
minutes, through a 220 μm thick layer of six different cystic fibrosis mucus samples, of 
varying elastic and viscous modulus values, was measured. Fluorescent intensity was used as 
a measure of particle concentration.  
 
Further, similar studies of the diffusion, through human cystic fibrosis mucus, of 100 nm, 200 
nm and 500 nm diameter fluorescent, carboxylate-modified polystyrene particles were then 
later conducted by Hanes et al. 
77, 79
 using multiple particle tracking. Both studies used mucus 
obtained from cystic fibrosis patients produced spontaneously during respiratory therapy 
36, 77
. 
Using MPT allowed examination of the transport rates and properties of individual particles, 
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enabling Hanes et al. 
77, 79
  to observe exactly how many particles moved faster or slower than 
the average and by what extent. The overall observations of these two studies were that an 
extremely low percentage of particles could traverse through cystic fibrosis mucus. The 
studies showed that the largest, ~500 nm in diameter, particles were almost completely 
hindered 
36
. The additional insight provided by MPT allowed Dawson et al. 
77
 to observe that 
the mean diffusion coefficient became dominated by relatively few but fast-moving particles 
as the particle diameter was reduced from 500 nm to 100 nm 
77
.  
 
These studies also revealed that particles diffused significantly faster through the more 
viscous mucus samples 
36, 77
. This is contrary to the predictions of the Stokes-Einstein 
equation, which defines diffusivity as being inversely proportional to viscosity, Equation 1. 
These studies hypothesised that the size-dependent behaviour of the particles could be 
attributed to the complicated, porous, mesh network structure of mucus, through which 
smaller particles face less steric obstruction by travelling through fluid filled pores 
36, 77
. 
Sanders et al. 
25, 36
 hypothesised that in low viscoelastic mucus, a more homogeneous 
microporous network might be present, with many free biopolymer chains 
36
. In comparison, 
more viscoelastic mucus samples are composed of a more heterogeneous macroporous 
network, with a limited amount of free biopolymer chains 
25
. Both the macroporous channels 
as well as a low amount of free biopolymer chains may facilitate the faster transport of larger 
nanoparticles through mucus with a higher viscoelasticity 
36
.  
 
 
Figure 1.9: a) SEM micrograph of CF Mucus obtained by Sander et al. 36, b) SEM micrograph of Cervical Mucus 
72. Both images show the complicated and variable porous mucus mesh structure.  
a) b) 
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Through a series of experimental work 
25, 36, 75
 supported by previous studies into the mucus 
network structure 
72, 76, 101
, Sanders et al. 
36
 proposed that because 124 nm diameter 
carboxlylate-modified polystyrene particles were only retarded by a factor of 1.3, compared to 
buffer, it could be expected that water channels in mucus were large enough to allow passage 
of these particles 
25
. This hypothesis was supported by their Electron Microsopy (EM) data, 
and that of previous studies by Saltzman et al. 
72
 and Yudin et al. 
101
, which revealed pores in 
the mucus structure with an average diameter of 100 nm-400 nm, Figure 1.9 
25, 72, 101
. They 
concluded that the difference in transport rates of 124 nm, 240 nm and 560 nm particles was 
mainly caused by stronger steric obstruction with increasing particle size 
36
.  
 
This pore theory was then further supported in studies by Dawson et al. 
77
, who observed that 
cystic fibrosis mucus microviscosity, as probed by 100 nm and 200 nm diameter particles, was 
an order of magnitude lower than its macroviscosity, suggesting that particles dispersed in 
cystic fibrosis mucus are transported primarily through lower viscosity, fluid-filled pores 
within a highly viscoelastic matrix 
77
. Through a series of studies, the authors found that the 
average mean squared displacements of the 100 nm, 200 nm and 500 nm diameter particles 
indicated that the particle transport behaviour is characteristic of caged particles, moving in a 
porous, elastic network, with particle diameters larger than the effective mesh size of the 
mucus network 
77
. The studies also revealed that although the average particle transport rates 
for all particle sizes decreased with increasing time, a small but significant fraction of the 
smaller (100 nm and 200 nm diameter) particles exhibited less hindered diffusive transport 
rates. This implies that the mesh size is not homogeneous and that smaller particles may 
undergo less hindered transport during periods in which they move through larger pores. 
Dawson et al. 
77, 79
 also observe that the distribution of particle mean squared displacements 
was sharply reduced as particle diameter increased from 100 nm and 200 nm to 500 nm, 
suggesting that 100 nm and 200 nm diameter particles move in pores too small for the 500 nm 
diameter particles. Dawson et al. 
77
 interpreted the faster motion of 100 nm and 200 nm 
diameter particles as diffusion through areas of lower viscosity within the fluid-filled pores of 
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the mucus mesh structure. The authors therefore sought to understand the apparent, lower 
microviscosity acting on the smaller particles within the pores. They investigated how the 
microviscosity differed from the bulk viscosity of the sample, which had been measured using 
rheometry 
77
. Dawson et al. 
77
 used the Stokes-Einstein equation, Equation 1, to extract the 
effective microviscosities acting on each particle size from the diffusion coefficient values 
derived from MPT. The microviscosities of cystic fibrosis mucus probed by 100 nm and 200 
nm diameter particles were reported to be 15 and 7 times lower than the bulk sample 
viscosity, respectively 
77
. Dawson et al. 
77
 reported similar observations to Sanders et al. 
36
 
regarding the effects of cystic fibrosis mucus with reduced bulk viscoelasticity on particle 
diffusion. They observed that a 50 % reduction of the cystic fibrosis mucus viscoelasticity 
narrowed the distribution but did not significantly alter the ensemble average diffusion rate 
77
. 
Overall they concluded that human cystic fibrosis mucus contains a significant number of 
pores with diameters greater than 200 nm but less than 500 nm 
77
. The studies conducted by 
Sanders et al. 
25, 75, 100
 and other previous studies 
77, 79, 102, 103
 estimated that pore sizes range 
from 100 nm-400 nm. These reports together therefore suggest the actual pores are in the 100 
nm-500 nm in diameter range. Direct determination of an absolute pore size is yet to be 
achieved.  
 
1.6.2  Mucus Pore Size 
The structure of mucus is difficult to observe and numerous attempts have been made to 
prepare mucus for electron microscopy with methods designed to cause minimal distortion. 
35
. 
An EM micrograph from the study conducted by Sanders et al. 
36
 is shown in Figure 1.9.a, 
from which the authors derived pore diameters of 100 nm–400 nm. Sanders et al. 36 base their 
pore diameter predictions on a previous study by Yudin et al. 
101
, which used Transmission 
Electron Microscopy (TEM) and a study by Saltzman et al. 
72
, Figure 1.9.b, which used 
Scanning Electron Microscopy (SEM) to measure the pore size of human cervical mucus 
72, 
101
.  
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Figure 1.10: A schematic of the image projected from TEM samples, showing the image obtained from a) a thin 
sample „slice‟, b) shows how the multiple layers of a three dimensional sample produce an image of the 
overlapping layers. 
    
The sample dehydration and fixing methods for both TEM and SEM alter the mucus structure 
considerably 
61
. When fresh mucus is prepared for electron microscopy, most fixation 
methods yield a random mesh of thick individual fibres about 30 nm – 100 nm in diameter 35, 
104, 105
. This is approximately 10 fold thicker than the 3 nm – 10 nm diameter of a mucin fibre 
determined biochemically 
35
. The much thicker, and often straighter, fibres seen in images of 
mucus gels, Figure 1.9.b, are probably thickened in part from the tendency of other 
constituents of a mucus gel (antibodies, albumin, etc) to adsorb to mucin fibres during 
preparation of the gel for electron microscopy. The metals used to increase electron contrast 
also increase the apparent fibre diameter. However, these two effects can at most double the 
apparent thickness of mucin fibres 
35
. Thus the published evidence to date suggests that 
conventional fixing methods may somehow cause mucin fibres to aggregate together laterally 
to become „cables‟ 3-10 times thicker than individual mucin fibres 35. In addition to effects of 
sample preparation, the electron microscopy method itself may distort the observed structure. 
TEM can be compared to a projector with the sample „slices‟, acting as slides through which 
the electron beam travels and projects the sample image onto a screen 
106
. For a three 
dimensional structure such as mucus, multiple layers are thus projected as overlapping, which 
specimen 
imaging plate 
a) b) 
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can mean that the projected pore size may be reduced due to the overlapping of layers 
106
. 
Figure 1.10.a shows a case in which a thin sample „slice‟ is projected; the TEM image is an 
accurate representation of the sample. Figure 1.10.b shows a schematic of how the projection 
of the multiple layers of a three dimensional sample are imaged as overlapping.        
 
Similarly in SEM, the metallic coating of the sample preparation acts as a blanket covering the 
different layers, meaning that layers lower down in the three dimensional structure may 
appear in the same plane as the sample surface, which can distort and reduce the measured 
pore size 
106
. Saltzman et al. 
72
 attempted to use SEM to determine the average mesh size of 
human cervical mucus 
72
, but found that the average mesh size within the gel was difficult to 
determine from SEM micrographs due to the three-dimensional nature of the samples and 
sample shrinkage during drying 
72
.  
 
Direct comparison across previous EM studies is difficult due to the large degree of variability 
between each study. The problem is that the diameters of the cables and the mesh-spacing 
between them depend markedly on the methods used to visualise the mucus gel structure 
35
. 
Each study uses different imaging techniques and different mucus samples from different 
patients, often from different mucosal epithelia. The mucus samples differ considerably in 
constituents, constituent concentrations, viscoelasticity, sample collection, handling, storage 
and preparation which all affect the mucus mesh structure. A recent study by Broughton-Head 
et al. 
61
, offers an explanation for the discrepancies in the measured pore size reported by 
previous studies. Broughton-Head et al. 
61
, used Atomic Force Microscopy (AFM) to measure 
the average pore diameter of CF mucus samples from patients 
61
. AFM is a high-resolution, 
non-obstructive measurement technique which does not require fixing, metal-coating or high-
vacuum storage of mucus samples as required by EM techniques 
61
. The average pore 
diameter from the study was measured to be 471.8 nm + 120.4 nm 
61
. The AFM studies 
observed a macroporous structure of CF mucus and demonstrated highly variable pore sizes 
(160 nm–1440 nm) with an average diameter larger than previously measured 61. These 
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observations demonstrate that human CF mucus samples un-modified by fixing techniques for 
microscopy, have a heterogeneous, macroporous structure as hypothesized by Sanders et al. 
25
.  
 
Interestingly, the study found considerable intra and inter-sample variation in the 
measurement of mucus pore size. The coefficient of variability for pore diameter was greater 
than 30 % within each sample and 39.5 % between samples 
61
. The large degree of variation 
between and within samples offers an explanation for the differences in measured and derived 
pore sizes from previous studies to date 
36, 72, 77, 101
. It appears that there cannot be a single 
average pore size which characterises all mucus samples, even if they are from the same 
epithelia, same patient, collected on the same day by the same methods and measured within 
minutes of each other. The mucus structure is inconsistent, varying considerably within each 
extruded sample and depends upon many conditions which are difficult to regulate.  
 
The most recent study of particle diffusion through mucus was carried out by Lai et al. 
81
, in 
which ~500 nm diameter fluorescent, carboxylate-modified, PEGylated polystyrene particles,  
were observed to diffuse through cervicovaginal mucus as fast as 100 nm diameter particles 
81
. 
This unexpected outcome could be attributed to the large degree of variability between mucus 
samples and be a result of a mucus sample with a particularly large average pore size, which 
would be consistent with the average pore size of 471.8 nm + 120.4nm as measured by 
Broughton-Head et al. 
61
. This study shows that any pore effects acting on diffusing particles 
are subject to the large variations within and between mucus samples. It is therefore difficult 
to generalise over all samples as some may contain pores larger than 500 nm through which 
particles up to 500 nm in diameter may diffuse freely, whilst other samples may only contain 
pores up to 300 nm resulting in two different diffusive patterns for particles smaller and 
greater than 300 nm in diameter. 
 
It is not yet known how mesh spacing changes with mucin concentration. If a mucus gel 
structure is assumed to be roughly comparable to a cubic lattice structure, the average fibre 
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spacing should be proportional to (fibre diameter)/(mucin concentration)
1/2
. However, as 
mucin concentration increases, the tendency for individual mucin fibres to aggregate into 
thicker cables is likely to increase, causing a corresponding increase in mesh spacing between 
cabled fibres, as hypothesised by Sanders et al. 
35, 36
.  
 
1.6.3  Sub-100 nm Diameter Nanoparticle Diffusion 
Although it is difficult to generalise and state one definitive pore size for the mucus mesh 
structure, it can be concluded from the previous literature, that nanoparticles less than 100 nm 
in diameter should be small enough to diffuse these lower viscosity pores 
36, 61, 72, 77, 101
. The 
previous literature therefore speculates that sub-100 nm nanoparticles have the ability to 
diffuse through fluid-filled pores, within which the effective viscosity is up to 15-fold lower 
than that of the bulk mucus sample 
77
. This offers the possibility of greatly enhanced diffusive 
ability. There have been relatively few previous studies in the field addressing sub-100 nm 
diameter nanoparticle transport properties through CF mucus. A study by Bhat et al. 
40
 
investigated the diffusion of various drugs through CF mucus, but size was not measured and 
the focus of the research was not the effect of size, but more to evaluate the barrier properties 
of mucus to the various compounds. Size based studies for sub-100 nm diameter nanoparticles 
have been carried out through mucus samples from different epithelia, such as human cervical 
mucus 
72, 76
 and reconstituted gastrointestinal mucus 
73
 which, although chemically and 
structurally different to CF mucus, can be used to provide some insight.  
 
A study by Olmsted et al. 
76
, using FRAP, into the diffusion of macromolecules and virus-like 
particles in human cervical mucus, revealed that most of the protein aggregates tested (<20 
nm in diameter) were able to diffuse in samples of mucus as fast as in water. This indicated 
that interaction with the complicated mucus mesh structure in human cervical mucus does not 
hinder particle motion 
76
. These results confirmed the observations presented in studies of 
antibody diffusion by Saltzman et al. 
72
, who also used FRAP to investigate the diffusive 
abilities of proteins and antibodies ranging from 0.86nm to 28nm in diameter 
72
 through 
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human cervical mucus. The authors reported that particles as large as viruses, ~28nm in 
diameter, could diffuse rapidly through human cervical mucus, provided that particles form no 
adhesive interactions with the mucus glycoproteins 
72
. Saltzman et al. 
72
 showed that the 
largest antibodies of 9.4 nm, 11 nm and 15 nm diameter diffused at approximately the same 
rate in mucus as in water 
72
. Olmsted et al. 
76
 then showed that 38 nm and 55 nm diameter 
virus particles could diffuse unhindered in mucus 
76
. These studies show the potential of 
nanoparticles, less than 100 nm in diameter, to diffuse as rapidly through mucus as through 
water, depending on the characteristics of the mucus mesh environment 
72, 76
. Furthermore, 
neither of the two studies found the Stokes-Einstein equation suitable for modelling the 
observed relationship between particle size and diffusivity 
72, 76
. However, these results were 
obtained using fluorescence recovery after photobleaching (FRAP). The use of FRAP poses 
several problems, for example, the movement of aggregates into the observation field, can be 
mistaken for the fast motion of several nanoparticles back into the observation field. The 
results presented by Olmsted et al. 
76
 show no correlation between size and diffusivity and 
neither do those by Saltzman et al. 
72
. Furthermore, particles and proteins are shown to have 
diffused through mucus samples faster than through PBS 
72
. The only particles studied by a 
form of multiple particle tracking (with very low frame rates of 1.5 seconds per frame 
76
), 
diffused 112 time slower through the mucus samples than through PBS. As discussed in 
section 1.5.2, FRAP has many limitations as a technique and has the potential for large errors. 
The errors in the study by Olmsted et al. 
76
 range from 2 %-67 % and likewise in the study by 
Saltzman et al. 
72
 the average error is 49 %. The particles, viruses and proteins used in these 
studies were all different with varying surface characteristics, it is therefore difficult to 
generalise and correlate size with diffusion systematically through the results of these studies.   
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1.6.4  Particle Muco- Adhesion 
Previous studies have shown substantial interaction between carboxylate-modified 
nanoparticles and the mucus network 
25, 40
. Olmsted et al. 
76
 observed that high concentrations 
of nanoparticles adhered to the mucins and collapsed the mucus gel into thick “cables” of 
aggregated mucin strands 
76
. Dawson et el 
78
 also reported that the zeta potential of 200 nm 
diameter carboxylate-modified polystyrene particles decreased from -5 mV to -17.5 mV after 
30 minutes incubation in pig gastric mucin 
78
, indicating mucin adhesion to the particle 
surface 
78
. A study carried out by Lindman et al. 
107
 investigated the effects of nanoparticle 
size and hydrophobicity on protein adsorption on particles, when in blood. They examined the 
adsorption of Human Serum Albumin (HSA, 66 kDa) on polymer particles ranging from 70 
nm to 700 nm in diameter 
107
. The authors found that the large curvature of 70 nm diameter 
nanoparticles prevented protein binding to the nanoparticle surface 
107
. This report suggests 
that nanoscale sizes may also offer the additional benefit of reduced particle-environment 
interaction due to high surface curvature. Lindman et al. 
107
 hypothesise a size limit; above 
which binding properties are independent of curvature and approach those of a ”flat” surface 
and below which binding properties depend strongly upon the surface curvature of the 
nanoparticles 
107
.  
 
From their experiments, they find this limit to occur for particles between 70 nm – 120 nm in 
diameter and expect the coverage to approach a constant value for all particle sizes greater 
than 120 nm in diameter 
107
. The study by Lindman et al. 
107
 suggests that nanoscale effects on 
nanoparticle-environment interactions must be given careful consideration, as they differ from 
microscale effects 
107
. Reduced nanoparticle-environment interactions would mean that 
experimental conditions using nanoparticles may be closer to those assumed in models, such 
as the Stokes-Einstein equation. However, the study does report that there is surface coverage 
of nanoparticles, just at a much lower degree 
107
. The study therefore suggests that 
nanoparticle-environment interactions may still affect nanoparticle diffusion through mucus, 
but to a lesser extent than for particles greater than 100 nm in diameter.  
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1.6.5 Surface Modification of Particles - PEGylation 
A popular method that has been explored for reducing therapeutic interactions with the mucus 
environment is PEGylation 
41
. PEGylation is a pharmaceutical technology that involves the 
covalent attachment of polyethylene glycol (PEG) chains to a drug or therapeutic to improve 
its pharmacokinetic and immunological profiles, and thus enhance its therapeutic effect 
108
. 
PEG is a synthetic polyether that is readily available in a range of molecular weights. PEG has 
been found to be non-toxic and its approval by the US Food and Drug Administration has lead 
to its wide use in drugs, foods and cosmetics 
108
. PEGylation is a well-established technology 
used extensively to enhance the clinical properties of therapeutics, such as stability, solubility 
and longer circulation 
109
. At present there are nine PEGylated products on the market, seven 
of which are classified as nanomedicines and are listed in Table 1.1 
108
.  
 
Studies into the effects of PEGylation on particle transport through mucus have also shown 
enhanced diffusivity by the reduction of particle interactions with the environment 
41, 81, 110, 111
. 
Previous studies have shown that coating nanoparticles with PEG results in particles with a 
hydrophilic and near-neutral surface charge that can minimise the effects of muco-adhesion 
81, 
111
. This type of particle coating was inspired by the ability of viruses to traverse human 
mucus samples rapidly, as reported by Olmsted et al. 
76
, due to their small size and net-neutral 
surface properties 
76, 81, 109, 111
. Work by Hanes‟ group 81 investigated the effects of PEGylation 
on the transport of 100 nm, 200 nm and 500 nm diameter carboxylate-modified, polystyrene 
particles through human mucus samples 
81
. Their study unexpectedly found that large 
nanoparticles 500 nm and 200 nm in diameter, when PEGylated, diffused through mucus 
samples faster than 100 nm PEGylated nanoparticles 
81
. Overall, Lai et al. 
81
 found that 
PEGylation greatly improved the diffusivities of the all particle sizes by 20-fold, 400-fold and 
1100-fold for 100 nm, 200 nm and 500 nm diameter particles respectively 
81
. In a later study, 
work by the same group 
41
 investigated the effects of the density of the surface PEG-coating 
41
. In this work, the authors found that a 40 % lower surface coverage caused a significant 
decrease in the average transport rate for the 100 nm diameter nanoparticles 
41
. The 
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unexpectedly low diffusivity of the 100 nm nanoparticles was therefore attributed to 
insufficient surface coverage and the authors were able to engineer 100 nm nanoparticles that 
rapidly traversed the mucus barrier 
41
. The exact nature and effect of particle PEGylation 
therefore remains ambiguous as the reported effects appear to enhance the transport of larger 
particles much more than smaller particles 
41, 81
. Once again, all previous studies have only 
investigated the effects of PEGylation on the diffusion of particles greater than 100 nm in 
diameter 
41, 81, 110
. It would therefore be beneficial to examine the effects of PEGylation on the 
transport of nanoparticles less than 100 nm in diameter through the mucus environment. 
 
 
1.7  Aims and Objectives 
 
Knowledge of the size and surface characteristic combinations for optimal delivery of 
nanoparticles would be important in developing nanomedicine. Suggested nanoparticle 
attributes such as increased surface area to volume ratios, decreased effects of gravity and 
decreased adhesion due to surface curvature offer the potential for improved nanoparticle 
delivery through biological fluids. An understanding of how these attributes change with 
decreasing size and their influence on nanoparticle diffusivity is required to allow researchers 
to develop nanoparticle therapeutics with the optimal properties for the efficient and 
successful treatment of many diseases. 
 
According to previous studies as discussed in Section 1.6, nanoparticles less than 100 nm in 
diameter, if PEGylated, would be subject to lower muco-adhesion due to the net-neutral 
nanoparticle surface charge and therefore have enhanced ability to diffuse through lower 
viscosity pores in the mucus mesh structure more effectively. It is therefore necessary to 
investigate these hypotheses in a systematic and controlled way in order to understand and 
appreciate the effects of these phenomena on therapeutic delivery. 
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The aim of this study is to understand the effect of size and surface charge on the diffusivity 
of nanoparticles through reconstituted mucus as a model for human mucus. The use of a 
model mucus solution allows experiments to be carried out in a controlled and systematic 
manner to avoid the large variations in human samples as discussed in Section 1.6.2. This 
study will investigate the nature of lower viscosity pores in the mucus mesh structure and 
elucidate whether nanoparticles are small enough to diffuse through lower viscosity pores in 
the mucus mesh structure, and whether diffusivity within these pores is consistent with 
Stokes-Einstein predictions within these pores. This study will also investigate the effects of 
coating carboxylate-modified, polystyrene nanoparticles with a uniform layer of PEG on 
nanoparticle diffusivity through the mucus environment. 
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CHAPTER 2: FLUORESCENT NANOPARTICLE 
PREPARATION AND CHARACTERISATION 
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Fluorescence is used to measure particle diffusion in all of the experimental techniques 
discussed in Section 1.5. In multiple particle tracking, fluorescence microscopy is used to 
trace the distance a particle travels between frames of a known time period. Fluorescent 
particles are used to contrast the particle against the environment through which it diffuses. 
For vertical diffusion chamber experiments, fluorescence is used as a measure of particle 
concentration. The relationship between fluorescent intensity and particle concentration can 
be determined by measuring the fluorescent intensity of several known concentrations of 
particles. Once this relationship has been determined, the concentration of a particle sample 
can be calculated from its fluorescent intensity. Finally, FRAP uses photo-bleaching to bleach 
the fluorescent signals of particles in a given area. The diffusion coefficient is then derived 
from the rate at which particles move back and the fluorescent signal is restored back into the 
observation area. A wide range of fluorescent particles with well-defined and monodisperse 
sizes are needed to enable the systematic correlation of size with diffusivity. The particle size 
must be the only variable to allow accurate determination of size effects on diffusivity, 
therefore the surface characteristics of all the particles sizes must be kept as constant as 
possible. The test particles chosen must be representative of the drug and gene delivery 
particles which they will model, to enable the results and correlations seen to be applicable to 
real situations.  
 
Some previous diffusion studies have used drug and gene delivery particles such as antibodies 
72
 and lipoplexes 
74-76, 78, 100
. Lipoplexes are self-assembling particles that are formed when 
liposomes are mixed with DNA. They consist of lipids with hydrophobic head groups and 
hydrophilic tail groups, see Figure 2.1. When hydrated, these lipids aggregate together to 
form self-assembled liposomes which enclose an aqueous compartment. If DNA is introduced 
when the liposomes are forming it becomes encapsulated within the aqueous compartment, 
forming a lipoplex. It is, however, difficult to produce monodisperse drugs, lipoplexes, 
antibodies or gene complexes with defined sizes and uniform surface characteristics. 
Commercially available fluorescent, carboxylate-modified, polystyrene particles are therefore 
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often used as a model for gene and drug delivery particles. Fluorescent, carboxylate-modified, 
polystyrene particles (PS-NP-COOH) have been used in a wide range of studies  
25, 36, 73, 77, 79
 
because they have sizes and surface characteristics comparable to lipoplexes and other 
transfection systems currently being developed 
36
 and are available in well-defined, 
monodisperse sizes.   
 
Figure 2.1: A diagram showing the self assembly of liposomes from lipids with a hydrophobic head group and a 
hydrophilic tail group during hydration. If DNA is present during hydration a lipoplex is formed in which the DNS 
is encapsulated into the centre of the liposome.  
 
Previous studies have used fluorescent, carboxylate-modified, polystyrene particles of just 
three sizes: 100 nm, 200 nm and 500 nm in diameter (manufacturer reported sizes) 
25, 36, 77, 79, 
100
. The smallest commercially available sizes are 20 nm and 40 nm in diameter. 20 nm, 40 
nm, 100 nm and 200 nm diameter yellow/green fluorescent, carboxylate-modified, 
polystyrene nanoparticles (Molecular Probes, Inc), as shown in Figure 2.2, were therefore 
used for this study. These nanoparticles were used for vertical diffusion chamber experiments 
as described in Chapter 4 and multiple particle tracking experiments as described in Chapter 
5.  
 
hydrophobic head group 
hydrophilic tail group 
lipids 
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Four nanoparticle sizes is sufficient to obtain a fair indication of the size dependence of 
nanoparticle behaviour, but, a systematic correlation would require at least five different sizes. 
This is because establishing the line of best fit for a correlation is more accurate with five data 
points or more. Unfortunately, other fluorescent, carboxylate-modified, polystyrene 
nanoparticle sizes less than 200 nm in diameter were not commercially available. The multiple 
particle tracking experiments carried out with the four available nanoparticle sizes, as 
discussed in Section 5.5.1, showed that the area of interest, which required further 
investigation, was the diffusion of nanoparticles less than ~50 nm in diameter. As polystyrene 
nanoparticles were not commercially available in that size range, microemulsion 
polymerisation was considered as a procedure for synthesising the required fluorescent, 
carboxylate-modified polystyrene nanoparticles. Unfortunately, examination of the literature 
on microemulsion polymerisation 
112, 113
 showed that the smallest polystyrene nanoparticles 
that could be synthesised were ~20nm in diameter (as measured by TEM) 
112, 113
. This 
technique could therefore not be used to obtain the polystyrene nanoparticles in the size-range 
needed. Therefore, other possible sources of nanoparticles had to be considered. No other 
manufacturers could provide a set of five defined nanoparticle sizes less than 200 nm in 
diameter, which is the size range of interest for this study. 
  
The closest available solution were carboxylate-modified quantum dot nanoparticles (QD-NP-
COOH) manufactured by Molecular Probes, Figure 2.2. These quantum dot nanoparticles also 
have carboxylate-modified surfaces, are fluorescent and 12.5 nm in diameter, therefore 
suitable for experiments. The quantum dot nanoparticles used were 705 nm emitting 
CdTe/ZnS quantum dots with a core diameter of ~5 nm, coated by a polymer and 2000Da 
weight PEG chains bearing carboxylate groups at their extremities 
114
. The fluorescent, 
carboxylate-modified, polystyrene and quantum dot nanoparticles were carefully characterised 
to ensure their suitability for obtaining a correlation of nanoparticle size against diffusivity.  
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Figure 2.2: A diagram showing the carboxylate-modified polystyrene and quantum dot nanoparticles with relative 
sizes. The polystyrene nanoparticles have carboxylate functional groups on the surface. The quantum dot 
nanoparticles have PEG2000 chains with carboxylate functional groups on the end.  
 
The commercially purchased carboxylate-modified quantum dot nanoparticles (QD-NP-
COOH) and carboxylate-modified polystyrene nanoparticles (PS-NP-COOH) were 
characterised using dynamic light scattering (DLS). The zeta potential of the quantum dots 
and nanoparticles was determined using laser Doppler electrophoresis. Both the size and zeta 
potential of the nanoparticles were measured using a Zetasizer (Malvern, UK).  
 
 
2.1 Dynamic Light Scattering 
 
Dynamic light scattering is a particle sizing technique based on the notion that larger particles 
have slower diffusive motion 
115
. The manufacturer-reported nanoparticle diameters were 
measured using Transmission Electron Microscopy which measures the core size of dry 
particles. Once in solution, particles acquire a slightly larger hydrodynamic diameter which 
encompasses the ions affiliated to the particle for stabilization. DLS measures this effective 
hydrodynamic radius, which is more relevant for this study, as the nanoparticles are used in 
solution.  
 
DLS measures fluctuations in the intensity of light scattered by the particles during Brownian 
motion in the sample cell. The rate at which these intensity fluctuations occur depends on the 
20 nm-200 nm 12.5 nm 
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particle size; small, faster moving particles cause the intensity to fluctuate more rapidly than 
large, slower moving particles 
116
. The intensity signal from the sample is auto-correlated by 
comparing the intensity value at time t, to time t+δt, t+2δt, and so on. Perfect correlation is 
indicated by unity (1.00) and no correlation is indicated by zero (0.00) 
115
. The auto-
correlation function of a signal from a random source will decrease with time, until at some 
time, effectively t=∞, there will be no correlation. If the particles are large, the signal will be 
changing slowly and the correlation will persist for a long time, Figure 2.3.a. If the particles 
are small and moving rapidly then the correlation will reduce more quickly, Figure 2.3.b. 
 
 
 
Figure 2.3: Representations of the autocorrelation functions for a) large particles and b) small particles. The rate at 
which the correlation reduces indicates the size of the nanoparticles. The steepness of the drop gives the 
polydispersity 115, 116. 
 
a) 
b) 
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The time at which the correlation starts to significantly decay is an indication of the mean size 
of the sample 
116
. More monodisperse samples have a steeper line of decay. The size is 
obtained from the auto-correlation function by a fit to either one single exponential, or 
multiple exponentials, giving the mean particle size and an estimate of the size distribution. 
An autocorrelation function G(τ) is constructed of the scattered intensity, where τ is a short 
time interval, Equation 7 
116
. 
                                                           (Equation 7) 
For a large number of monodisperse particles, the autocorrelation function is an exponential 
decaying function, Equation 8 
116
, 
                                                              (Equation 8) 
  where, D is the diffusion coefficient: 
                                                        (Equation 9) 
and, n is the refractive index, λ0 is the laser wavelength and θ is the scattering angle: 
  
   
  
    
 
 
                                                     (Equation 10) 
 
The mean hydrodynamic radius of the sample determined from the diffusion coefficient using 
the Stokes-Einstein equation, Equation 1. For a polydisperse sample G(τ) is the sum of all the 
exponential decays contained in the auto-correlation function, giving the size distribution as a 
function of light intensity. This representation of the data is appropriate if the distribution is a 
single fairly smooth peak, denoting a small distribution. However, according to the theory of 
Raleigh scattering 
82
, I α d6, where I is the intensity of light scattered and d is the particle 
diameter. Hence larger particles scatter more light than smaller particles 
82
. If the sample 
contains a wide range of particle sizes, the distribution will show a substantial tail, or more 
than one peak. As can be seen in Figure 2.4, representation of the data as a function of 
intensity can be very misleading if the sample contains more than one particle size or the 
possibility of aggregates as the smaller particles are largely under-represented. Figure 2.4 
shows an example case of a sample in which two populations of particles 5 nm and 50 nm in 
diameter are present in equal proportions. Due to the higher light scattering intensity of the 50 
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nm particles, there appear to be solely 50 nm particles in the sample in an intensity 
distribution representation.  
 
  
Figure 2.4: Graphs showing particle size distribution as represented by a) intensity and b) number as obtained 
from dynamic light scattering using a zetasizer. 
 
Using Mie Theory the size distribution can be determined as a function of the particle number 
of each size, which is a truer representation of the distribution. This subtle difference can 
easily produce misleading size distributions and the style of data presentation must be 
carefully selected for the sample population.  
 
 
2.2  Carboxylate-Modified Nanoparticle Sizing using DLS 
 
Dynamic light scattering was used to determine the hydrodynamic diameter of carboxylate-
modified quantum dots and polystyrene nanoparticles, as described in Section 2.1. Five 
different carboxylate-modified nanoparticle sizes were chosen for the diffusion experiments. 
Sizing experiments were carried out in triplicate as described in Section 7.4. The nanoparticle 
radius distribution by number are shown in Figure 2.5. 
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Figure 2.5: A diagram showing the number distribution of measured nanoparticle radii for each nanoparticles size. 
The size experiments were carried out in triplicate as shown by the three peaks of different colours.  
 
Figure 2.5, shows the number of nanoparticles of each size within the sample (the „Number 
Distribution‟). The width of the distribution shows the variance in nanoparticle radii within 
the nanoparticle sample. A sharper distribution peak signifies a more monodisperse 
population. The graphs in Figure 2.4 show the distribution for each of the three measurements 
QD-NP-COOH – 12.5 nm
PS-NP-COOH(27) – 27.15 nm
PS-NP-COOH(44) – 44.35 nm
PS-NP-COOH(89) – 88.73 nm
PS-NP-COOH(200) – 200.43 nm
diameter 
diameter 
diameter 
diameter 
diameter 
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taken for each size. As can clearly be seen, the differences between repeat measurements 
become smaller as the nanoparticle size increases. This reflects the stability and 
monodispersity of the samples. The larger nanoparticle distributions are also sharper than 
those of the smaller nanoparticles. These factors all show that the larger nanoparticle samples 
are more monodisperse and have less tendency to aggregate. The higher variance in the 
distribution of the smaller nanoparticles is due to the continuous aggregation and 
disaggregation of the nanoparticles in solution, which continuously changes the measured 
sizes of the nanoparticles within the samples. This is why repeat measurements and averages 
of the repeats are necessary to obtain an accurate estimation of the mean nanoparticle size. A 
summary of the average size and polydispersity measurements determined from the three 
repeat measurements is shown in Table 2.1. The polydispersity is the width of the particle size 
distribution. As noted above, the manufacturer-reported nanoparticle diameters were 
measured using Transition Electron Microscopy which measures the dry nanoparticles. The 
nanoparticle diameters as measured by dynamic light scattering can be seen to be a little larger 
than the manufacturer-reported sizes. This is due to the differences in the measurement 
techniques. The size of principle interest for this study is the hydrodynamic diameter, as 
measured by DLS, because the quantum dots and nanoparticles will be in aqueous solution 
during the experimental procedure. 
 
Particle Manufacturer
Reported 
Diameter (nm) 
Measured 
Diameter (nm) 
Polydispersity 
Index 
QD-NP-COOH - 12.5 + 1.82 0.375 + 0.455 
PS-NP-COOH(27) 20 27.15 + 1.70 0.294 + 0.023 
PS-NP-COOH(44) 40 44.35 + 2.25 0.433 + 0.093 
PS-NP-COOH(89) 100 88.73  + 1.94 0.026 + 0.010 
PS-NP-COOH(200) 200 200.43 + 1.30 0.022 + 0.004 
 
Table 2.1: Manufacturer-reported & measured nanoparticle diameters and polydispersity of all five carboxylate-
modified polystyrene and quantum dot nanoparticle samples. The measured diameter and polydispersity values are 
based on an average of three repeated measurements. 
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The polydispersity index is a measure of the variance in nanoparticle size within the sample; 
values closer to zero denote a more monodisperse sample. Samples become more polydisperse 
due to a greather variation in the discrete particle size or through aggregation of the 
nanoparticles. As can be seen from Table 2.1 and Figure 2.5 the larger 89 nm and 200 nm 
diameter particles are very monodisperse and suggest less aggregation in solution. The 
polystyrene and quantum dot nanoparticles less than 44 nm in diameter show a higher degree 
of polydispersity. This is for two reasons; a higher tendency to aggregate due to instability in 
solution and because regulation of nanoparticle size at this scale during synthesis is more 
difficult to achieve.  
 
 
2.3  Measurement of Carboxylate-Modified Nanoparticle Zeta Potential 
 
A Zetasizer instrument (Malvern, UK) was used to measure the zeta potential of the 
nanoparticles. It is measured by Laser Doppler Electrophoresis. In this technique, a voltage is 
applied across a pair of electrodes at either end of a cell containing the particle dispersion 
117
. 
Charged particles are attracted to the oppositely charged electrode and their motion can be 
used to determine their charge. The speed at which they move to the electrode depends on the 
strength of the surface charge. Light scattered by the moving particle experiences a frequency 
shift, the size of which depends on the mobility of the nanoparticle 
117
. The zeta potential is 
calculated from this frequency shift. 
 
Nanoparticle Measured 
Diameter (nm) 
Polydispersity 
Index 
Zeta Potential 
(mV) 
QD-NP-COOH 12.5 + 1.825 0.375 + 0.455 -42.60 + 2.762 
PS-NP-COOH(27) 27.15 + 1.704 0.294 + 0.023 -14.45 + 0.472 
PS-NP-COOH(44) 44.35 + 2.259 0.433 + 0.093 -15.63 + 0.305 
PS-NP-COOH(89) 88.73  + 1.945 0.026 + 0.010 -37.00 + 1.734 
PS-NP-COOH(200) 200.43 + 1.305 0.022 + 0.004 -60.63 + 2.551 
 
Table 2.2: Measured nanoparticle diameters and zeta potential of all five carboxylate-modified quantum dot and 
nanoparticle samples. All nanoparticles have a negative surface charge.  
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The zeta potential of the nanoparticles was measured using Laser Doppler Electrophoresis, as 
outlined in Section 7.5. The zeta potential measurements are shown in Table 2.2, each 
obtained from the average of three repeat measurements. The zeta potential is a measure of the 
surface charge of the quantum dot and polystyrene nanoparticles, which can all be seen to be 
negative for carboxylate-modified nanoparticles, Table 2.2. Although for the polystyrene 
nanoparticles, surface charge decreases with decreasing size, the quantum dots have a slightly 
more negative charge. This is a characteristic which should be taken into consideration when 
examining the calculated diffusion coefficient values from multiple particle tracking. 
 
 
2.4  Surface Modification of Quantum Dot Nanoparticles 
 
The use of fluorescent, carboxylate-modified polystyrene and quantum dot nanoparticles 
allows investigation into the diffusion of negatively charged nanoparticles through mucus. As 
discussed in Section 1.6.5, PEGylation has emerged as a method for enhancing particle 
diffusivity by reducing particle interaction with the mucus environment 
41
. This in turn can 
then improve the bioavailability and pharmacokinetics of therapeutic agents 
108
. PEGylation of 
nanoparticulate drug carriers has also been shown to enhance particle diffusion through 
human mucus samples 
81, 110, 111
. PEGylation is the process by which molecules of activated 
polyethylene glycols chemically react with a particle to cover the surface with a „brush‟ of 
PEG chains 
41, 108
. Coating nanoparticles with PEG neutralises their surface charge.  This type 
of particle coating was inspired by the ability of viruses to traverse human mucus samples 
rapidly, as reported by Olmsted et al. 
76
, due to their small size and net-neutral surface 
properties 
76, 81, 109, 111
. Another focus of this study is to understand the effects of PEGylation 
on nanoparticle diffusion, to understand if PEGylation provides significantly improved 
diffusivity. The overall aim is to understand the contributing effects of size and surface charge 
to understand which characteristic has the greatest effect on nanoparticle diffusivity through 
mucus.  
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Commercially available quantum dot and polystyrene nanoparticles were therefore surface 
modified to obtain a wider range of nanoparticle sizes for multiple particle tracking 
experiments and to investigate the effects of PEGylation on nanoparticle diffusivity through 
mucus samples. Fluorescent (yellow-green), carboxylate-modified, polystyrene nanoparticles 
were only commercially available in four different sizes, therefore to obtain a wider range of 
PEGylated nanoparticles, amino functionalised quantum dots were coated with PEG chains of 
750 Da and 5000 Da using amide-coupling biconjugate techniques. This gave a total range of 
six sizes, four PEGylated polystyrene nanoparticles and two PEGylated quantum dot 
nanoparticles, all with the same surface chemistry.    
 
2.4.1  Quantum Dot Nanoparticle PEGylation 
The quantum dot nanoparticles used were 705 nm emitting CdTe/ZnS quantum dots with a 
core diameter of ~5 nm, coated by a polymer and 2000 Da weight PEG chains bearing amino 
groups at their extremities 
114
. These quantum dot nanoparticles were then further 
functionalised to obtain quantum dots coated by methoxy-PEG chains of 750 Da and 5000 Da, 
to obtain PEGylated quantum dot nanoparticles with two difference sizes. The PEGylation 
protocol used, Figure 2.6, was as outlined by Daou et al. 
114
, described in Section 7.2. 
 
Figure 2.6: A schematic showing the amide coupling bioconjugate PEGylation of amino-modified CdTe/ZnS 
quantum dots with a core diameter of ~5 nm with PEG750 and PEG5000. The PEGylation protocol used was as 
outlined by Daou et al. 114, described in Section 7.2. 
45 
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Briefly, the quantum dots, 8 μM supplied in borate buffer (50 mM pH 8.3), were first 
exchanged against mucus buffer (85 mM Na
+
, 75 mM Cl
-
, 3 mM Ca
2+
, 20 mM HEPES, pH 
7.4) using a Microcon YM100 spin column. 1 μmol of the methoxy-PEG dissolved in 875 μL 
anhydrous DMSO was then added to 125 μL of the quantum dots solution. The mixture was 
stirred for 30 minutes in the dark at room temperature. The resulting PEGylated quantum dots 
were then dialysed overnight against mucus buffer to purify the sample and remove and un-
reacted PEG chains. The PEGylated quantum dots were then characterised using dynamic 
light scattering, Section 2.1.   
 
2.4.2  PEGylated Quantum Dot Nanoparticle Sizing 
Amino-modified quantum dot nanoparticles (QD-NP-NH2) PEGylated with PEG750 (QD-NP-
PEG750) and PEG5000 (QD-NP-PEG5000) were sized, using dynamic light scattering to 
determine the hydrodynamic diameter as described in Section 2.1, see Section 7.4 for detailed 
description. The addition of PEG chains to the surface of the quantum dots using amide-
coupling bioconjugation will increase the nanoparticle diameter due to the additional bulk of 
the PEG chain. This can be seen from the schematic in Figure 2.6 showing both the amino-
modified quantum dot nanoparticle (QD-NP-NH2) and the PEGylated quantum dot 
nanoparticle (QD-NP-PEG) with the larger PEG chain attached, after coupling.  
 
Sizing of the PEGylated quantum dot nanoparticles is an important measurement to determine 
whether PEGylation has occurred. Coupling of the PEG chains to the quantum dot 
nanoparticle surface leads to a significant and measureable increase in the nanoparticle 
diameter depending on the length of PEG chain attached.  The PEGylated nanoparticle radius 
distributions by number are shown in Figure 2.7. From these distributions the increase in 
nanoparticle size due to the addition of the PEG chains can clearly be seen. 
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As expected the QD-NP-PEG5000 quantum dot nanoparticles are larger than the QD-NP-
PEG750 quantum dot nanoparticles due to the larger length of the PEG5000 chains. 
Importantly, the distributions of each repeat measurement are closer for the PEGylated 
quantum dot nanoparticles than for the amino-modified quantum dot nanoparticles, this is due 
to the decreased effects of aggregation that occur from the neutralisation of the surface charge 
by the addition of the PEG layer. A summary of the average size and polydispersity 
measurements obtained from the three repeat measurements is shown in Table 2.3; a clear 
increase in nanoparticle diameter due to PEGylation is evident.  
 
 
 
 
Figure 2.7: A diagram showing the number distribution of measured nanoparticle radii for each nanoparticles size. 
The size experiments were carried out in triplicate as shown by the three peaks of different colours.  
 
 
 
Before PEGylation: 
QD-NP-COOH – 16.69 nm
After PEGylation with PEG750: 
QD-NP-PEG750 – 27.53 nm
After PEGylation with PEG5000:
QD-NP-PEG5000 – 35.81 nm
diameter 
diameter 
diameter 
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Nanoparticle 
Un-PEGylated 
Diameter (nm) 
PEGylated 
Diameter (nm) 
Polydispersity 
Index 
QD-NP-NH2 16.69 + 2.477 - 0.339 + 0.048 
QD-NP-PEG750 16.69 + 2.477 27.53 + 1.63 0.438 + 0.076 
QD-NP-PEG5000 16.69 + 2.477 35.81 + 1.88 0.509 + 0.095 
 
Table 2.3: Shows the measured diameters and polydispersity of the un-PEGylated and PEGylated quantum dot 
nanoparticles. All nanoparticles can be seen to have increased in diameter due to the addition of a PEG layer. 
 
The approximate increase in diameter due to the addition of 750 Da methoxy-PEG to the 
surface of the quantum dot nanoparticles was ~11 nm. The approximate increase in diameter 
due to the addition of 5000 Da methoxy-PEG to the surface of the quantum dot nanoparticles 
was ~22 nm. The quantum dot nanoparticles can be seen to have polydispersity index values 
close to or slightly greater than the original carboxylate-modified nanoparticle samples, Table 
2.3. A small increase in the polydispersity index would be expected through PEGylation as the 
PEG chains themselves are slightly varied in length, and because PEGylation of aggregates 
may occur during the PEGylation process if some of the quantum dot nanoparticles are in an 
aggregated state. Lengthy sonication of the quantum dot solutions was carried before 
PEGylation to reduce the effects of aggregation. However, as can be seen from the 
distribution of nanoparticle sizes in Figure 2.7, there was a deviation of some 2.5 nm about 
the mean particle size of 16.69 nm. This variance occurs because it is difficult to prepare 
quantum dots with exactly the same size. 
 
2.4.3  Zeta Potential Measurements of PEGylated Quantum Dot Nanoparticles  
The zeta potential of the PEGylated quantum dot nanoparticles (QD-NP-PEG) was measured 
using laser Doppler electrophoresis, as outlined in Section 2.3. Measuring the zeta potential of 
the PEGylated quantum dot nanoparticles is also an important measurement to determine 
whether PEGylation has occurred. Coupling of the PEG chains to the quantum dot 
nanoparticle surface leads to significant and measureable neutralisation of the surface charge 
of the quantum dot nanoparticles. This occurs because the methoxyl end-group of the PEG 
chain is neutrally charged. The commercially bought quantum dot nanoparticles used for 
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PEGylation have amino end groups and therefore carry a positive charge. These quantum dot 
nanoparticles are different to the carboxylate-modified nanoparticles previously mentioned. 
The positively charged amino-modified quantum dot nanoparticles were used for PEGylation 
to comply with the PEGylation protocol outlined by Daou et al. 
114
, as outlined in Section 
2.4.1. The zeta potential measurements of the quantum dot nanoparticles pre- and post-
coupling with PEG are shown in Table 2.4. The zeta potential values clearly show that 
PEGylation results in neutralisation of the quantum dot nanoparticle surface charge, verifying 
that PEGylation has occurred.   
  
Nanoparticle Diameter (nm) 
Un-PEGylated 
Zeta Potential 
(mV) 
PEGylated 
Zeta Potential 
(mV) 
QD-NP-NH2 16.69 + 2.477 +11.35 + 0.537 - 
QD-NP-PEG750 27.53 + 1.639 +11.35 + 0.537 +0.11 + 0.832 
QD-NP-PEG5000 35.81 + 1.881 +11.35 + 0.537 +3.43 + 0.569 
 
Table 2.4: The measured diameters and zeta potential of the PEGylated quantum dot nanoparticle samples. The 
surface charge is largely neutralised after PEGylation. 
 
 
2.5  Surface Modification of Polystyrene Nanoparticles 
 
To obtain a sufficiently wide range of neutrally charged nanoparticle sizes for multiple 
particle tracking experiments, four differently sized fluorescent, carboxylate-modified 
polystyrene nanoparticles were coated by methoxy-PEG chains of 750 Da. The PEGylation 
protocol used was a modification of the protocol outlined by Lai et al. 
81
, shown in Figure 2.8, 
and described in detail in Section 7.3. Briefly, the nanoparticles, supplied in 2 % Azide 
solution were first exchanged against mucus buffer (85 mM Na
+
, 75 mM Cl
-
, 3 mM Ca
2+
, 20 
mM HEPES, pH 7.4) using a Microcon YM100 spin column. 20 mg methoxy-PEG (750 Da) 
was dissolved in 1 mL of 50 mM 2-(N-morpholino) ethanesulfonic acid (MES) buffer (pH 
6.0). This was then added to 1 mL (2 % solids) of the carboxylate-modified, polystyrene 
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nanoparticles and stirred for 15 minutes at room temperature. To this mixture, 8 mg of EDC 
was added and the solution pH was adjusted to 6.5 with dilute NaOH. The mixture was stirred 
for 2 hours in the dark at room temperature. The reaction was then quenched by adding 7.5 
mg glycine and then stirring for 30 minutes at room temperature. The PEGylated 
nanoparticles were purified by overnight dialysis against mucus buffer. They were then 
characterised using dynamic light scattering, Section 2.1. 
 
 
 
Figure 2.8: A schematic showing the amide coupling bioconjugate PEGylation of fluorescent, carboxylate-
modified polystyrene nanoparticles with core diameters of ~5 nm with PEG750, n=45. The PEGylation protocol 
used was a modification of the protocol outlines by Lai et al. 81, as described in Section 7.1. 
 
2.5.1  PEGylated Nanoparticle and Quantum Dot Characterisation 
Dynamic light scattering was used to determine the hydrodynamic diameter of PEGylated 
polystyrene nanoparticles, as described in Section 2.1. Four different PEGylated polystyrene 
nanoparticle sizes were synthesised for diffusion experiments, along with the two PEGylated 
quantum dot nanoparticles, giving a total of six different PEGylated nanoparticle sizes for 
multiple particle tracking experiments, each having the same surface functionalisation. The 
size measurements shown in Figures 2.9.a and 2.9.b are summarised in Table 2.5, which 
shows the change in nanoparticle diameter caused by the PEGylation process.  
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The increase in diameter due to the addition of 750Da methoxy-PEG to the surfaces of the 
nanoparticles ranged from ~14 nm-25 nm and was 19.5 nm on average. This is therefore an 
additional layer of ~10 nm all around the nanoparticles. Once again the polydispersity index 
of the larger 112 nm and 219 nm diameter particles was very low, due mainly to the 
monodispersity of the original carboxylate-modified particle populations, Table 2.5, before 
PEGylation. The nanoparticles and quantum dots less than 60 nm in diameter can be seen to 
have polydispersity index values close to or slightly lower than the original carboxylate-
modified nanoparticle samples, Table 2.5.  
 
 
 
Figure 2.9.a: A diagram showing the size distribution of 27 nm and 44 nm polystyrene nanoparticles before and 
after PEGylation. The size experiments were carried out in triplicate as shown by the three peaks of different 
colours.  
Before PEGylation: 
PS-NP-COOH(27) – 27.15 nm
After PEGylation with PEG750: 
PS-NP(27)-PEG750 – 51.23 nm
Before PEGylation: 
PS-NP-COOH(44) – 44.35 nm
After PEGylation with PEG750: 
PS-NP(44)-PEG750 – 60.12 nm
diameter 
diameter 
diameter 
diameter 
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Figure 2.9.b: A diagram showing the size distribution of 89 nm and 200 nm polystyrene nanoparticles before and 
after PEGylation. The size experiments were carried out in triplicate as shown by the three peaks of different 
colours.  
 
 
The decrease in the polydispersity index is an effect of less aggregation due to the neutral 
surface charge of the PEGylated nanoparticles. This effect can be seen to be substantial for the 
44 nm diameter nanoparticles, as the polydispersity index has decreased from 0.433 to 0.158. 
However for the 27 nm diameter nanoparticles there is no large change in the polydispersity 
index. This could be because the nanoparticles aggregated before PEGylation occurred, 
leading to some conjoined nanoparticles with a PEGylated surface A degree of polydispersity 
will arise from the variation in the length of the PEG chains themselves. 
 
Before PEGylation: 
PS-NP-COOH(89) – 88.73 nm
After PEGylation with PEG750: 
PS-NP(89)-PEG750 – 112.23 nm
Before PEGylation: 
PS-NP-COOH(200)
200.43 nm
After PEGylation (PEG750): 
PS-NP(200)-PEG750
219.17 nm
diameter 
diameter 
diameter 
diameter 
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Nanoparticle 
Un-PEGylated 
Diameter (nm) 
PEGylated 
Diameter (nm) 
Un-PEGylated 
Polydispersity 
Index 
PEGylated 
Polydispersity 
Index 
PS-NP(27)-PEG750 27.15 + 1.70 51.23 + 6.14 0.294 + 0.023 0.241 + 0.032 
PS-NP(44)-PEG750 44.35 + 2.25 60.12 + 2.87 0.433 + 0.093 0.158 + 0.029 
PS-NP(89)-PEG750 88.73  + 1.94 112.23 + 1.45 0.026 + 0.010 0.021 + 0.008 
PS-NP(200)-PEG750 200.43 + 1.30 219.17 + 1.00 0.022 + 0.004 0.016 + 0.013 
 
Table 2.5: Shows the measured diameters and polydispersity of all four PEGylated polystyrene nanoparticle 
samples. All nanoparticles can be seen to have increased in diameter through PEGylation. 
 
Looking at the nanoparticle radius distributions by number for both the un-PEGylated and 
PEGylated polystyrene nanoparticles together, as shown in Figure 2.9, gives an idea of the 
increase in nanoparticle size due to PEGylation and allows one to compare the width of the 
distributions and the sharpness of the distribution peaks. From the polydispersity index values 
of the 44 nm diameter nanoparticles, Table 2.5, it appears that the relatively high 
polydispersity index is a result of a portion of the nanoparticles being aggregated before 
PEGylation, with an even larger proportion of 27 nm nanoparticles appearing to have 
aggregated before PEGylation. Aggregation leads to larger, non-spherical nanoparticles within 
the sample. Dynamic light scattering determines the hydrodynamic diameter of these non-
spherical particles as the diameter of sphere with the same diffusion speed as the aggregated 
particle. The very low polydispersity index of the larger 89nm and 200nm nanoparticles 
reflects the effects of the variation in PEG length and variance in size from the synthesis of 
the nanoparticles.  
 
2.5.2  Zeta Potential Measurements of PEGylated Quantum Dot Nanoparticles  
The zeta potential of the PEGylated polystyrene nanoparticles was measured using Laser 
Doppler Electrophoresis, as outlined in Section 2.3. As discussed in Section 2.4.3, 
measurement of the zeta potential is an important method to determine whether PEGylation 
has been successful. The changes in the nanoparticle zeta potential due to PEGylation are 
shown in Table 2.6. The large increase in the zeta potential of all nanoparticles to near-neutral 
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through PEGylation shows that a dense surface coverage of the nanoparticles was achieved. 
The PEGylated polystyrene nanoparticles have a similar surface charge to the PEGylated 
quantum dot nanoparticles which have zeta potentials of +0.11 mV and +3.43 mV for 
PEG750 and PEG5000 respectively.  
 
 Nanoparticle Diameter (nm) 
Un-PEGylated 
Zeta Potential 
(mV) 
PEGylated 
Zeta Potential 
(mV) 
PS-NP(27)-PEG750 51.23 + 6.14 -14.45 + 0.472 -3.60 + 1.02 
PS-NP(44)-PEG750 60.12 + 2.87 -15.63 + 0.305 -2.48 + 0.74 
PS-NP(89)-PEG750 112.23 + 1.45 -37.00 + 1.734 +1.79 + 0.19 
PS-NP(200)-PEG750 219.17 + 1.00 -60.63 + 2.551 +1.09 + 0.18 
 
Table 2.6: Shows the measured zeta potential of all four PEGylated quantum dot and nanoparticle samples. All 
nanoparticles can be seen have more neutral surface charges through PEGylation. 
 
 
2.6  Discussion 
 
Dynamic light scattering was used to measure the sizes of commercially available fluorescent, 
carboxylate-modified polystyrene and quantum dot nanoparticles. A series of five highly 
monodisperse and well-defined, negatively charged nanoparticle sizes were obtained for 
multiple particle tracking experiments to investigate the nature of their diffusion through 
mucus solutions. This series of nanoparticles are representative of the gene and drug delivery 
particles for which this study aims to investigate the effects of size on diffusivity. Dynamic 
light scattering was used to measure the hydrodynamic radius of the nanoparticles, as opposed 
to the manufacturer-reported sizes measured by transition electron microscopy. This is 
because TEM measures the dry diameter of the nanoparticles, the nanoparticles however 
acquire a slightly larger hydrodynamic diameter which encompasses the ions affiliated to the 
particle for stabilization once in solution. The nanoparticle sizes chosen for this study range 
from 12.5 nm – 220 nm in diameter, which is smaller than nanoparticles used for previous 
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studies. Previous studies have investigated the diffusivity of particles 100 nm in diameter and 
greater 
25, 36, 41, 77, 79, 100, 102
. The main focus of this study is the effect of nanoscale sizes less 
than 100 nm in diameter, on diffusivity through mucus but including particles up to 220 nm in 
diameter within the sample size range gives an overlap in the calculated diffusivity values of 
this study and previous studies, to allow comparisons to be made. 
 
The neutralisation of particle surface charge has emerged as a method for enhancing particle 
diffusivity through mucus, as discussed in Section 1.6.5. PEGylation, in particular, is a 
neutralisation technique which has received much interest and seen considerable success in 
previous studies for particles greater than 100nm in diameter. The effects of PEGylation have, 
however, not as yet been systematically investigated for nanoparticles less than 100 nm in 
diameter. Thus, to investigate the effects of PEGylation on the diffusion of nanoparticles less 
than 100 nm in diameter through mucus, commercially bought fluorescent, carboxylate-
modified polystyrene and quantum dot nanoparticles were PEGylated to obtain a size range of 
six nanoparticle sizes, ranging from 27.53 nm to 219.17 nm in diameter, with near neutral 
surface charges (-5 mV – 5 mV). The PEGylated nanoparticles synthesised are of similar sizes 
to the negatively charged carboxylate-modified nanoparticles so that comparisons can be 
made between the effects of neutral and negative surface charges on nanoparticle diffusivity 
through mucus. The PEGylation procedures used were as outlined in Section 7.2 and Section 
7.3. PEGylation can be seen to be successfully achieved from the increase in nanoparticle 
sizes as shown in Sections 2.4.2 and 2.5.1 and also from the neutralisation of the nanoparticle 
surface charge as shown in Sections 2.4.3 and 2.5.2.  
 
The nanoparticle characterisation and PEGylation experiments have produced a series of 
eleven monodisperse and well-defined nanoparticle sizes, up to 220 nm in diameter, of 
negative and neutral surface charges for investigation into the effects of nanoparticle size and 
surface charge on diffusivity through the complicated mucus mesh structure. This series of 
eleven nanoparticle sizes enables the systematic correlation of nanoparticle size with 
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diffusivity to determine if reducing the size of gene and drug delivery particles into the 
nanoscale can provide the benefits of enhanced diffusive ability. A better understanding of the 
correlation between nanoparticle size and diffusivity can provide information to researchers 
developing gene and drug delivery particles regarding what is needed to optimise diffusivity 
and enable the particles to efficiently pass through the mucus layer. This would improve the 
ability of delivery particles to reach the cells targeted for the correction of genetic diseases, 
such as cystic fibrosis.  
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CHAPTER 3: MODEL MUCUS PREPARATION  
AND CHARACTERISATION 
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Reconstituted mucus was used as a model system to exclude the potentially large effects of 
variability from patient samples, and to allow data reproducibility. The effects of the large 
degree of variation between human mucus samples on particle transport measurements poses 
an obstacle to the accurate analysis of particle transport in mucus. The high degree of 
variability in the chemical composition of mucus samples from patients can have 
unidentifiable effects on mucus viscoelasticity and particle adhesion, especially for patients 
affected by infection or inflammation. In addition to the mucin glycoproteins, protein, DNA 
and water, a large number of other constituents such as lipids, cellular and serum molecules, 
secreted immunoglobins, alginate, hyaluronan, electrolytes, microorganisms, plasma proteins 
and other debris of inflammatory response and sloughed cells are present in human mucus, 
although at lower concentrations 
25, 61, 62
.  The concentration of these constituents varies 
considerably between patient samples, and it is difficult to quantify their interaction with 
particles and their influence on particle transport. It is also difficult to quantitatively 
understand their effect on the mucus mesh structure and viscoelastic properties, due to the 
large number of parameters involved. 
 
For the aims of this study and to obtain a simplified and accurately measurable experimental 
setup, reconstituted model mucus samples were used. Reconstituted mucus has been used in a 
number of particle transport studies 
40, 73
, and it has been shown that the viscoelastic and gel 
forming properties of purified mucin are similar to native mucus samples 
118, 119
. Studies in 
reconstituted mucus can be used to develop a foundation of knowledge about particle 
transport in the mucus environment with a manageable, reduced number of parameters. Once 
enough information is gathered, the experimental observations of particle transport studies in 
human mucus samples could then be embarked upon from a position of greater understanding. 
The use of reconstituted mucus also eliminates the effects of sample handling, such as 
freezing/thawing which may alter the network properties of the mucus mesh structure 
25
. 
Human samples can also undergo physical degradation after collection through the action of 
endogenous and bacterial proteases 
120
. Sanders et al. 
25
, investigated these effects to find that 
  77 
the protease degradation results in decreased viscoelasticity of the mucus by cleavage of the 
protein backbone of mucin biopolymers 
25
. They found that mucus viscoelasticity dropped by 
more than 30 % after 2 hours of incubation at 37 °C 
25
. As shown in the study by Broughton-
Head et al. 
61
, breaking the mucus structure down into its most fundamental constituents offers 
a great deal of insight. Their study showed a concentration-dependent increase in the barrier 
function of DNA to fluorescent, carboxylate-modified polystyrene nanoparticle transport 
61
. 
Mucin also showed a concentration-dependent increase in the barrier function to particle 
transport. However, when mucin was combined with DNA, the effect was not cumulative, 
instead a significantly reduced barrier effect was observed compared to the barrier effect of 
DNA alone 
61
. From these observations they hypothesized that the addition of mucin to the 
homogeneous microporous DNA network may have rendered the barrier heterogeneous and 
macroporous resulting in the reduced barrier effect 
61
. A comprehensive, controlled 
understanding of the effects on mucus structure resulting from the combination of mucin and 
DNA would undoubtedly assist in understanding nanoparticle diffusion through mucus 
samples.   
 
 
3.1  Reconstitution of Model Mucus Samples 
 
Mucus was reconstituted as directed in a study carried out by Sanders et al. 
36, 74
. Sanders et al. 
36, 74
 conducted a study to determine the proportion of the mucus constituents; mucin, DNA 
and albumin present in mucus samples obtained from cystic fibrosis patients during routine 
respiratory therapy 
36, 74
. From this data they proposed a protocol to reconstitute model mucus 
which has similar consistency and viscoelasticity properties to the mucus samples obtained 
from cystic fibrosis patients and thus would be representative of real mucus from the 
perspective of particle transport 
40
. The reconstitution of mucus is fully described in Section 
7.7. Briefly, the model mucus was made by adding mucin (31 mg/mL), linear DNA (5.6 
mg/mL) and albumin (33 mg/mL) to 5.0 ml mucus buffer and stirring overnight (~16 hours) at 
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4 ºC. The mucus buffer mirrored the electrolyte composition in CF mucus 
74
. It contained 85 
mM Na
+
, 75 mM Cl
-
, 3 mM Ca
2+
, and 20 mM HEPES at pH 7.4, and was made using the 
procedure described in Section 7.6.  
 
Once the model mucus had been reconstituted, careful characterisation was important to 
ensure that the model mucus had the same structural and viscoelasticity properties as human 
mucus. Characterisation was carried about by rheology and fluorescence imaging to ensure 
that the model mucus samples had a complicated mesh structure representative of human 
mucus samples, as discussed in Sections 1.6.1 and 1.6.2. A rheometer was used to determine 
the viscoelastic properties of the model mucus and fluorescence imaging was used to image 
the structure of the mucin within the model mucus.  
 
3.1.1  Rheological Characterisation of Mucus 
The viscosity of a fluid describes its internal resistance to flow. The measured viscosity of 
human mucus samples from previous studies shows a high degree of variability between 
samples, as discussed in Section 1.3.1. It is therefore impossible to determine one absolute 
viscosity value for mucus, in the same way that it is impossible to determine an absolute pore 
size, as discussed in Section 1.6.2. The viscosity of the mucus samples therefore have to be 
carefully measured and taken into account when comparisons are made across different 
samples. At the macroscopic level, mucus is a non-Newtonian pseudo-plastic gel. This means 
that under low shear, it behaves like an elastic solid and regains shape over time; under high 
shear, it behaves like a viscous liquid eventually deforming irreversibly 
34, 42
.    
 
The viscosity of the reconstituted mucus samples was measured using a controlled-stress cone 
and plate rheometer (Physica, UDS 200), as described in Section 7.8. A 50 mm cone was used 
at 1 ° and a temperature of 21 °C. The shear viscosity and shearing stress (for thixotropy) of 
the sample was measured between shear rates of 0.01 s
-1
 and 1000 s
-1
. The viscosity is 
measured by placing the sample fluid onto the horizontal plate, the cone is then placed onto 
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the plate so that the angle between the surface of the cone and the plate is 1 °, as shown in 
Figure 3.1. The plate is rotated with increasing sheer rates, with the resulting force on the 
cone being continuously measured. 
 
Figure 3.1: A diagram of a controlled-stress cone and plate rheometer. The sample fluid is placed onto the 
horizontal plate, the cone is then placed onto the plate and rotated with increasing sheer rates, with the resulting 
force on the cone being continuously measured. 
 
Figure 3.2 shows the viscosity profile of the model mucus with increasing shear rates. The 
viscosity profile shows that the model mucus becomes thinner with increasing shear stress, 
which mimics the behaviour of human mucus as discussed in Section 1.3.1. At shear rates of 
10 s
-1 
(which mimic physiological shear rates 
121
) the bulk viscosity of the model mucus was 
measured to be ~1000 cP. The viscosity of water is 1 cP at 21 °C 
122
, the model mucus is 
therefore 1000 times the viscosity of water. 100 % glycerol is ~1300 cP at 21°C, 94 % 
glycerol is ~430 cP 
122
, similar to that of the model mucus. 
 
Figure 3.2: Viscosity profile of model mucus, as measured by a cone-plate rheometer at 21°C. At shear rates of 
10s-1 (which mimic physiological shear rates 121) the bulk viscosity of the model mucus was measured to be 
~1000cP. 
R = 50mm 
α = 1° 
T = 21°C 
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Figure 3.3: Thixotropy diagram showing pseudo-plastic behaviour of model mucus as measured by a 
cone-plate rheometer at 21°C. 
 
Shear-thinning is a property of pseudo-plastics such as mucus. The viscosity of the fluid 
decreases with shear rates, as can be seen from Figure 3.2, above 0.03 s
-1
.  The pseudoplastic 
characteristics of a fluid can be determined by examining its thixotropic profile, Figure 3.3. 
During thixotropic profiling, an increasing shear rate is applied to the plate and the resulting 
shear stress on the cone is continuously measured. The shear rate is increased up to a limit of 
1000 s
-1
, which is the range of interest for this study. The shear rate is then reduced, and the 
resulting shear stress on the cone is again continuously monitored. The difference between 
behaviour of the fluid during increasing and decreasing shear rates gives an indication of its 
pseudoplastic characteristics.     
 
A pseudoplastic is characterised by shear thinning behaviour as shown in Figure 3.2, the 
viscosity of the fluid decreases with increasing shear rates. Another characteristic of a 
pseudoplastic is that when the shear rate is increased and then subsequently reduced, the shear 
stress reduces at the same rate of the increase. This is shown in Figure 3.3, in which the 
forward and backward profiles of the relationship between the shear rate and the shear stress 
are the same. The model mucus solution therefore also behaves like a non-Newtonian pseudo 
plastic, like human mucus. The viscoelasticity properties of the model mucus solution can 
therefore be seen to match those of human mucus. 
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3.1.2  Fluorescence Staining of Mucin in Mucus Samples 
Once the viscoelasticity properties of the model mucus samples were characterised, it was 
necessary to investigate the structure of the model mucus samples. The model mucus samples 
should have the complicated mesh structure of human mucus as described in Section 1.6.1. As 
discussed in Section 1.6.2, using electron microscopy techniques to measure the mucus pore 
size has seen limited success due to the effects of the sample preparation 
61
. Fluorescence 
staining and microscopy was therefore used as a technique to examine the structure of the 
model mucus samples. As fluorescence microscopy measures the fluorescent signal of the 
mucin within the mucus samples, it cannot be used to accurately measure the size of pores in 
the mucus samples but it can show the nature of the model mucus structure.  
 
The model mucus samples were prepared as described in Section 3.1. Once prepared, the 
mucin within the model mucus was stained as described in Section 7.9. Briefly, 10 μL of the 
model mucus was placed on a microscope slide, using 100 % ethanol as a fixative. A TRITC 
(Tetramethyl Rhodamine Isothiocyanate) conjugate was used to bind to the mucin within the 
model mucus. The sample was then covered with a coverslip and sealed. Once bound to the 
mucin the TRITC can be imaged using fluorescent microscopy, showing the structure of the 
mucin within the model mucus sample. TRITC can be excited with a wavelength of 532 nm 
and the fluorescent signal can be detected between 610 nm and 630 nm. An image of the 
mucin structure within the 1xMUC model mucus can be seen in Figure 3.4. The image was 
obtained using a Zeiss Axiovert 200 inverted microscope with a 10x objective. The light areas 
in the image, Figure 3.4, show the presence of TRITC stained mucin. The 1xMUC model 
mucus structure can be seen to be complicated and porous (dark areas) and similarities can be 
seen between Figure 3.4 and the SEM and TEM images of mucus as obtained by Sanders et 
al. 
36
, Figure 1.9a and Saltzman et al. 
72
, Figure 1.9b. The fluorescent images unfortunately do 
not have the clarity or resolution of the electron microscopy images. The fluorescent images 
do however show that the 1xMUC model mucus solutions have a complicated mesh pore 
structure representative of human mucus. There are areas of varying mucin concentration and 
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areas in which there appears to be no obstacle to particle motion (dark areas). The mucin 
fibres can be seen to be long and entangled as would be expected from the discussion in 
Section 1.6.1. However, the resolution and clarity of the fluorescent imaging is such that 
individual fibres cannot be seen.  
  
 
Figure 3.4: A fluorescent microscopy image of the 1xMUC model mucus in which mucin fibres have been stained 
using a TRITC conjugate. Images were taken using a Zeiss Axiovert 200 Invert Microscope, with a 10x objective. 
 
 
3.2  Model Mucus Samples with Increased (8xMUC) Mucin Concentration 
 
During the course of multiple particle tracking experiments with carboxylate-modified 
nanoparticles, it became apparent that the smallest nanoparticles, 27 nm and 44 nm in 
diameter, could only be tracked for short times of ~5 seconds, as discussed in Section 5.5.1. 
This gave rise to errors in the diffusion coefficient calculation and precluded measurements of 
the smallest 12.5 nm diameter nanoparticles. Pilot studies showed that the 12.5 nm diameter 
nanoparticles diffused through the mucus samples faster than the 27 nm and 44 nm diameter 
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nanoparticles and the signal from these 12.5 nm diameter nanoparticles was therefore lost 
from the focal plane in less than 5 seconds. One solution to address this issue and make the 
smaller nanoparticles traceable for longer would be to increase the bulk viscosity of the model 
mucus sample. This would reduce the diffusivity of the smaller nanoparticles and allow them 
to be tracked for longer times. It would also allow investigation into the effect of mucin 
concentration on the diffusivity of the nanoparticles. For these reasons, another model mucus 
sample with 8x the mucin concentration (8xMUC) of the original model mucus (1xMUC) was 
reconstituted as described in Section 3.1. Briefly, the model mucus was made by adding 
mucin (248 mg/mL), linear DNA (5.6 mg/mL) and albumin (33 mg/mL) to 5.0 mL mucus 
buffer and stirring overnight (~16 hours) at 4 ºC. The mucus buffer used simulated the 
electrolyte composition in cystic fibrosis mucus 
74
. It contained 85 mM Na
+
, 75 mM Cl
-
, 3 
mM Ca
2+
, and 20 mM HEPES at pH 7.4 and was made as described in Section 7.6.  
 
Once the 8xMUC model mucus had been reconstituted, careful characterisation was again 
important to ensure that the model mucus had the same structural and viscoelasticity 
properties as human mucus, and to examine the difference between the 8xMUC and 1xMUC 
model mucus samples. Characterisation was carried about by rheology and fluorescence 
imaging to ensure that the model mucus samples had a complicated mesh structure 
representative of human mucus samples, as discussed in Sections 1.6.1 and 1.6.2.  
 
3.2.1  Rheological Characterisation of Mucus 
The viscosity of the reconstituted 8xMUC mucus samples was again measured using a 
controlled-stress cone and plate rheometer (Physica, UDS 200), as described in Section 7.8. A 
50mm cone was used at 1 ° and a temperature of 21 °C. The shear viscosity and shearing 
stress (for thixotropy) of the sample was measured between shear rates of 0.01 s
-1
 - 1000 s
-1
. 
At shear rates of 10 s
-1 
(which mimic physiological shear rates 
121
) the bulk viscosity of the 
model mucus was measured to be ~20,000 cP. This is 20,000 times the viscosity of water 
which is ~1 cP at 21°C 
122
. 
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3.2.2  Fluorescence Staining of Mucin in Mucus Samples 
Once the viscoelasticity properties of the 8xMUC model mucus samples were characterised, a 
TRITC conjugate was used to stain the mucins within the 8xMUC model mucus, and 
fluorescent microscopy was used to image the structure of the mucus. The 8xMUC model 
mucus samples were prepared as described in Section 3.1. Once prepared, the mucin within 
the model mucus was stained as described in Section 7.9. Briefly, 10 μL of the model mucus 
was placed on a microscope slide, using 100 % ethanol as a fixative. As previously 
mentioned, a TRITC (Tetramethyl Rhodamine Isothiocyanate) conjugate was used to bind to 
the mucin within the model mucus. The sample was then covered with a coverslip and sealed.  
 
 
Figure 3.5: A fluorescent microscopy image of the 8xMUC model mucus in which mucin fibres have been stained 
using a TRITC conjugate. Images were taken using a Zeiss Axiovert 200 Invert Microscope, with a 10x objective. 
 
An image of the mucin structure within the 8xMUC model mucus can be seen in Figure 3.5. 
The image was obtained using a Zeiss Axiovert 200 inverted microscope with a 10x objective. 
The light areas in the image, Figure 3.5, show the presence of TRITC stained mucin. The 
fluorescent image shows that the 8xMUC model mucus solutions have a complicated mesh 
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pore structure representative of human mucus, with areas of varying mucin concentration and 
the presence of pores. 
 
 
3.3  A Comparison of the Two Mucus Samples 
 
The images of the 1xMUC, in Figure 3.4, and 8xMUC, in Figure 3.5, model mucus samples 
show that both of the samples have a complicated mesh structure. The presence of pores in the 
mucus structure can clearly be seen and similarities with the SEM and TEM images, Figure 
1.9, can also be seen, although, the fluorescent images do not have the clarity and resolution 
of electron microscopy images. The 1xMUC and 8xMUC model mucus samples are 
representative of human mucus samples and were consequently selected for this work. 
Differences between the two samples can also be seen from the characterisations carried out in 
this chapter. The image of the 8xMUC, Figure 3.5, clearly shows the presence of an increased 
concentration of mucin covering the image. There are fewer pores (dark areas) in the image of 
the 8xMUC, Figure 3.5, and the average pore size appears smaller. In this work we 
investigate the differences in the diffusivity of the nanoparticles between the two samples and 
seek to establish whether the hindrance caused by the increased mucin concentration is 
proportional to the effective increase in the bulk viscosity. The overall bulk viscosity of the 
8xMUC model mucus is 20 times that of the 1xMUC model mucus. One important question 
we seek to answer is whether the pores in either of the model mucus samples have a cut-off 
for nanoparticle size, allowing nanoparticles smaller than the cut-off to diffuse faster through 
the mucus pores, whilst hindering the motion of nanoparticle sizes larger than the cut-off.  
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CHAPTER 4: VERTICAL DIFFUSION CHAMBERS 
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The first experimental technique investigated for measuring nanoparticle diffusion through 
mucus, used vertical diffusion chambers. This choice was made as vertical diffusion chambers 
had previously been used for many diffusion studies and appeared to be promising apparatus 
40, 75
. At the time the studies using vertical diffusion chambers were started, multiple particle 
tracking was also piloted as a technique. However imaging and tracking of the smaller 27 nm 
and 44 nm nanoparticles was impossible due to the low intensity of the nanoparticles‟ 
fluorescence signal and the lack of a camera fast enough camera for capturing MPT movies, 
with the only available camera to me offering frame rates of just 7 frames per second. Vertical 
diffusion chambers could overcome the problems surrounding multiple particle tracking, 
because (although low) the fluorescent signals of even the smallest nanoparticles could be 
measured with a spectrofluorophotometer, as described in Section 4.1.2. Measurements 
involving 27 nm, 44 nm and 89 nm diameter polystyrene nanoparticles through the 1xMUC 
model mucus are described in this Chapter. At the time this work was undertaken, the 200 nm 
diameter particles had not yet been purchased as the main aim of the study was to investigate 
the diffusive properties of nanoparticles less than 100 nm in diameter. This study was also 
carried out before the quantum dot nanoparticles were purchased and PEGylated. 
Unfortunately, as explained below, the technique was found to be rather unreliable and was 
ultimately abandoned in favour of multiple particle tracking, which became feasible with the 
arrival of new imaging equipment at the Facility for Imaging by Light Microscopy (FILM) at 
Imperial College London, capable of imaging 27 nm and 44 nm diameter nanoparticles at 
frame rates of up to 32 frames per second. The vertical diffusion chamber measurements 
described in this chapter, although ultimately unsuccessful, are included here for completeness 
and to illustrate the limitations of the approach when applied to nanoparticles. This section 
also introduces some of the background theory relating to nanoparticle diffusion in a uniform 
media. 
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4.1  Experiments using Vertical Diffusion Chambers 
 
Vertical diffusion chambers are an old, yet frequently used apparatus for understanding 
particle diffusion through membrane barriers and have been widely used to study diffusion 
through mucus 
25, 40, 73, 89, 90
. A typical system consists of a donor compartment which is 
separated from an acceptor compartment by a membrane barrier through which diffusion is to 
be measured. 
 
4.1.1  Mucus Container Construction 
A „snapwell‟ is used to hold the test barrier in place between the donor and acceptor 
compartments. A snapwell is a device used for tissue culture, it contains a 12 mm tissue-
culture membrane supported on a plastic ring, Figure 4.1. As mucus is a fluid, and not a solid 
barrier, the snapwell holder had to be adapted for use with mucus by adding a „mucus 
container‟ to hold the sample between the donor and acceptor compartment, as shown in 
Figure 4.1. The mucus containers were a modified version of those proposed by Norris et al. 
73
.  The tissue-culture membrane in the snapwell was carefully removed with a scalpel. A 
washer shape was punched out of double-sided sticky tape, which was used to stick a 
polycarbonate membrane, with a pore size of 0.4 µm, to the snapwell. An additional washer, 
to provide the depth of the container, was made by placing four layers of laboratory parafilm 
on top of each other and covering each side with a layer of double-sided sticky tape.  
 
 
     
 
polycarbonate membranes snapwell 
double-sided sticky tape washers 
parafilm washer 
mucus 
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Figure 4.1: A schematic of ‘mucus container’ construction and attachment to the snapwell, for containment of the 
mucus sample 73. 
The washer shape was then punched out of these layers to give a self-adhesive washer with a 
depth of approximately 0.5 mm, an internal radius of 5.0 mm and an external radius of 6.0 
mm. These parafilm washers were attached to a second polycarbonate membrane using the 
double-sided sticky tape on one side. The sample 1xMUC model mucus was then placed 
inside the parafilm washer, and sealed with the other polycarbonate membrane, attached to the 
snapwell using the double-sided sticky tape, as shown in Figure 4.1 and Figure 4.2.   
 
 
Figure 4.2: Photographs showing the snapwell with parafilm rings and polycarbonate membranes used to construct 
the mucus container for vertical diffusion chamber experiments. 
 
The polycarbonate membranes used for the construction of the mucus packets were chosen 
with a pore size of 0.4 µm. This was to overcome problems regarding mucus leakage from the 
mucus packet into the donor and acceptor compartments. The study by Norris et al. 
73
, 
evaluated the loss of mucin from the mucus packet using varying pore sizes. Their 
investigation showed that 90 %-95 % of mucus could be retained with a pore size of 1.0 µm, 
Norris et al. 
73
 experimented with nanoparticles up to 1.1 µm, and therefore needed a larger 
pore size to allow nanoparticles to diffuse through unhindered. As the largest nanoparticle size 
for our study was 89 nm in diameter, the pore size of the polycarbonate membrane could be 
reduced, attempting to allow virtually unhindered diffusion of the nanoparticles whilst 
retaining more of the mucus within the container. A pore size of 0.4 µm was chosen to ensure 
flexibility for future experiments involving larger nanoparticles. 
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 4.1.2  Nanoparticle Solutions 
Nanoparticle solutions were supplied in varying concentrations in distilled water with Na2N3 
(for bacterial inhibition). For comparability between the diffusion experiments, the initial 
nanoparticle concentration in the donor compartment (measured in nanoparticle/mL) was set 
to be the same for each nanoparticle size. The nanoparticle solutions were made by diluting 
the stock solutions in the mucus buffer. The initial nanoparticle concentration was set at 
1.08x10
12  
nanoparticles/ml. This concentration was chosen based on the results of calibration 
and pilot studies of the vertical diffusion chamber technique, which showed that a readily 
measureable fluorescence signal could be obtained at this concentration after allowing 40 
minutes for particle diffusion. The amount of nanoparticle stock solution mixed with mucus 
buffer for each particle size, can be seen in Table 4.1. 
 
Nanoparticle Measured 
Diameter 
(nm) 
Commercially Provided 
Concentration 
(particles/mL) 
Amount Used to obtain 
1.08x10
-12
 particles/ML 
(μL/mL) 
PS-NP-COOH(27) 27.15 + 1.704 2.6x10
15
 0.41 
PS-NP-COOH(44) 44.35 + 2.259 1.1x10
15
 1.00 
PS-NP-COOH(89) 88.73  + 1.945 3.6x10
13
 30.00 
Table 4.1: Shows the measured diameters and zeta potential of the PEGylated quantum dot nanoparticle samples. 
All PEGylated quantum dot nanoparticles have  more neutral surface charges through PEGylation. 
 
4.1.3  Experimental Procedure 
50 μl of the reconstituted CF mucus solution was placed in the mucus packet snapwell during 
assembly and then placed between the donor and acceptor compartments. The donor and 
acceptor compartments were simultaneously filled with 3.0 ml of fluorescent nanoparticle 
solution (1.08x10
12 
nanoparticles/ml) and 3.0 ml of mucus buffer solution respectively, to 
prevent a difference in hydraulic pressure across the mucus membrane. A gentle flow of 
nitrogen gas was used to carefully mix the solutions in the donor and acceptor compartments 
to prevent the nanoparticles from falling to the bottom or becoming attached to the chambers. 
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After 40 minutes, 600 µl of the solution in the acceptor compartment was collected and its 
particle concentration was measured as described in Section 4.1.4. 
4.1.4  Fluorescence Measurements 
Once the experiment had been carried out, the fluorescence intensity of the solution in the 
acceptor compartment was measured using a Shimadzu RF-5301PC Spectofluorophotometer. 
For the yellow-green nanoparticles used, the excitation wavelength was set at 488 nm and the 
detection wavelength at 510 nm. The experiment was carried out in triplicate for each 
nanoparticle sample.  
 
4.1.5  Diffusion Coefficient Calculation 
The diffusion coefficient (D) can be derived from the rate of change of particle concentration, 
by finding a solution to the diffusion equation, Equation 11, for the specific conditions of the 
experimental setup 
123, 124
. The diffusion equation relates the rate of change of concentration at 
a given position to the spatial variation of the concentration at that point, Equation 11, where 
D is the diffusion coefficient, c is the concentration, t is time and x is the position 
82
. 
 
2
2
x
c
D
t
c





                                            (Equation 11) 
 
The diffusion equation can be derived from Fick‟s first law of diffusion, Equation 12, which 
describes the passive transport of particles from an area of high concentration to an area of 
low concentration, until a uniform concentration is achieved throughout 
83
. Fick‟s first law 
states that the number of particles that flow through a unit area per unit time (Flux, J) is 
proportional to the gradient in concentration, c, at that point. 
     
  
  
                                                  (Equation 12) 
Fick‟s first law of diffusion can be derived by considering the transport of particles due to a 
change in concentration. This can be shown in Figure 4.3, in which there are two boxes with 
volumes δA on either side of x. 
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Figure 4.3: A diagram for Fick‟s first Law 
 
We want to measure the rate of transport of the particles per unit time, Flux, J, as a function of 
the concentrations on either side of x. The volume of each box is equal to δA, where A is 
assumed to be constant over all x and δ = vτ, the distance a particle can move in τ seconds with 
velocity v. δ must be small enough such that the average concentration at time, t, is c(t, x - δ/2) 
for the left hand side and c(t, x + δ/2) for the right. This means that the average concentration 
is the same at any place in each box, there is no concentration gradient within the box. The 
assumptions state that only one-dimensional motion is allowed; particles travelling to the right 
are considered positive flux, those travelling left are considered negative flux. 
 
The number of particles in each box can be calculated by multiplying the volume (δA) with 
the concentration c, therefore: 
 No. particles in left had box is δAc(t, x - δ/2) 
 No. particles in left had box is δAc(t, x + δ/2) 
Based on the random walk model half of the molecules of each side would cross the line at x 
during an interval of τ seconds, therefore: 
no. particles crossing x during a period τ is equal to 
 
 
        
 
 
  
 
 
        
 
 
  
where the negative sign is due to motion from right to left, rather than left to right.  
 
 
 
δδ
x
A
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The flux, J(t, x), is defined as the rate of particles crossing x per unit of area per unit of time, 
which can be given by dividing the no. particles crossing x during τ by τ: 
   
 
 
 
 
        
 
 
         
 
 
    
  
  
                     
 
 
as δ -> 0:  
   
  
  
 
  
          
  
  
 
 
The diffusion equation can then be derived from Fick‟s first law as follows. Figure 4.4 shows 
particle transport through a volume of area, A, and depth Δx, with J(x) as the flux in, and J(x+ 
Δx) as the flux out.  
 
Figure 4.4: A diagram for the derivation of the diffusion equation from Fick‟s first Law 
 
It follows that: (where N is the number of particles) 
  
  
                
and: (where c is the concentration, and V is the volume) 
          
Therefore: 
   
  
  
                 
with: 
             
  
  
          
Therefore: 
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A
J(x) J(x + Δx)
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  in the limit Δx -> 0                                (Equation 13) 
From Equation 12 and Equation 13: 
  
  
  
 
  
   
  
  
    
   
   
  
which is the diffusion equation for 1 dimension. For 2 or 3 dimensions: 
  
  
      
Applying this to the diffusion chamber experiments, we show in Figure 4.5, the initial and 
boundary conditions for the diffusion equation. 
 
 
Figure 4.5: Diagrams showing the experimental setup as determined by the initial and boundary conditions for the 
diffusion equation. At time t=0, the donor compartment has a concentration of C0, and the acceptor compartment 
has a concentration of 0. At time t=40 min, some of the nanoparticles in the donor compartment have moved into 
the acceptor compartment, the concentration in the acceptor compartment is now CD. 
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Initial and boundary conditions must be specified to derive a solution from the diffusion 
equation. In the ideal case, the experiment is modelled by Figure. 4.5, in which the donor and 
acceptor compartments are assumed to be part of one long cylinder with the mucus membrane 
at x=0 of zero depth. In order to calculate the diffusion coefficient, the relationship between 
the particle concentration in the acceptor compartment and the diffusion coefficient must be 
established. Figure 4.5 shows that the initial conditions for this experiment are that: 
 At time t=0 and x=0  the concentration is C0, the donor concentration 
0)0,0( Cc   
 At time t=0, for all x>0 (the acceptor compartment) the concentration is 0. 
0)0,( xc  
The boundary conditions for this experiment assume that the donor compartment 
concentration remains at C0 even as some of nanoparticles move from the donor compartment 
to the acceptor compartment. This will only hold true if a very small number of nanoparticles 
diffuse through the barrier, relative to the number of nanoparticles in the donor compartment, 
in which case: 
 At all t, the concentration at x=0 is C0. 
0),0( Ctc   
 As x->∞, the concentration = 0. 
 
The general solution for the diffusion equation under these conditions is: 







Dt
x
erfcCtxc
2
),( 0                                (Equation 14) 
Where erfc is the complementary error function which describes the concentration curve of 
the particles in the acceptor compartment. Multiplication of the erfc by C0 gives the amplitude 
of the donor concentration. N(t), the number of particles in the acceptor compartment is 
therefore the area under the concentration curve of the acceptor compartment, which is found 
by taking the integral between x=0 and x=∞. The multiplication by πr2 accounts for the area 
of the cylinder. 
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               (Equation 15) 
Using Equation 15, the diffusion coefficient can be calculated from an experimental 
determination of N(t), at any time t, chosen here to be 40 mins on the basis of prior 
experience. As a large quantity of the acceptor compartment sample (600 μL of the 3.0 mL 
capacity) is needed to measure the nanoparticle concentration using the 
spectofluorophotometer, the measurement can only be taken once at the end of the experiment 
without disturbing the hydraulic pressure across the test barrier. This is arguably the single 
biggest problem with this technique – the inability to obtain multiple measurements (from a 
single mucus sample) for statistical analysis.     
 
 
4.2  Preliminary Observations with Vertical Diffusion Chambers 
 
Vertical diffusion chambers were used to investigate the diffusion of 27 nm, 44 nm and 89 nm 
diameter fluorescent, carboxylate-modified, polystyrene nanoparticles through 1xMUC model 
mucus samples. The diffusion coefficient for each nanoparticle size was then calculated as 
described in Section 4.1.5. The calculated diffusion coefficients and effective viscosity based 
on an average of three repetitions, using three mucus samples from the same batch, are shown 
in Table 4.2.   
 
Particle Measured 
Diameter 
(nm) 
Diffusion Coefficient 
(m
2
s
-1
) 
Effective Viscosity 
(cP) 
PS-NP-COOH(27) 27.15 + 1.704 1.06x10
-15 
+ 1.62 x10
-16
 22.45
 
+ 1.67 
PS-NP-COOH(44) 44.35 + 2.259 1.32x10
-16 
+ 9.25 x10
-17 
110.38
 
+ 2.34 
PS-NP-COOH(89) 88.73  + 1.945 2.85x10
-17 
+ 1.98 x10
-17
 255.477
 
+ 2.10 
Table 4.2: Shows the diffusion coefficients and effective viscosities calculated from vertical diffusion experiments 
of 20 nm, 44 nm and 89 nm diameter fluorescent, carboxylate-modified, polystyrene nanoparticles through 1xMUC 
model mucus. 
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The effective viscosity shows that smaller nanoparticles diffuse as if through a fluid with a 
lower viscosity fluid than the bulk viscosity of 1000cP as measured in Chapter 2. The 
effective viscosities also suggest that, as the nanoparticle radius decreases, the nanoparticles 
may be subject to a decreasing effective viscosity. Figure 4.6, shows a plot of the diffusion 
coefficient against nanoparticle radius for diffusion through 1xMUC model mucus. As can be 
seen from Table 4.2, the diffusion coefficients for all nanoparticle sizes show sizeable errors 
of ~15 %, 70 % and 69 % for the 27 nm, 44 nm and 89 nm diameter nanoparticles 
respectively. With only three data points it is not possible to assert whether the data is 
consistent with the Stokes-Einstein equation, although it does obey the expected trend of 
diminishing diffusivity with increasing nanoparticle size. The data suggests that the 
nanoparticles are able to diffuse through lower viscosity areas in the mucus structure as 
proposed by Sander et al. 
25, 36
 and Hanes et al. 
77, 79
. However due to the errors in the 
calculated diffusion coefficient values it is difficult to obtain reliable values for the effective 
viscosity.  
 
 
 
Figure 4.6: A graph showing the dependence of nanoparticle diffusivity on radius, obtained using vertical 
diffusion chambers. 
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4.3  The Suitability of the Vertical Diffusion Chambers Technique 
 
The diffusion coefficient values obtained, above, had large errors, ranging from 15 % - 70 %. 
The assumptions on which calculation of the diffusion coefficient is based, are difficult to 
sustain. Calculation of the diffusion coefficient from the number of particles collected in the 
acceptor compartment is complicated. The fluorescence of the nanoparticles is used to 
determine the concentration of nanoparticles in the acceptor compartment through 
fluorescence intensity measurements. This procedure can be erroneous as photobleaching of 
fluorophore-based nanoparticles can occur rapidly. Calculation of the diffusion coefficient is 
carried out using the diffusion equation for time-dependent diffusion processes, Equation 11. 
The diffusion coefficient can be calculated from the rate of change of nanoparticle number in 
the acceptor compartment provided that various conditions and assumptions hold. One of the 
assumptions presiding over the experimental procedure is that the nanoparticle concentration 
in the donor compartment (C0) remains constant. This is difficult to reproduce in reality, using 
the vertical diffusion chamber apparatus, as the concentration in the donor compartment 
decreases over time as the nanoparticles pass into the acceptor compartment. It is therefore 
very difficult to keep the concentration in the donor compartment constant, at least with the 
equipment available, meaning Equation 14 may not hold true. Another cause of possible error 
is the hindering effect of the nanoparticle diffusion through the polycarbonate membranes, of 
the mucus packet, which needs to be negligible for the experimental techniques to give results 
that are representative of the mucus rather than the entire membrane–mucus–membrane 
assembly. The effect of the polycarbonate membrane would not be present in reality and 
therefore has the potential to add a degree of error to the experimentally determined diffusion 
coefficient values. Hence the diffusion coefficients obtained from vertical diffusion chamber 
experiments will always be lower because of the hindering effects of the polycarbonate 
membranes. The technique also assumes that the mucus sample is retained within the mucus 
packet. Although, the studies by Norris et al. 
73
, implied that the use of polycarbonate 
membranes with a pore size of 0.4 µm could retain all mucus within the container, the 
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polycarbonate membrane is unable to prevent the mucus buffer, on either side of the mucus 
container, from passing through the membrane and diluting the mucus sample within the 
container for the duration of the experimental procedure. A combination of these individual 
deviations from the assumptions of the experiment gave rise to unacceptable errors. Due to the 
poor quality of the data obtainable from vertical diffusion chambers, this approach was 
pursued no further. Optimisation of the experimental technique would have required building 
improved diffusion chambers, for example with a very large donor compartment relative to 
the acceptor compartment to enable the assumption of a the donor concentration remaining 
constant to be held. A method for containing the mucus layer, which does not obstruct the 
motion of the nanoparticles, let mucus leak out or buffer dilute the mucus sample would also 
have been needed. Overall, use of the vertical diffusion chambers for the investigation of 
diffusion through mucus was deemed unreliable (even though they are quite suitable for 
investigating nanoparticle diffusion through polycarbonate membranes for which the 
apparatus was intended).  
 
Fortunately, the arrival of new imaging equipment at Imperial College London during the 
course of these measurements meant that multiple particle tracking experiments became 
feasible, and a decision was made to abandon the experimentally fraught vertical diffusion 
chamber measurements in favour of multiple particle tracking which (as outlined in Chapter 
5) offers significant experimental advantages. Vertical diffusion chamber experiments had 
suggested that the diffusivity of nanoparticles might not be governed by the bulk viscosity of 
the mucus sample, and multiple particle tracking experiments offered a means of investigating 
this in more detail. 
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CHAPTER 5: MULTIPLE PARTICLE TRACKING 
 
  101 
Multiple particle tracking has emerged as a popular technique for understanding particle 
diffusion through various environments 
79, 86, 92, 93
 and has been widely used to investigate the 
diffusion of micron-sized particles through mucus 
77, 79, 94, 102, 103
. Multiple particle tracking 
uses high-speed, high-resolution, fluorescence video microscopy to capture the motion of a 
number of individual fluorescent particles in a real-time movie clip 
78, 86-88, 94
. The movies 
simultaneously track the trajectories of a number of particles. Frame-by-frame analysis of 
particle positions enables the determination of individual particle displacements between 
frames. 
 
Multiple particle tracking is a versatile technique which can be used to study many different 
environments. Its suitability for tracking particles in the 100 nm – 500 nm diameter range, 
through mucus has been demonstrated in a series of studies by Hanes‟ et al. 77, 79, 94, 102, 103. The 
technique however, has not been used to study the diffusion of nanoparticles less than 100 nm 
in diameter through mucus, or other biological environments. 
  
Several steps were required to establish the experimental procedure for the new nanoparticle 
size range, and obtain a full data set from which conclusions about the nanoparticle diffusion 
in model mucus samples could be drawn. The first step was to validate the multiple particle 
tracking procedure for nanoparticles smaller than 200 nm in diameter. This was achieved by 
measuring the diffusion coefficients of the nanoparticles through glycerol, which is a 
Newtonian fluid and so would be expected to yield results that are consistent with the Stokes-
Einstein equation. The second step, after the validation of the experiment setup was to 
investigate the diffusion of fluorescent, carboxylate-modified polystyrene nanoparticles 
through 1xMUC model mucus samples. Measurements of 27 nm, 44 nm, 89 nm and 200 nm 
particles demonstrated that all nanoparticle sizes diffuse through the mucus at much higher 
rates than would be expected from the Stokes-Einstein equation for the bulk viscosity of the 
1xMUC sample (of 1000 cP). However, the trajectories of the smallest 27 nm and 44 nm 
nanoparticles could only be tracked for 5 seconds, which although measureable, lead to 
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greater noise in the data. These experiments also highlighted the need for more nanoparticle 
sizes smaller than the smallest 27 nm diameter nanoparticles to investigate the effects of 
reducing the nanoparticle diameter further still. In order to track the smaller nanoparticles for 
longer, the bulk viscosity of the 1xMUC model mucus was increased by increasing the mucin 
concentration by a factor of eight to slow down the diffusion of the smallest nanoparticles to 
an experimentally accessible level. The diffusion of five fluorescent carboxylate-modified 
nanoparticles 12.5 nm, 27 nm, 44 nm, 89 nm and 200 nm in diameter was then measured 
through the 8xMUC model mucus to correlate nanoparticle size with diffusivity.     
 
A further focus of this study was to investigate the effect of PEGylation on the diffusion of 
nanoparticles through mucus. As described in Section 1.6.5, PEGylation has been explored for 
reducing therapeutic interaction with the mucus environment so as to enhance diffusivity and 
improve delivery. A series of six PEGylated nanoparticles ranging from 27 nm – 219 nm in 
diameter, were therefore prepared as described in Chapter 2, and used multiple particle 
tracking to investigate the effect of their near-neutral surface charge on diffusivity.   
  
 
5.1  The Multiple Particle Tracking Experimental Setup  
 
Multiple particle tracking uses fluorescence microscopy to visualise and capture the motion of 
a population of fluorescent nanoparticles in a liquid environment through video imaging. 
Individual movie frames are then analysed sequentially to determine the co-ordinates of 
specific nanoparticles as they progress in time. The diffusion coefficient of the nanoparticles 
can then be determined by analysing the motion of the nanoparticles. 
  
5.1.1 Fluorescence Microscopy 
Fluorescence microscopes use a series of mirrors to direct excitation light to a localised spot 
on the sample. Light/fluorescence emitted by the sample is then directed to a video camera 
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(Hamamatsu EM-CCD) for visualisation. Using a Xenon lamp and band pass filter, the 
sample is illuminated at a specific wavelength. Both the yellow-green polystyrene 
nanoparticles (Molecular Probes, Inc) and the quantum dot nanoparticles (Molecular Probes, 
Inc) are excited at 488 nm. The polystyrene nanoparticles emit at 515 nm, whilst the quantum 
dot nanoparticles emit at 705 nm which cannot be seen by the naked eye, therefore all 
focusing must be done using the camera (which has a spectral range of 300 nm – 1000 nm).  
 
 
 
 
Figure 5.1: Schematic representations showing the light path within an inverted microscope. Light is directed 
using mirrors to illuminate and excite the nanoparticles in the sample. The fluorescence emitted by the 
nanoparticles is once again directed by mirrors to the camera which captures the image. Emission filters are used to 
eliminate background fluorescence.  
 
 
Nanoparticle 
Measured 
Diameter (nm) 
Fluorescein Equivalents 
per Nanoparticle 
(supplied by manufacturer) 
 
PS-NP-COOH(27) 
27.15 + 1.704 1.8 × 10
2
 
PS-NP-COOH(44) 44.35 + 2.259 3.5 × 10
2
 
PS-NP-COOH(89) 88.73  + 1.945 7.4 × 10
3
 
PS-NP-COOH(200) 200.43 + 1.305 1.1 × 10
5
 
 
Table 5.1: A table showing the fluorescein equivalents per nanoparticle size. As can be seen from the table, the 
larger nanoparticles have a higher fluorescent signal due to the increased fluorescein equivalents they can hold. 
Xenon 
Lamp Excitation 
filter 
Emission 
filter 
CCD 
Camera 
Sample 
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Filters are used to (partially) block background fluorescence, scattered excitation light and 
residual autofluorescence. Schematics of the light path for an inverted microscope are shown 
in Figure 5.1. The obtained image can be optimised, for visual clarity, by changing the laser 
intensity (gain), detection thresholds (offset) and the filters used for the excitation and 
detection beams.   
 
5.1.2  Preparation of Samples for Multiple Particle Tracking. 
300 µl of the model mucus was placed into a vial, to which 20 µl of nanoparticle solution, 
0.02 % w/v, was added. (The nanoparticle samples were sonicated for one hour before use to 
break down any aggregates which may have formed during storage). In the case of glycerol; 
the nanoparticles were added to the sample and gently vortexed overnight at room 
temperature. Due to the viscous nature of glycerol, dilution and homogenisation of aqueous 
glycerol solutions requires vigorous mixing. When adding nanoparticles in solution there is a 
risk of forming water pockets containing nanoparticles, as shown in Figure 5.2.b. So, it is 
important to carefully homogenise the glycerol-nanoparticle solutions. The protocol used was 
based on the one outlined by Hanes et al. 
103
 for MPT experiments in glycerol, although the 
vortexing step they used was omitted to avoid disrupting the mucus mesh structure 
88, 102
. 
Hence, in the case of mucus; nanoparticles were added to the sample, just before the sample 
was placed onto the microscope stage, and stirred well, using a pipette tip, to ensure uniform 
dispersion, as shown in Figure 5.2.  
 
Figure 5.2: Diagrams representing the sample preparation for MPT; a) shows the sample before the nanoparticle 
solution is added, b) shows the (green) water pockets of the nanoparticle solution which form, c) shows the stirring 
of the nanoparticle solution into the sample to ensure dispersion, d) shows a homogenised solution. 
a) b) c) d) 
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200 µl of the mucus/nanoparticle solution was then transferred into a Labtek coverglass 
chambered 8 well sample holder (Nunc, Thermo Fisher Scientific), suitable for inverse 
microscopy. The sample holder was then placed onto the microscope stage and left for 30 
minutes to equilibrate at room temperature, for the mucus/nanoparticles to reach equilibrium 
after having been disturbed by the motion of handling and transfer to the microscope stage. 
 
5.1.3  Experimental Procedure 
A Zeiss Axiovert 200 inverted microscope with a fully motorised stage was used for the MPT 
experiments, controlled by C-Imaging Simple-PCI acquisition software. An incubation 
chamber was used to control the temperature of the sample. A Hamamatsu EM-CCD camera 
was used for high-speed imaging (provided by the Facility of Imaging by Light Microscopy at 
Imperial College London, UK). Due to the low fluorescence intensity of the smallest 
nanoparticles, binning was employed to increase the signal quality. By combining the signal 
from four pixels (in a 2x2 square configuration) a two-fold increase in the signal to noise ratio 
was achieved at the expense of a four-fold reduction in spatial resolution. Imaging areas, of 
size 773 μm x 773 μm, within the mucus were chosen at random for observation. 
Approximately 10-20 traceable particles could be seen in each area, therefore 5-10 areas were 
chosen at random per sample. Typical single frame images for 27 nm and 200 nm particles are 
shown in Figure 5.3. The image of the 27 nm nanoparticles is less intense and noisier than the 
image of the 200 nm particles. Since the larger nanoparticles can be loaded with more 
fluorescein and so emit more intensity upon excitation, see Table 5.1 
125
. Aggregates can also 
be seen in Figure 5.3.a (circled in blue), whereas the larger 200 nm diameter particles are 
evidently more monodisperse. This agrees with the polydispersity indices, measured by 
dynamic light scattering, as discussed in Chapter 2, are 0.294 and 0.022 for the 27 nm and 
200 nm diameter nanoparticles respectively. Care must therefore be taken during analysis not 
to include aggregate trajectories in MSD calculations, which would incorrectly reduce the 
average mean squared displacement. This would in turn affect the diffusion coefficient 
calculation, resulting in much lower apparent diffusivity values.  
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Figure 5.3: Typical single frame images of multiple tracking experiments for a) 27 nm and b) 200 nm diameter 
nanoparticles in mucus. The difference in signal to noise ratio can clearly been seen due to the low fluorescent 
signal of the smaller 27 nm diameter nanoparticles. Aggregates (circled in blue) can also been seen in a) this 
accounts for the higher polydispersity index of the 27 nm diameter nanoparticle sample of 0.294 compared to the 
0.022 polydispersity index of the 200 nm diameter particles, as determined by dynamic light scattering.     
 
a) 27 nm 
b) 200 nm 
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If all the frames of a single movie clip are laid on top of each other and the fluorescent signals 
projected through, the trajectories of the nanoparticle motion can clearly be identified, see 
Figure 5.4, and Figure 5.5. The smaller 27 nm and 44 nm diameter nanoparticles can be seen 
to move further than the larger 89 nm and 200 nm diameter nanoparticles in a time period of 5 
seconds. 
 
 
 
 
Figure 5.4: Multiple frame images overlayed to show the particle trajectories of a) 27 nm b) 44 nm c) 89 nm and 
d) 200 nm diameter nanoparticles in 1xMUC model mucus. The 89 nm and 200 nm diameter particles appear 
almost stationary over the 5 s time scale of the movie, whereas the smaller 27 nm and 44 nm diameter 
nanoparticles show random motion. 
 
50μm 
a) b) 
c) d) 
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Figure 5.5: Trajectories of a) a 27 nm nanoparticle (enlarged from Figure 5.4.a) and b) a 44 nm nanoparticle 
(enlarged from Figure 5.4.b) diffusing through mucus.   
 
The 89 nm and 200 nm diameter nanoparticles remain almost stationary over the 5 second 
time scale of the movie and therefore appear slightly larger due to small fluctuations of 
motion, whereas the smaller 27 nm and 44 nm diameter nanoparticles move in a seemingly 
random manner as expected for Brownian motion. The intensity of the smaller nanoparticles 
can also be seen to increase and decrease between frames as they move in and out of the plane 
of focus.  
 
 
5.2  Methods for Obtaining Nanoparticle Trajectories  
  
Two methods were used to trace the nanoparticle trajectories from the movie clips and to 
extract accurate co-ordinate lists. The following section describes the two software packages 
evaluated and then discusses the benefits of each one and how well they performed relative to 
one another. For the benefit of future students, the analytical procedure used will be discussed 
in full detail. The first software package Volocity, is not specifically designed for extracting 
nanoparticle trajectory co-ordinates from a series of movie frames, and a „macro‟ based on a 
combination of its functions therefore had to be improvised to serve this purpose. The second 
software package used, View5D, is not commercially available, but was obtained through a 
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collaboration with Dr. Rainer Heintzmann at Kings College, London. As detailed instructions 
are not available for either software package (at least not for the current purpose of extracting 
nanoparticle trajectory co-ordinates), the following is therefore intended as a „user manual‟ for 
researchers wishing to continue this work. 
 
5.2.1 Volocity 
The movie clips were initially analysed using the software package Volocity (Version 4.0.1, 
Improvisation Ltd) to obtain the particle displacements of 50 particles, for a minimum of 100 
frames, from which the MSD and diffusivity of the particle population was calculated. Each 
experiment was repeated in triplicate to ensure reliability of the results.  
 
Volocity applies intensity and sizing restrictions to identify individual nanoparticles. All 100 
images must be loaded into the software package; the parameters are set for 1 image, and then 
applied to all images in the sequence. Firstly the scale (i.e size) of the image must be specified 
so that the co-ordinates of the nanoparticle centroid are in the correct units. The contrast must 
then be optimised so that the nanoparticles can clearly be seen and distinguished in order to 
accurately set the analysis parameters. The image shows the nanoparticle‟s fluorescent signal, 
which is not the same size as the nanoparticle itself. A „size‟ threshold is then set which 
corresponds to the size of the fluorescence „halo‟ surrounding each nanoparticle rather than 
the size of the actual nanoparticle itself, (which would be too small to resolve). All parameters 
must be set by hand, and tend to be different for each movie and for each nanoparticle size. 
Therefore this initialisation process must be repeated carefully for each new movie. Figure 5.6 
shows the effects of applying different intensity and size thresholds.  
 
In Figure 5.6.a, the intensity threshold is set far too low, even very low fluorescent signals are 
therefore included and nanoparticles appear very large as any scattered light in the areas 
around the nanoparticles appear to emanate from the nanoparticle itself. It is difficult to 
distinguish individual particles and areas of noise are also selected as possible nanoparticles.  
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Figure 5.6: Shows the detection of 100 nm nanoparticle centroids by Volocity when a) the intensity threshold is 
too low, b) the size threshold is too low and c) both the intensity and size thresholds have been correctly set. If the 
intensity threshold is too low as in a) areas of low fluorescent intensity around individual nanoparticles are 
included in the nanoparticle centroid and it is impossible to correctly identify nanoparticle co-ordinates. When the 
size threshold is too low, as in b), the nanoparticles are difficult to distinguish from background noise. Parameters 
must be carefully chosen to ensure nanoparticles can be tracked through the movie as in c). 
a) 
b) 
c) 
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In Figure 5.6.b, the size threshold is set too low, and the nanoparticles are difficult to 
distinguish from background noise. The software parameters must therefore be set very 
carefully to identify the nanoparticles reliably within a given frame; thought must also be 
given to the other frames in the movie, in which nanoparticles will have moved in and out of 
focus and will therefore have a reduced fluorescent signal. These threshold values must 
therefore always be set slightly lower than the minimum needed to correctly identify a 
nanoparticle, as in Figure 5.6.c. If the parameters are not set correctly, it is impossible to track 
the nanoparticle motion through all frames in the movie. On many occasions, the parameters 
must be re-optimised at intervals during the movie to ensure that the nanoparticles can be 
traced accurately.  
 
Once the individual nanoparticles have been clearly identified, the „Track‟ routine of the 
software is used to follow the trajectories of individual particles, shown in Figure 5.7, which 
outputs a list of the nanoparticles‟ centroid co-ordinates in each frame. The tracks are given 
individual ID numbers and can be sorted by their track length. Volocity outputs the 
nanoparticle co-ordinate information in a large table. The co-ordinates of all nanoparticles 
identified, including those which are incorrect or cannot be tracked for the full length of the 
movie, are output in a single list. The track ID numbers for the desired nanoparticle tracks are 
not always sequential, therefore the list must first be analysed to select the required 
information before MSD calculations can be performed.  
 
Unfortunately, it was very difficult to track substantial quantities of the smaller 27 nm and 
44nm diameter nanoparticles without losing the fluorescent signal due to the nanoparticle 
motion in and out of the focal plane in the z direction. Unfortunately, the intensity and size 
thresholding by Volocity did not seem robust enough in use and many nanoparticle 
trajectories were lost during analysis due to unsuccessful tracking. Care must also be taken to 
avoid nanoparticle aggregates, which are much easier to track due to their larger fluorescent 
signal and slower motion. 
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Figure 5.7: Shows the tracks identified by volocity for 200nm diameter nanoparticles. Not all tracks correspond to 
the full length of the movie, due to diffusion out of the focal plane. Care must be taken when selecting which tracks 
are used for MSD calculation to ensure aggregates are not included. 
 
5.2.2  View5D 
View5D is an ImageJ plugin, made by Rainer Heintzmann at Kings College, London. The 
programme can be used to display 2D image sequences in three dimensions for 3D imaging of 
samples, where the z dimension corresponds to time. For the purpose of multiple particle 
tracking, the software was used to identify and track individual nanoparticles to calculate their 
mean squared displacement and hence diffusion coefficient. As in Volocity, the image 
sequence of each movie must first be imported into the software programme. View5D displays 
the movie in three planes as shown in Figure 5.8. View5D automatically enhances the contrast 
of each individual frame to obtain the best settings. The view in the top left shows the movie 
in the xy plane, the view in the top right shows the movie in the yz plane, and the view in the 
bottom left shows the movie in the xz plane. As can be seen from Figure 5.8, the distribution 
of individual nanoparticles in the mucus sample can be seen in the xy frame, much like the 
images analysed by volocity. This view enables the user to see whether the nanoparticle can 
be tracked through all frames in the movie. It also gives a clear view of the nanoparticle 
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trajectory. Using the mouse, slices through the xy plane can be selected to give the 
corresponding xz and yz planes. A coloured track then shows the motion of the nanoparticle 
centroid as it moves through the frames of the movie.  
 
The xz and yz planes allow the software-calculated tracks to be displayed alongside 
nanoparticle‟s position in each frame, enabling the user to ensure that the software-calculated 
track closely follows the motion of the nanoparticle. In some instances the track may seem to 
have breaks in it or else it may tail off as shown in Figure 5.8. However this is often just the 
trajectory moving in and out of the xz or yz plane, and the presence of the track can be 
checked my moving the cursor around in the various views. Often if the track disappears in 
the xz plane it can still be seen in the yz plane, which is why it is very helpful to have both 
views to use, to ensure that the nanoparticle is tracked accurately. 
 
 
Figure 5.8: A screen shot of the View5D plugin for ImageJ. View5D shows the multiple particle tracking movie in 
the xy plane, the xz plane and the xz plane, allowing greater visibility and verification of the nanoparticle 
trajectories. The calculated nanoparticle co-ordinate lists are displayed the in the window in the bottom right hand 
corner. 
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Figure 5.9: Screen shots of the particle trajectories tracked by the View5D algorithm, the two particle tracks are 
shown in pink and blue and overlay the particle images in the xz and yz planes. Applying a red colour glow to the 
images can often improve the visibility of the nanoparticle trajectory for better verification and analysis.  
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Figure 5.9 shows the tracks obtained for two nanoparticles. The cursor must be in the correct 
xy position to see the nanoparticle track in the xz and yz planes. The program also has a „red 
glow colourmap‟ function which enhances the contrast between the track and the background, 
making it easier to see if the calculated trajectory reliably matches the nanoparticle track. 
 
Care must again be taken to ensure that the nanoparticles chosen are not aggregates, although 
fortunately they are quite simple to distinguish due to their larger size and higher fluorescent 
signal. Nanoparticles were generally selected in batches of 5-10 since due to the large 
computational effort required to process the nanoparticle co-ordinates, larger batch sizes 
caused the computer to freeze up. Generation of the nanoparticle co-ordinate information 
could take between 15-20 minutes for each 5-10 batch routine. Once printed into the lower 
right hand window, the co-ordinate data was copied and pasted into a spreadsheet, for mean 
squared displacement calculation. 
 
5.2.3  A Comparison of Nanoparticle Tracking Techniques 
Both of the nanoparticle tracking techniques could track the nanoparticle trajectories and 
produce co-ordinate lists for mean squared displacement calculations. The main differences in 
the two techniques were in terms of ease of use, reliability and processing time. 
 
Although both programs were user-friendly and had simple stages, View5D had less stages to 
be carried out for each routine. When using Volocity, the contrast had to be enhanced by eye 
for each movie, and the settings could only be chosen for one frame which were then applied 
to all frames. However, in View5D the contrast enhancement was automatically adjusted for 
each individual frame upon initialisation. Volocity also required the intensity and size 
thresholds to be set each time for each individual movie, selecting the optimal parameters 
could often be tricky and time consuming. The results output by Volocity were heavily 
dependent on the parameters chosen, leaving room for human error and meaning that a few 
different combinations often had to be tried before a confident selection of the parameters 
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could be made. These parameters did not need to be set by View5D as nanoparticle tracking is 
more of a primary function of the program, unlike in Volocity. Due to the parameter-based 
nature of Volocity, it often seemed that nanoparticle tracks visible to the eye were not being 
included in the tracks generated due to some frame positions being outside the „visibility‟ 
range of the chosen parameters. No amount of optimisation seemed able to cater for the 
parameter requirements of all trackable nanoparticles in the image sequence, leading to the 
loss of some nanoparticle trajectories in each movie. This generally meant that more movies 
needed to be captured during the microscopy stage of the experiment.  
 
Selection of the nanoparticles could be done very quickly and confidently with View5D as 
being able to see the nanoparticle‟s motion in the xz and yz allowed for easy tracking. Once 
the parameters had been set in Volocity and the nanoparticles chosen in View5D, both 
programs took a long time to generate the co-ordinate lists. The programs were both 
processor-heavy and the computer could not be used for other tasks whilst generating co-
ordinate lists for both programs. The co-ordinate lists generated by both programs consisted of 
a long list of all nanoparticle co-ordinates and required pre-processing before mean squared 
displacement calculations could be determined, as described in Section 5.3.1. 
 
Overall, View5D was the simplest and more reliable program to use and was able to track 
nanoparticles with lower fluorescent signals that Volocity would often overlook. The stages 
involved in analysis using View5D were also simpler and produced more nanoparticle 
trajectories per movie than Volocity. This meant that fewer nanoparticle movies needed to be 
captured during the microscopy stage of the process. View5D was therefore chosen as the 
most suitable software package for reliable extraction of the nanoparticle trajectory co-
ordinates from the multiple particle tracking movies.   
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5.3  Mean Squared Displacement Calculation 
 
 
  
Figure 5.10: A diagram showing the displacement values calculated for mean squared displacement calculation. 
The distance a nanoparticle travels is calculated between two subsequent frames, every second frame and every 
third frame to obtain a measure of the average displacement of a nanoparticle with increasing time. The diffusion 
coefficient can be obtained from this measure. 
 
The mean squared displacement is calculated in the manner shown in Figure. 5.10 
91
. The 
distance a particle moves in a time interval of τ is squared and averaged. The same is then 
calculated for the distance the particle moves in a time interval of 2τ, 3τ and so on. A 
correlation of average mean squared displacement against time can then be plotted from these 
values. The diffusion coefficient (D) is then calculated by fitting the experimental mean 
squared displacement values to Equation. 6. 
 
5.3.1 Pre-Processing: Separation of Individual Nanoparticle Co-ordinate Lists 
For the purpose of this study, and to increase the efficiency of data analysis, a software 
package, called MSDcalculator, was written to extract the nanoparticle co-ordinate data and 
calculate the mean squared displacement from the raw data file exported by View5D and 
Volocity. A detailed description of how MSDcalculator functions is provided in Appendix A. 
The raw data file lists from both View5D and Volocity were formatted to have the same 
general structure so that both are compatible with macro MSDcalculator. These lists are 
imported into and saved as excel spreadsheets. Before mean squared displacement 
calculations can be performed, these large co-ordinate lists must be separated into the co-
ordinate lists of each individual nanoparticle. The macro creates an output file and for each 
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Track ID, creates a new excel sheet, named with the Track ID and the corresponding 
nanoparticle co-ordinates. The centre of mass of the nanoparticle population must be 
calculated in order to correct for any effects of convection that may occur within the sample 
during experimentation, which is done by adding the x co-ordinate values for each 
nanoparticle for a single time point together and dividing by the total number of nanoparticles, 
under the assumption that all nanoparticles have the same mass. The mean squared 
displacement algorithm takes the x and y coordinates and calculates the nanoparticle 
displacements using Equation 16.  
 
)()( 1212 xxyyMSD                             (Equation 16) 
 
As shown in Figure 5.10, the displacement is calculated between the second and first frame, 
the third and first frame, the fourth and first frame and so on.  
 
 
5.4  Validation of the Multiple Particle Tracking Technique 
 
Glycerol was chosen as a control medium to verify the accuracy of the multiple particle 
tracking approach because it is a purely viscous fluid which does not display any 
microstructure, and can be considered to be perfectly homogeneous 
88
. Diffusion through 
glycerol can be expected to be Brownian and follow the Stokes-Einstein equation.  
 
The experimental procedure was tested by using MPT to determine the diffusion coefficients 
for 27 nm, 44 nm, 89 nm and 200 nm diameter fluorescently-labelled, carboxylate-modified, 
polystyrene nanoparticles through 94 % glycerol, at a room temperature of 21°C as described 
in Section 7.11. The co-ordinates of the centroids of the fluorescent nanoparticles embedded 
in glycerol were captured using fluorescence microscopy.  
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The time averaged mean squared displacements (MSD) of each of the nanoparticles were 
derived from the co-ordinates using Equation 6, where τ is the time step 4, from which 
distributions of MSDs and nanoparticle diffusion coefficients were calculated, as described in 
Section 5.4.1.  
 
  
  
Figure 5.11: Graphs showing the average mean squared displacements vs time for the diffusion of 27nm, 44nm, 
89nm and 200nm diameter nanoparticle diffusion through glycerol, the mean squared displacement varies linearly 
with time (R2=0.99) indicating Brownian motion. 
 
Verification of the technique was required to ensure that both the experimental setup and the 
calculations performed during analysis were correct. Through this verification, the effects of 
drag mentioned in Section A.2 were observed and measures were taken to minimise these 
effects, leading to the addition of the centre of mass correction stages in the mean squared 
displacement macro as outlined in Section A.2. The experimental results showed that the mean 
squared displacement of each nanoparticle size through glycerol varied linearly with time, 
indicating Brownian motion, as expected for diffusion through glycerol, Figure 5.11. 
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Figure 5.12: Nanoparticle diffusivity as a function of nanoparticle radius for the diffusion of nanoparticles 27 nm, 
44 nm, 89 nm and 200 nm in diameter through glycerol. The data fits the Stokes-Einstein equation well, Equation 
1, η=410 cP, R2 = 0.99.  
 
Furthermore, when diffusivity was plotted against nanoparticle radius, as shown in Figure 
5.12, the experimental data fit the Stokes-Einstein equation (R
2
 = 0.99) as expected for 
nanoparticle diffusion through a Newtonian fluid such as glycerol, with a viscosity measure of 
~410 + 7 cP as compared to the measured value of 1000 + 21cP 
122
. These tests showed that 
the experimental and analytical techniques used produce accurate results and can recreate 
known theoretical data. This provided the confidence required to use the experimental 
technique to understand the more complicated mucus environment. 
 
 
5.5  Transport Properties of Nanoparticles through Reconstituted Mucus 
 
The transport properties of carboxylate-modified and PEGylated polystyrene and quantum dot 
nanoparticles through samples of reconstituted model mucus were investigated using multiple 
particle tracking, as described in Section 7.8. For each nanoparticle size, the mean squared 
displacements of 50 nanoparticles were calculated for a minimum period of 5 seconds, each 
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experiment was carried out in triplicate to ensure reproducibility. Carboxylate-modified, 
polystyrene nanoparticles were used for comparability to previous studies 
25, 36, 73, 76, 77, 81
, due 
to their availability in a range of sizes. PEGylated nanoparticles were used to investigate the 
effects of reducing nanoparticle charge to near-neutral on diffusivity through mucus. 
 
5.5.1  Preliminary Nanoparticle Diffusion through Reconstituted Mucus 
As described in Chapter 3, a protocol for the reconstitution of mucus was obtained from a 
publication by Sanders et al. 
74
, in which they investigated the average concentration of the 
major electrolytes and mucus components in 24 cystic fibrosis mucus samples obtained from 
different patients. Using this protocol, 1xMUC model mucus was reconstituted for multiple 
particle tracking experiments as outlined in Section 7.7. The 1xMUC model mucus was 
characterised as described in Section 7.8 & 7.9, and was found to have a macroscopic 
viscosity of ~1000 cP at shear rates of 10 s
-1
 which mimic physiological shear rates 
121
. 
Multiple particle tracking was used to investigate the transport properties of 27 nm, 44 nm, 89 
nm and 200 nm diameter fluorescently-labelled, carboxylate-modified polystyrene 
nanoparticles through 1xMUC model mucus.  
 
The mean squared displacement was determined as a function of time for each nanoparticle 
size, Figure. 5.13. The mean squared displacements can be seen to increase linearly with 
increasing time intervals for all nanoparticle sizes (R
2≥0.99), indicating that the nanoparticles 
diffuse through the 1xMUC model mucus by random walk dynamics that are consistent with 
Brownian motion. These are similar to the correlations obtained for the diffusion of the same 
nanoparticle through glycerol, Figure 5.12.  
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Figure 5.13: Average mean squared displacements for the diffusion of 27 nm, 44 nm, 89 nm and 200 nm particle 
diffusion through reconstituted mucus, diffusivity is linear with time indicating Brownian motion (R2 ≥ 0.99). 
 
 
The diffusion coefficents were then calculated from the average mean squared displacements 
by fitting the experimental data to Equation 6, where the dimension of space, d, is set as 2 
because the nanoparticle motion is tracked in two dimensions and α indicates the extent of the 
impediment caused by obstacles, which tends to 1 for the case of Brownian motion.  
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Figure 5.14: A graph showing nanoparticle diffusivity as a function of nanoparticle radius for the diffusion of 27 
nm, 44 nm, 89 nm and 200 nm in diameter nanoparticles through mucus.  
 
In the case of the diffusion of 27 nm, 44 nm, 89 nm and 200 nm diameter carboxylate-
modified, polystyrene nanoparticles through 1xMUC model mucus, the experimental data did 
not fit the Stokes-Einstein equation perfectly, (R
2
 = 0.81) as shown in Figure 5.14. Although 
the use of just four nanoparticle sizes means one should be careful not to infer too much from 
the data. The experimental diffusion coefficient values (Experimental Dmucus), as shown in 
Table 5.2, for all nanoparticle sizes are much higher than the expected diffusion coefficient
 
values calculated from the Stokes-Einstein equation for the bulk viscosity (1000 cP) of the 
1xMUC sample (Stokes-Einstein Calculated Dη=1000 cP).  
 
Measured 
Diameter (nm) 
Experimental 
Dmucus (m
2s-1) 
Stokes-Einstein 
calculated 
 Dη=1000cP (m
2s-1) 
Effective 
Viscosity (cP) 
Stokes-Einstein 
calculated 
 Dη=400cP (m
2s-1) 
Experimental 
Dglycerol (m
2s-1) 
27.15 + 1.704 4.9x10-14 + 2.0x10-15 1.1x10-14 323 2.8x10-14 2.7x10-14 
44.35 + 2.259 2.2x10-14 + 1.0x10-15 7.6x10-15 441 1.9x10-14 1.9x10-14 
88.73  + 1.945 9.3x10-15 + 9.0x10-16 4.0x10-15 434 1.0x10-14 1.1x10-14 
200.43 + 1.305 5.4x10-15 + 6.0x10-16 1.9x10-16 421 4.8x10-15 4.5x10-15 
Table 5.2: A table showing the experimental diffusion coefficients for 27 nm, 44 nm, 89 nm and 200 nm 
nanoparticle diffusion through mucus. The table also shows the expected theoretical Stokes-Einstein predicted 
diffusivity values for nanoparticle diffusion through mucus samples with a bulk viscosity of 1000 cP and 400 cP 
and through glycerol with a bulk viscosity of 410 cP.   
                                                    
                                                    
                                                    
                                                    
                                                    
                                                    
                                                    
0 20 40 60 80 100
0.0
5.0x10
-15
1.0x10
-14
1.5x10
-14
2.0x10
-14
2.5x10
-14
3.0x10
-14
3.5x10
-14
4.0x10
-14
4.5x10
-14
5.0x10
-14
Mucus Diffusion Coefficients
D
iff
u
s
io
n
 C
o
e
ff
ic
ie
n
t 
(m
2
s
-1
)
Nanoparticle Radius (nm)
  124 
The Stokes-Einstein equation, Equation 6, was used to calculate the „effective‟ viscosity of 
the sample, i.e the viscosity a fluid would need to have, according to the Stokes-Einstein 
equation, for the nanoparticles of the given size to diffuse through at the measured diffusivity. 
The average effective viscosity „felt‟ by the 27 nm, 44 nm, 89 nm and 200 nm diameter 
nanoparticles was approximately 400 cP + 55 cP, which is lower than the bulk viscosity of the 
1xMUC sample of 1000 cP as characterised in Section 3.1. This data therefore suggests that 
all four nanoparticle sizes diffuse through lower viscosity, fluid-filled pores in the mucus 
structure as suggested in the studies by Sanders et al. 
25, 36
 and Hanes et al. 
77, 79
 as discussed in 
Section 1.6.2. 
 
The average effective viscosity (410 cP) is similar to the bulk viscosity of 94 % glycerol 
(~430 cP). A comparison of the diffusion coefficients of each nanoparticle size through both 
glycerol and mucus is shown in Figure 5.15. The calculated diffusion coefficients of the 44 
nm, 89 nm and 200 nm nanoparticles through both glycerol and mucus are similar, as also 
shown in Table 5.2.    
  
Figure 5.15: A graph showing a comparison of experimental diffusion coefficients of 27 nm, 44 nm, 89 nm and 
200 nm diameter nanoparticles through both mucus and glycerol samples.  
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The smallest 27 nm diameter nanoparticles, however, diffuse through mucus as if through an 
environment with a viscosity of 323 + 12 cP, this is 3 times lower than the measured bulk 
viscosity of the mucus sample. The difference between the effective viscosity values for the 
44 nm, 89 nm and 200 nm values is small and all values can effectively appear to have a 
significant lower effect of viscosity. The data also seems to suggest that although all the 
nanoparticles sizes diffuse through lower viscosity pores, the smallest 27 nm nanoparticles are 
able to gain access to areas of substantially lower viscosity than the other (larger) 
nanoparticles. However, as this occurs for only one nanoparticle size, further investigation 
with additional sizes smaller than 27 nm in diameter were needed before any firm conclusions 
could be drawn. 
 
Figure 5.16 shows the variation of the mean squared displacement with time for the 
nanoparticles, for n=50. For all nanoparticle sizes, the spread of mean squared displacements 
is seen to be wider for diffusion through mucus than through glycerol. The wider variation 
indicates that the nanoparticles are diffusing at a larger range of different speeds through the 
mucus. This could be due to lower viscosity pores in the mucus structure, which are not 
present in the homogeneous glycerol environment.  
 
For the 27 nm diameter nanoparticles, there appears to be almost two populations; those with 
mean squared displacements very similar to that of the 27 nm diameter nanoparticle diffusion 
through glycerol, and then a separate population of faster moving nanoparticles. These results 
indicate that nanoparticles diffusing through 1xMUC model mucus undergo the same 
diffusive process as in glycerol, however, some of the nanoparticles manage to diffuse faster 
than would be expected through a homogeneous fluid with the same bulk viscosity of the 
glycerol sample. This observation is consistent with the results of multiple particle tracking 
experiments of 100 nm, 200 nm and 500 nm polystyrene particles through mucus by Hanes et 
al. 
77
, which stated that the mean diffusion coefficient became dominated by relatively few but 
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fast-moving particles as the particle diameter was decreased, as the smaller particles were able 
to move through lower viscosity pores in the mucus structure 
77
.  
 
 
 
  
Figure 5.16: A diagram showing the distribution of mean squared displacements for nanoparticles 27 nm, 44 nm 
and 89 nm in diameter through both mucus and glycerol samples.  
 
The ensemble-averaged probability distributions of particle displacements are shown in 
Figure 5.17, for 27 nm, 44 nm, 89 nm and 200 nm diameter particles through both glycerol 
and mucus. The distributions can be seen to be Gaussian in shape, which is as expected for a 
purely diffusive system where the particle motion is Brownian 
86
, where σ is the variance of 
the distribution, x is the particle displacement and μ is the mean displacement. 
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Figure 5.17: A comparison of the probability distributions of nanoparticle displacements of 27 nm, 44 nm, 89 nm 
and 200 nm diffusion through both mucus and glycerol samples at 0.03 s, 0.05 s, 0.1 s, 1 s, 2 s and 5 s.  
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When the data was fit to the probability density function for a Gaussian distribution with a 
known time lag τ, Equation 17, the fits for all time lags were close with a minimum R2 of 
0.96. There is more „noise‟ in the probability distributions of the 27 nm and 44 nm diameter 
nanoparticles. They occur in the case of the 1 second and 2 second probability distributions 
because of the difficulty capturing long movies of 27 nm and 44 nm diameter nanoparticles 
due to their fast diffusive motion, there are therefore less displacement values to average over. 
The 89 nm and 200 nm diameter particles move slowly and therefore remain in the 
microscope‟s field of view for long time periods. Movies of the 89 nm and 200 nm diameter 
particles could be captured for up to 20 seconds. At a frame rate of 32 frames per second, this 
means that 640 different displacements could be calculated for each particle, allowing for 
more sampling of averaged displacement values. Due to the significantly faster diffusive rates 
of the 27 nm and 44 nm diameter nanoparticles, especially through mucus, movies could only 
be captured for a maximum of 5 seconds. This only allowed 160 different displacements to be 
calculated for each nanoparticle, just one quarter of the number possible with the larger 
particles. It is for this reason that it is important to verify the diffusion coefficient values 
calculated from the mean squared displacement by examining the probability distributions of 
the particle displacements.           
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In the case of a purely diffusive system in which the particle motion is Brownian, Equation 17 
can be written as a function of both displacement and time, P(x,τ) as shown in Equation. 18, 
where D is the diffusion coefficient. The mean displacement, μ, is zero for Brownian motion, 
as the particle moves in all directions with the same probability. The variance of the 
distribution therefore provides a measure of the diffusion coefficient. 


2
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Figure 5.18: The experimental D values calculated from the probability distributions of particle displacements 
through glycerol and mucus, as a function of the time lag, τ. 
 
Equation 19 was used to calculate the diffusion coefficient for different lag times, τ. The 
experimental D values calculated from the probability distributions of particle displacements 
through glycerol and mucus, as a function of the time lag, τ, are shown in Figure 5.18.  
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Measured 
Diameter (nm) 
Dmucus from mean 
squared displacement 
(m2s-1) 
Dmucus from 
probability 
distribution (m2s-1) 
Dglycerol from mean 
squared 
displacement (m2s-1) 
Dglycerol from 
probability 
distribution (m2s-1) 
27.15 + 1.704 4.9x10-14 + 2.0x10-15 4.9x10-14 + 1.9x10-15 2.7x10-14 + 2.16x10-15 2.9x10-14 + 2.0x10-16 
44.35 + 2.259 2.2x10-14 + 1.0x10-15 1.8x10-14 + 1.1x10-15 1.9x10-14 + 1.63x10-15 2.1x10-14 + 5.8x10-16 
88.73  + 1.945 9.3x10-15 + 9.0x10-16 9.1x10-15 + 1.3x10-16 1.1x10-14 + 1.44x10-15 1.2x10-14 + 6.0x10-16 
200.43 + 1.305 5.4x10-15 + 6.0x10-16 5.3x10-15 + 1.7x10-16 4.5x10-15 + 7.23x10-16 4.3x10-15 + 1.4x10-16 
 
Table 5.3: A comparison of the D values calculated from the mean squared displacement and the probability 
distribution. 
 
Figure 5.18 shows that the nanoparticles require some time before they reach steady-state 
diffusion, this is shown by the sharp drop in the calculated diffusion coefficient before the 
function reaches a plateau as the time lag increases. The diffusion coefficient values for the 89 
nm and 200 nm particles, which could be calculated for longer time lags, show that the plateau 
is reached between 1 and 2 seconds. This indicates that in order to obtain an accurate 
measurement of the diffusion coefficient, the particles must be tracked for longer than 2 
seconds and ideally up to a minimum of 5 seconds, which is why all particles were tracked for 
a minimum of 5 seconds in this study.  Table 5.3 and Figure 5.19 compare the diffusion 
coefficient values calculated from the mean squared displacement and the probability 
distribution. The diffusion coefficient values are in good agreement. 
 
Figure 5.19. A diagram showing a comparison of the diffusion coefficient values obtained from the mean squared 
displacement and the probability distributions of the nanoparticle displacements. 
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 Overall the data suggests that all nanoparticle sizes diffuse through lower viscosity pores in 
the mucus mesh structure. In addition, the data suggests that the 27 nm diameter nanoparticles 
have the ability to diffuse through pores with an even lower effective viscosity than the other 
nanoparticles. Unfortunately it is difficult to fully understand the nature of this enhanced 
diffusivity when it has been observed for only one nanoparticle size. For this reason it was 
necessary to conduct further experiments to verify this diffusive behaviour. Two 
improvements were needed to produce the data required: 
 Experimentation with further nanoparticle sizes, smaller than 27nm in diameter to see 
if smaller nanoparticles had increased diffusive abilities 
 The ability to track the nanoparticles for time periods longer than 5 seconds in order 
to obtain enough displacement values to allow for better statistical sampling 
 
 
5.5.2  Nanoparticle Diffusion through Mucus with increased Mucin Concentration 
 
As discussed in Section 5.5.1, further fluorescent, carboxylate-modified nanoparticle sizes 
were required to understand the relationship between nanoparticle size and diffusion through 
mucus. The only additional fluorescent nanoparticles with a carboxylate-modified surface 
commercially available were functionalised quantum dots from Invitrogen. These quantum 
dots have a cadmium selenide core with a zinc sulfide shell. This core-shell quantum dot was 
then further coated with a polymer (PEG2000) layer which allows dispersion in aqueous 
solutions. The polymer coating has carboxyl surface groups and measured at 12.5 nm in 
diameter. 
 
To address the limitation of the time nanoparticles could be tracked in the mucus environment 
without the fluorescent signal being lost in the z direction, further investigation was carried 
out into the mucus constituent composition. It follows from the literature, Section 1.6, and the 
Stokes-Einstein equation that nanoparticles diffuse more slowly though mucus samples with a 
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higher bulk viscosity. It is difficult to model mucus exactly, as human samples vary 
considerably in constituents and viscosity as discussed in Section 1.6.2. The protocol used to 
reconstitute the 1xMUC model mucus was based on the study by Sanders et al. 
74
, which 
measured the mucus constituent concentrations found in 24 samples. During the course of this 
work, a further study by Broughton-Head et al. 
61
 investigating the large degree of variation in 
mucus composition and new work by Hanes‟ group 42 both stated that the viscosity of human 
airway mucus can range between ~1,000-70,000 cP 
42, 77
. The 1xMUC model mucus had a 
viscosity of only 1000 cP, the decision was therefore made to increase the mucin 
concentration of the reconstituted mucus sample to fit more centrally within the newly 
reported viscosity range. Preliminary tests showed that increasing the mucin concentration to 
8x the concentration recommended by Sanders et al. 
74
, allowed even the smallest 12.5 nm 
diameter carboxylate-modified quantum dots to be tracked for 1000 frames at 32 frames per 
second. These movies were used to track nanoparticles for 30 seconds, giving 960 
nanoparticle co-ordinates for the mean squared displacement and displacement probability 
distribution calculations.  
 
Multiple particle tracking was used to investigate the transport properties of 12.5 nm 
carboxylate-modified quantum dots and 27 nm, 44 nm, 89 nm and 200 nm diameter 
fluorescently-labelled, carboxylate-modified polystyrene nanoparticles through 8xMUC 
model mucus. The overall viscosity of the 8xMUC model mucus sample was 20,000 cP as 
characterised by rheology, outlined in Section 7.8.      
 
The mean squared displacements as a function of time for each nanoparticle size are shown in 
Figure 5.20. Once again the mean squared displacements increase linearly with time for all 
nanoparticle sizes (R
2≥0.99), indicating that the nanoparticles diffuse through mucus by 
Brownian motion. There is therefore no evidence of any nanoparticle interaction or adhesion 
to the mucus mesh structure. 
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Figure 5.20: Average mean squared displacements for the diffusion of 12.5nm, 27nm, 44nm, 89nm and 200nm 
carboxylate-modified nanoparticle diffusion through 8xMUC reconstituted mucus, diffusivity is linear with time 
indicating Brownian motion (R2 ≥ 0.99). 
 
It should be noted that in some instances the calculated mean squared displacement values 
may appear to fluctuate or tail off slightly for the largest time intervals (~25-30 seconds) this 
is because the error in the mean squared displacement value increases with the time interval. 
For displacement calculations of subsequent frames, there are 959 displacement values which 
are averaged, however for displacement values between frame intervals of 25-30 seconds 
there are less than 100 displacement values which are averaged. Therefore the standard 
deviation is higher. The linearity is based on a fit in which R
2 
is at least 0.99.  
 
The diffusion coefficient was calculated by fitting the experimental mean squared 
displacement data to Equation 6, as shown in Table 5.4. The calculated diffusion coefficients 
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were plotted against nanoparticle radius as shown in Figure 5.21. This time, the diffusivity 
showed an excellent fit to the Stokes-Einstein equation, with a calculated viscosity of ~5110 
cP. This data suggests that the increased diffusivity of the 27 nm diameter nanoparticle 
diffusion through the 1xMUC model mucus sample may have been anomalous and that, in the 
8XMUC mucus sample at least, all the nanoparticles are subject to the same effective 
viscosity in the lower viscosity pores in the mucus mesh structure. Diffusion within these 
lower viscosity pores follows the Stokes-Einstein equation for an effective viscosity of ~5110 
cP. This data agrees with the previous literature that pore sizes within the mucus mesh 
structure are 100 nm-500 nm in diameter 
36, 72, 74, 77, 101
, as discussed in Section 1.6.2. It is 
difficult to determine a universal mucus mesh pore size, as that large variation in the measured 
pore size is due to variation between mucus samples. For the samples used in this study, the 
evident diffusion of all nanoparticle sizes up to 200 nm in diameter and the images obtained 
from fluorescent staining of the mucin in the mucus samples, Section 3.1.2, the minimum 
pores size can be considered to be at least ~300 nm, which agrees with the estimation of 471.8 
nm in the previous literature 
61
.  
 
Figure 5.21. A diagram showing the diffusivities of 12.5 nm, 27 nm, 44 nm, 89 nm and 200 nm nanoparticles 
through mucus as a function of nanoparticle radius. The data is consistent with the Stokes-Einstein equation, with 
an effective viscosity of 5110 cP. 
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The distribution of individual mean squared displacements for all nanoparticle sizes is once 
again wide, showing that there is a variety of different nanoparticle motions and speeds 
denoting areas of differing resistance within the mucus mesh, as shown in Figure 5.24. The 
diffusion of the 27 nm diameter nanoparticles conforms to the Stokes-Einstein equation for 
this instance, and this time does not have two populations as in Figure 5.16. This conformity, 
and the agreement of the 12.5 nm diameter carboxylate-modified quantum dots to the Stokes-
Einstein equation shows that carboxylate-modified nanoparticles, within the size range of 12.5 
nm – 200 nm in diameter, are consistent with the Stokes-Einstein equation for diffusion 
through the 8xMUC model mucus used, albeit with an effective viscosity that is 
approximately one quarter of the bulk value.  
 
The average effective viscosity, calculated from the Stokes-Einstein equation is 4 times less 
than the bulk viscosity of the mucus sample with a value of 5058 cP + 268 cP, consistent with 
nanoparticles moving through lower viscosity pores in the same sample. The best fit of η to 
the Stokes-Einstein equation is 5110 cP. 
 
Measured 
Diameter (nm) 
Experimental Dmucus 
(m2s-1) 
Stokes-Einstein 
calculated 
 Dη=20000cP (m
2s-1) 
Effective 
Viscosity (cP) 
Stokes-Einstein 
calculated 
 Dη=5110cP (m
2s-1) 
12.5 + 1.825 6.5x10-15 + 1.58x10-16 1.6x10-15 5292 6.2x10-15 
27.15 + 1.704 3.3x10-15 + 2.03x10-16 7.9x10-16 4779 3.1x10-15 
44.35 + 2.259 1.8x10-15 + 1.21x10-16 4.9x10-16 5385 1.9x10-15 
88.73  + 1.945 1.0x10-15 + 1.33x10-16 2.4x10-16 4846 9.5x10-16 
200.43 + 1.305 4.3x10-16 + 1.07x10-16 1.1x10-16 4989 4.2x10-16 
Table 5.4: A table showing the experimental and theoretical diffusion coefficients for the diffusion of 12.5 nm-200 
nm diameter carboxylate-modified nanoparticle through mucus samples.    
 
5.5.3  PEGylated Nanoparticle Diffusion through Mucus 
As described in Section 1.6.5, the PEGylation of therapeutics neutralises the surface charge 
and hence can increase bioavailability 
109
. The effect of PEGylation on the diffusivity of 
nanoparticles less than 100 nm in diameter was examined for this study. Nanoparticles and 
quantum dots were PEGylated as outlined in Section 2.4 to synthesis a size range of six 
PEGylated nanoparticles 28 nm, 36 nm, 51 nm, 60 nm, 112 nm and 219 nm in diameter. 
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Multiple particle tracking experiments were carried out for each nanoparticle size through the 
8xMUC model mucus as outlined in Section 7.11. Movies were, once again, captured for 1000 
frames at a frame rate of 32 frames per second. From these movies nanoparticles were tracked 
for 30 seconds in total. The calculated average mean squared displacements of each 
nanoparticle size as a function of the time interval are shown in Figure 5.22.  
 
 
Figure 5.22: Average mean squared displacements for the diffusion of 27.5 nm, 36 nm, 51 nm, 60 nm, 112 nm and 
219 nm diameter PEGylated nanoparticle diffusion through 8xMUC model mucus. The mean squared displacement 
varies linearly with time indicating Brownian motion (R2 ≥ 0.99). 
The average mean squared displacement is again observed to increase linearly with time for 
all nanoparticle sizes, showing that the nanoparticles are diffusing through the mucus 
environment by Brownian motion. Linearity of this nature shows that nanoparticles are not 
largely obstructed by the mucus mesh environment. 
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Measured 
Diameter (nm) 
Experimental Dmucus 
(m2s-1) 
Stokes-Einstein 
calculated 
 Dη=20000cP (m
2s-1) 
Effective 
Viscosity (cP) 
Stokes-Einstein 
calculated 
 Dη=5110cP (m
2s-1) 
27.53 + 1.639 3.0x10-15 + 2.34x10-16 7.9x10-16 5285 3.1x10-15 
35.81 + 1.881 2.5x10-15 + 1.51x10-16 6.1x10-16 4801 2.4x10-15 
51.23 + 6.143 1.8x10-15 + 1.97x10-16 4.1x10-16 4662 1.6x10-15 
60.12 + 2.873 1.5x10-15 + 1.29x10-16 3.6x10-16 4768 1.4x10-15 
112.23 + 1.450 7.2x10-16 + 1.73x10-16 1.9x10-16 5321 7.5x10-16 
219.17 + 1.002 3.7x10-16 + 1.01x10-16 1.0x10-16 5302 3.9x10-16 
Table 5.5: A table showing the experimental and theoretical diffusion coefficients for the diffusion of 27.5 nm-219 
nm diameter PEGylated nanoparticles through mucus samples.    
 
The diffusivity of each nanoparticle size through 8xMUC model mucus was calculated and 
plotted against nanoparticle radius. Figure 5.23, shows that the nanoparticle diffusion once 
again conforms to the Stokes-Einstein equation, with a fitting viscosity parameter of ~5100 + 
54 cP. This suggests that the PEGylated nanoparticles behave much like the non-PEGylated 
nanoparticles for diffusion through the 8xMUC model mucus samples.  
 
 
Figure 5.23: A diagram showing the diffusivities of 27.5 nm – 219 nm diameter nanoparticles through mucus as a 
function of nanoparticle radius. The data conforms to the predictions of the Stokes-Einstein equation. 
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Figure 5.24: Graphs showing a comparison of the variation in mean squared displacement of non-PEGylated and 
PEGylated nanoparticle diffusion through 8xMUC model mucus.  
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Both the non-PEGylated and PEGylated nanoparticles diffuse by Brownian motion through 
lower viscosity pores in the mucus mesh structure which appear to be large enough to allow 
essentially unhindered diffusion of particles up to ~220  nm in diameter.  
 
A comparison of the mean squared displacement distribution of the non-PEGylated 
nanoparticles with the PEGylated nanoparticles as shown in Figure 5.24, shows that the 
distribution is large and varied for all nanoparticle populations. Once again the distribution are 
wider than those of the same, or similarly sized nanoparticles through glycerol samples due to 
the need to traverse the complicated mucus mesh structure. Some of the PEGylated 
nanoparticle populations, such as the 60 nm diameter nanoparticles show a very wide 
distribution of mean square displacements. This is due to some of the 44 nm diameter 
nanoparticles aggregating before PEGylation, leading to larger PEGylated nanoparticles in the 
population. This is reflected in the large polydispersity index of the 44 nm nanoparticles as 
shown in Table 2.2. 
 
The average effective viscosity, determined from the Stokes-Einstein equation is 4 times less 
than the bulk viscosity of the mucus sample with an average of 5032 cP + 280 cP. The best fit 
of η to the Stokes-Einstein equation is ~5100 cP, which is similar to the value obtained from 
the diffusion experiments of non-PEGylated nanoparticles (~5110 cP).  
 
The data shows that both the non-PEGylated and PEGylated nanoparticles diffuse through an 
environment with a viscosity of ~5110 cP, 4 times lower than the bulk viscosity of 20,000 cP. 
The data suggests that for the size range measured (12.5 nm – 220 nm) nanoparticle size is the 
dominant parameter on which the diffusivity is dependent. The surface charge does not appear 
to significantly change the nanoparticle diffusivity. Both the negatively charged, non-
PEGylated nanoparticles and the near-neutral PEGylated nanoparticles diffuse through the 
8xMUC model mucus through with the same relationship between nanoparticle radius and 
diffusivity, as can be seen in Figure 5.25.   
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Figure 5.25: A diagram showing the diffusivities of all non-PEGylated and PEGylated nanoparticles through 
mucus. The nanoparticle diffusivities correlate with nanoparticle radius as predicted by the Stokes-Einstein 
equation. 
 
Figure 5.25, shows the correlation of diffusivity against nanoparticle radius for all non-
PEGylated and PEGylated nanoparticle together. The experimental data shows that all the 
nanoparticles investigated diffuse through lower viscosity pores in the mucus structure in 
accordance with the predictions of the Stokes-Einstein equation. There is no appreciable 
difference between the PEGylated and non-PEGylated nanoparticles.  
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CHAPTER 6: CONCLUSIONS AND  
FUTURE DIRECTION 
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6.1  Conclusions 
 
Classical diffusion of large particles greater than 100 nm in diameter is size dependent; with 
decreasing size resulting in increased diffusivity. The Stokes-Einstein equation, Equation 1, 
states that in the case of neutral particles diffusing through a Newtonian, homogeneous 
viscous fluid, diffusivity is inversely proportional to particle radius.  
 
Multiple particle tracking was used to investigate the diffusive motion of non-PEGylated and 
PEGylated fluorescent, carboxylate-modified polystyrene nanoparticles and quantum dots 
ranging from 12.5 nm to 219 nm in diameter through carefully controlled samples of 8xMUC 
model mucus. Reconstituted mucus was used to facilitate a systematic study of nanoparticle 
diffusion in the mucus mesh environment. This study aimed to investigate the nature of non-
PEGylated and PEGylated nanoparticle diffusion through mucus in a systematic and 
controlled manner. The study was carried out to obtain an understanding of the effects of 
nanoparticle size and surface charge on the diffusivity of nanoparticles up to 200 nm in 
diameter through mucus samples, with a particular interest in nanoparticles <100 nm in 
diameter. Understanding the relationship between nanoparticle size and diffusivity through 
mucus is useful for improving pulmonary delivery, in particular for the case of cystic fibrosis. 
No previous investigations into the diffusion of nanoparticles less than 100 nm in diameter 
through mucus to understand the relationship between diffusivity and nanoparticle size have 
been reported. 
 
In order to perform this study, commercially available nanoparticles were PEGylated as 
described in Section 7.2 & 7.3, to obtain a range of both negatively charged and near-neutral 
nanoparticles for multiple particle tracking experiments. The nanoparticle PEGylation and 
characterisation techniques are discussed in Chapter 2. 
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For experiments to be carried out in a controlled and systematic manner, model mucus 
samples were reconstituted and characterised, as described in Chapter 3, with careful control 
of the mucus constituents and constituent concentrations. A survey of the previous literature 
was carried out to understand the composition of mucus to enable reconstitution of a suitable 
mucus sample for experiments. The mucin within the model mucus samples were 
characterised, stained and imaged via fluorescence microscopy to ensure that the model 
mucus samples used had a complicated mucus mesh structure representative of human mucus 
samples. The stained mucus samples were used to evaluate the porous structure of the mucus 
samples.  
 
This study also assessed the suitability of different experimental methods for measuring the 
diffusivities of nanoparticles in complicated biological fluids, as described in Section 1.5. 
Both vertical diffusion chambers, Chapter 4, and multiple particle tracking, Chapter 5, were 
used to investigate the diffusive nature of fluorescent, carboxylate-modified nanoparticles 
through reconstituted mucus samples. The experiments conducted using the vertical diffusion 
chamber method suggested that nanoparticles <100 nm in diameter might be able to diffuse 
through mucus samples at rates faster than expected from the viscosity of the bulk mucus 
sample. However, due to limitations in the experimental procedure as discussed in Chapter 4, 
no firm conclusions could be drawn from the data and it was necessary to adopt a more robust 
experimental procedure. 
 
The equipment necessary for multiple particle tracking of the smaller 27 nm and 44 nm 
diameter nanoparticles became available through the course of this study. Multiple particle 
tracking had not previously been available as the cameras were not fast enough and the lasers 
were not bright enough to process the low fluorescent signals emitted by the smaller 27 nm 
and 44 nm diameter nanoparticles. This study therefore developed and enhanced the 
procedure based on the multiple particle tracking of larger nanoparticles 100 nm-500 nm in 
diameter by Hanes et al. 
79
. Multiple particle tracking was used to investigate the diffusive 
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nature of 12.5 nm diameter carboxylate functionalised quantum dots, 27 nm, 44 nm, 89 nm, 
200 nm diameter fluorescently-labelled, carboxylate-modified polystyrene nanoparticles, 27.5 
nm and 35.8 nm PEGylated quantum dots and 51 nm, 60 nm, 112 nm and 219 nm diameter 
PEGylated polystyrene nanoparticles, through samples of 8xMUC model mucus, as described 
in Chapter 5. 
 
Through the course of this study the MSDcalculator software was also written and fully 
explained as a tool for accurately and efficiently analysing the data obtained from multiple 
particle tracking. A guide for users of MSDcalculator is provided in Appendix A, to allow this 
software to be used in future multiple particle tracking experiments of this nature. The code 
for the software is provided in Appendix B.   
 
This study has shown that multiple particle tracking is an accurate technique suitable for the 
measurement of the diffusion coefficient of nanoparticles 12.5 nm-22 nm in diameter. The 
technique was validated for nanoparticle diffusion through glycerol which is a homogeneous, 
Newtonian fluid in which the Stokes-Einstein equation holds using the bulk viscosity. This 
validation showed that multiple particle tracking could reliably be used to investigate the 
diffusivity of nanoparticles in the complicated mucus environment. This study also showed 
that in order to obtain statistically robust experimental data nanoparticles should be tracked 
and evaluated for a minimum of 30 seconds to obtain enough nanoparticle displacements for 
accurate average mean squared displacement calculation. In order to achieve this, the bulk 
viscosity of the mucus sample had to be increased to 20,000 cP by using 8 times the mucin 
concentration outlined in the protocol by Sanders et al. 
74
. The use of reconstituted mucus 
allowed the mucin concentration to be changed in a controlled way which would have been 
impossible in human samples. 
 
Once the experimental technique had been validated and established, multiple particle 
tracking was used to investigate the diffusion of 12.5 nm-200 nm carboxylate-modified 
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nanoparticles and 27.5 nm-220nm PEGylated nanoparticles through mucus with a bulk 
viscosity of 20,000cP. This study found that all nanoparticles investigated diffuse through 
lower viscosity pores in the mucus mesh structure, with an effective viscosity of ~5110 cP, as 
shown in Figure 5.21. Nanoparticle diffusion within these pores is via Brownian motion and 
subject to microviscosities 4 times lower than the macroviscosity of the bulk mucus sample. 
This result is consistent with previous studies by Sanders et al. 
25, 36
 and Hanes et al. 
77, 79
, as 
discussed in Section 1.6.1, which found that nanoparticles smaller than the mucus mesh size 
can diffuse through lower viscosity pores in the mucus structure at much faster speeds than 
would be expected from the bulk viscosity of the mucus samples.     
 
The evidence shows that pores within the mucus mesh structure are large enough to allow 
less-hindered diffusion of nanoparticles up to 220 nm in diameter, suggesting that pores are at 
least ~300 nm in diameter, which is consistent with previous studies which state that pore 
sizes range between 100-500 nm 
36, 77
 (up to 1440 nm 
61
) and that the average pore size is 
471.8 nm in diameter 
61
, as discussed in Section 1.6.2. Within these lower viscosity pores, 
diffusivity is dependent upon nanoparticle size as hypothesised by the Stokes-Einstein 
equation, diffusion is inversely proportional to nanoparticle radius. 
 
This study focused on the diffusion of nanoparticles <100 nm in diameter through mucus. 
Nanoparticles up to 220 nm in diameter were used in experiments for comparability with 
previous studies which investigated the diffusion of nanoparticles 100 nm – 500 nm in 
diameter 
25, 36, 77, 79
. We found that all nanoparticles, even those up to 220 nm in diameter were 
able to diffuse through lower viscosity pores in the mucus structure offering enhanced 
diffusivity as desired for delivering drug and genes for therapeutic purposes. No particular 
improvement in diffusive ability was observed for nanoparticles smaller than <100 nm in 
diameter compared to the particles >100 nm in diameter investigated. Therefore, no additional 
benefit, other than the faster diffusion due to smaller nanoparticle size as modelled by the 
Stokes-Einstein equation, was observed for nanoparticles smaller than 100 nm in diameter. 
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Overall this study therefore suggests that reducing the size of therapeutics for pulmonary 
administration to smaller than ~300 nm in diameter will improve transport through the mucus 
layer as nanoparticles can diffuse through lower viscosity pores with an effective viscosity ~4 
times less than that of the bulk viscosity of the mucus sample. Once within these pores, further 
reduction of the nanoparticle size will offer enhanced diffusive ability for the therapeutic as 
modelled by the Stokes-Einstein equation. This type of quantitative information is useful for 
researchers developing nanoparticle therapeutic delivery systems to allow them to assess if a 
particular reduction in size, for example from 80 nm to 50 nm in diameter at the possible 
expense of therapeutic functionality or payload capability is worthwhile. 
 
Finally, due to the increasing interest in PEGylation of nanoparticle therapeutic systems for 
improved bioavailability and pharmacokinetics, as described in Section 1.6.5, the effect of 
nanoparticle PEGylation on the diffusivity of nanoparticles 27.5 nm-220 nm in diameter 
through the model mucus samples was evaluated using multiple particle tracking. Previous 
studies had shown substantial interaction between carboxylate-modified particles and the 
mucus environment due to the effects of muco-adhesion, as discussed in Section 1.6.4. This 
study, surprisingly, showed that PEGylated nanoparticles diffused through mucus with the 
same behaviour and size dependence as the non-PEGylated nanoparticles. The PEGylated 
nanoparticles were also small enough to diffuse through lower viscosity pores in the mucus 
structure where they were subject to the microviscosities ~4 times lower than the measured 
macroviscosities of the bulk sample. The PEGylated nanoparticle diffusivity was dependent 
on nanoparticle size once again as modelled by the Stokes-Einstein equation. The near-neutral 
surface charge of the PEGylated nanoparticles provided no enhanced diffusive ability. The 
PEGylated nanoparticle diffusivities correlated with the non-PEGylated nanoparticles, 
showing that at this scale the effects of surface charge are negligible in comparison to the 
effects of nanoparticle size on diffusivity through the mucus mesh environment. Once again 
results of this type are useful for researchers when deciding on the surface characteristics of 
therapeutics. If the surface charge is known not to affect the diffusivity of the therapeutic for 
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delivery purposes, the therapeutics surface may be synthesised according to other 
requirements, such as targeting or bioavailability.  
This study has systematically shown that, for nanoparticles (12.5 nm – 220 nm in diameter) 
diffusing through reconstituted mucus modelling the mucus lining the lung epithelial, size is 
the overruling factor affecting nanoparticle diffusivity. The effects of surface charge have 
been shown negligible compared to those of nanoparticle size. The further the size can be 
reduced, the faster the nanoparticle will be able to diffuse through the mucus environment 
with nanoparticle radius being inversely proportional to diffusivity as modelled by the Stokes-
Einstein equation.  
 
 
6.2  Future Direction 
 
This work has provided information which can guide researchers developing therapeutics for 
lung diseases such as cystic fibrosis. There are a number of ways in which this work can be 
enhance by further investigation, which are discussed in this Chapter. 
 
 
6.2.1  Increasing the Number and Range of Nanoparticle Sizes 
An important future direction for this work would be investigation into the diffusivity of more 
nanoparticle sizes of both non-PEGylated and PEGylated nanoparticle diffusion through 
mucus. Of particular interest would be investigation into the diffusivities of nanoparticles 
smaller than the ~12.5 nm diameter nanoparticles used in this study. In order to achieve this, 
further sources of highly-fluorescent, monodisperse nanoparticles would need to be found. 
Quantum dots have the ability to provide highly-fluorescent nanoparticles within the size 
ranges required. They would provide a stronger fluorescent signal than the fluorophore-based 
fluorescence of the polystyrene nanoparticles.  
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6.2.2  Increasing the Variety in Nanoparticle Surface Charges 
To further verify the effects of surface charge reported by this study, investigation into the 
diffusion of positively-charged nanoparticles would be beneficial. The effects of positive 
charge are not in the scope of this project, but may be shown to provide enhanced diffusivity 
or more hindered transport. Another variation on further work of this nature would be the 
investigation into the diffusion of highly-negative or highly-positively charged nanoparticles. 
The negatively-charged nanoparticles used in this study have a maximum surface charge of 
~60 mV. It would be interesting to investigate nanoparticles with a wider range of surface 
charges to understand if the results reported in this study apply for all negatively and near-
neutrally charge nanoparticles, or if there is a limit, above which the effects of surface charge 
become the dominating factor. 
  
6.2.3  Multiple Particle Tracking through Human Mucus Samples 
An important future direction for this work would be multiple particle tracking experiments of 
nanoparticles through mucus samples from human samples. Now that a baseline for this 
investigation has been achieved through this study, the next stage would be application to a 
real-life environment. This would start with mucus samples obtained from both healthy lungs 
and from patients suffering from cystic fibrosis. Investigation of this nature will allow the 
extent of enhanced diffusivity through lower viscosity pores in human mucus samples to be 
further understood. This study has shown the information that nanoparticles can diffuse 
through lower viscosity pores more efficiently than would be predicted from the bulk 
viscosity of the sample. However, the exact extent to which diffusivity is enhanced will differ 
between the model mucus and real human samples due to the increased complexity of human 
samples, as discussed in Section 1.3.  
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CHAPTER 7: MATERIALS AND METHODS 
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7.1  Materials 
 
All reagents used were obtained from Sigma-Aldrich unless otherwise stated. Fluorescent, 
carboxylate-modified, polystyrene nanoparticles 20 nm (F8787), 40 nm (F8795), 100 nm 
(F8803), 200 nm (F8811) from Invitrogen. CdTe/ZnS amino functionalised Quantum Dots – 
ITK705-amino (QD-PEG2000-NH2) supplied in 8 μm 50 mM borate buffer from Invitrogen. 
CdTe/ZnS carboxylate functionalised Quantum Dots – ITK705-carboxyl (QD-PEG2000-
COOH) supplied in 8 μm 50 mM borate buffer from Invitrogen. Microcon YM100 spin 
column from GE Healthcare. α-methoxy-ω-carboxylic acid succinimidyl ester poly(ethylene 
glycol) (NHS-PEGx-OCH3)(X=750 and 5000) from Iris Biotech GmbH. Mucin (bovine 
submaxillary, Type I-S, M2985), linear DNA (salmon testes, D1626) and Albumin (bovine, 
A7906) all from Sigma Aldrich. Labtek coverglass chambered 8 well sample holder (Nunc, 
Thermo Fisher Scientific). Vertical Diffusion Chamber System (Harvard Apparatus, 
Massachusetts, USA), Nucleopore track-etched polycarbonate membranes 25 mm diameter, 
0.4 μm pores (Whatman, UK). 
 
 
7.2 Quantum Dot PEGylation 
 
Commercially available QD-PEG2000-NH2 8 μM in borate buffer (50 mM borate, pH 8.3) were 
exchanged against mucus buffer (85 mM Na
+
, 75 mM Cl
-
, 3 mM Ca
2+
, 20 mM HEPES, pH 
7.4) using a Microcon YM100 spin column (3 x 4,000rpm, 10 min). The quantum dots were 
then sonicated for 1h in the dark. 1μmol of the α-methoxy-ω-carboxylic acid succinimidyl 
ester poly(ethylene glycol) (MeO-PEG-NHS) was dissolved in 875 μL anhydrous Dimethyl 
sulfoxide (DMSO), which was then added to 125 μL of the QD-PEG2000-NH2 in mucus buffer. 
The mixture was stirred in the dark at room temperature for 30 min. The PEG conjugated 
quantum dots were then purified against mucus buffer using dialysis with a 25000 MWCO 
dialysis membrane.    
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7.3 Nanoparticle PEGylation 
 
Commercially available fluorescent, carboxylate-modified, polystyrene nanoparticles with 
varying sizes (27 nm – 200 nm) in 2 mM NaN3 were exchanged against mucus buffer (85 mM 
Na
+
, 75 mM Cl
-
, 3 mM Ca
2+
, 20 mM HEPES, pH 7.4) using a Microcon YM100 spin column 
(3 x 4,000 rpm, 10 min). The nanoparticles were then sonicated for 1h in the dark. 20 mg 
Methoxy PEG (750Da) with a terminal amino functionality was dissolved in 1mL of 50 mM 
2-(N-morpholino) ethanesulfonic acid (MES) buffer (pH 6.0). This was then added to 1 mL 
(2% solids) of the carboxylate-modified, polystyrene nanoparticles and stirred for 15 min at 
RT. To this mixture 8 mg of 1-ethyl-3-(3-dimethyaminopropryl)-carbodiimide (EDC) was 
added and the solution pH was adjusted to 6.5 with dilute NaOH. The mixture was stirred for 
2h in the dark at RT. The reaction was quenched by adding 7.5 mg glycine and subsequently 
stirring for 30 min at room temperature. The PEGylated nanoparticles were purified by 
extensive dialysis against mucus buffer using dialysis with a 25000 MWCO dialysis 
membrane.    
 
 
7.4 Measurement of Nanoparticle Size using Dynamic Light Scattering 
 
PEGylated and non-PEGylated nanoparticles and quantum dots were sized in mucus buffer 
using a Malvern Zetasizer NS. Commercially available fluorescent, carboxylate-modified, 
polystyrene nanoparticles with varying sizes (27 nm – 200 nm) in 2 mM NaN3 were 
exchanged against mucus buffer (85 mM Na
+
, 75 mM Cl
-
, 3 mM Ca
2+
, 20 mM HEPES, pH 
7.4) using a Microcon YM100 spin column (3 x 4,000 rpm, 10 min). The nanoparticle 
solutions were sonicated for 1h in the dark. 0.7 mL of nanoparticle solution was placed into a 
disposable capillary cell, the size was measured using a Zetasizer. Each nanoparticle sample 
was sized three times.    
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7.5 Measurement of Nanoparticle zeta potential using Laser Doppler Electrphoresis 
 
The zeta potential of PEGylated and non-PEGylated nanoparticles and quantum dots were 
measured in mucus buffer using a Malvern Zetasizer NS. Commercially available fluorescent, 
carboxylate-modified, polystyrene nanoparticles with varying sizes (27 nm – 200 nm) in 2 
mM NaN3 were exchanged against mucus buffer (85 mM Na
+
, 75 mM Cl
-
, 3 mM Ca
2+
, 20 
mM HEPES, pH 7.4) using a Microcon YM100 spin column (3 x 4,000 rpm, 10 min). The 
nanoparticle solutions were sonicated for 1h in the dark. 0.7 mL of nanoparticle solution was 
placed into a disposable capillary cell. Each nanoparticle sample was sized in triplicate. 
 
7.6  Mucus Buffer 
 
Mucus buffer (85 mM Na
+
, 75 mM Cl
-
, 3 mM Ca
2+
, 20 mM HEPES, pH 7.4) was made by 
mixing 3.40 g CaCl, 5.60 g NaOH and 1.48 g HEPES in 1 L of ddH2O and regulating the pH 
to 7.4 using dilute HCl and NaOH. 
 
 
7.7 Mucus Reconstitution 
 
Mucus was reconstituted by adding mucus buffer to mucin (31 mg/mL), albumin (25 mg/mL) 
and DNA (2.7 mg/mL). The mucus was left to rest at 4 °C for 1h, then stirred gently. This was 
repeated several times. The sample was then left to rest overnight at 4 °C for 1h. To 
reconstitute mucus with 8x the mucin concentration the same procedure was followed using 
248 mg/mL mucin.  
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7.8 Mucus Rheology Characterisation 
 
Mucus was characterised using a control-stressed cone and plate rheometer (Physica, UDS 
200). 1 mL of the mucus sample was placed on the plate and a 50 mm cone was used at 1 ° at 
21 °C. The shearing stress and shear viscosity of the sample was measured between shear 
rates of 0.01 s
-1
 and 1000 s
-1
. Each measurement was done three times.  
 
 
7.9 Mucus Staining 
 
10 μL of mucus was placed on a microscope slide and left to adhere for 20 min at RT. 10 μL 
100 % ethanol was added to fix the sample and left for 45 min at RT. 5 μL of TRITC (10 
μg/mL in mucus buffer) was added to the mucus sample and left for 20 min in the dark at RT. 
The sample was then sealed with a coverslip and nail varnish. 
 
 
7.10 Vertical Diffusion Chambers 
 
50 μL of mucus was placed in the mucus container and sealed. The mucus container was 
placed in between the donor and acceptor compartments of the vertical diffusion chambers 
and fixed in place. The vertical diffusion chamber was placed into the heating block and the 
temperature was regulated to 37 °C. 3 mL of the nanoparticle solutions 1.08x10
12
 
nanoparticle/mL was added to the donor compartment and 3 mL of mucus buffer was added to 
the acceptor compartment. After 40 mins, 600 μL was taken from the acceptor compartment, 
the nanoparticle concentration was measured using fluorescence spectroscopy (Shimadzu RF-
5301PC Spectrofluorophotometer). A calibration curve was created by measuring the 
fluorescent intensity of nanoparticle solutions of known concentrations. This curve was then 
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used to calculate the nanoparticle concentration of the acceptor compartment based on the 
fluorescence intensity of the sample. 
 
 
7.11 Multiple Particle Tracking 
 
300 μL of mucus/glycerol was placed in vial, to which 20 μL of nanoparticle solution (0.02 % 
w/v) was added and stirred gently. 200 μL of this mixture was then transferred into the Labtek 
coverglass chambered 8 well sample holder. The sample holder was placed on the microscope 
stage and left to equilibrate for 30 min at RT. Areas were chosen at random for multiple 
particle tracking as detailed in Chapter 5. 
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APPENDIX A: MSDcalculator Software Package User Manual 
 
For the purpose of this study, and to increase the efficiency of data analysis, a software 
package, called MSDcalculator, was written to extract the nanoparticle co-ordinate data and 
calculate the mean squared displacement from the raw data files exported by View5D and 
Volocity. As MSDcalculator was created for the specific purpose of calculating mean squared 
displacements from multiple particle tracking experiments, the following explains, in detail, 
how the software can be used and is intended to serve as an instruction manual for future 
work. 
 
The raw data files from both View5D and Volocity were formatted to have the same general 
structure so that both were compatible with macro MSDcalculator. The first sheet of the raw 
data file contains a list of the required track IDs and the time span specified in number of 
frames, as shown in Figure A.1. A list of the nanoparticle‟s co-ordinates in all frames of the 
multiple particle tracking movie is needed to calculate the mean squared displacement.  
 
 
Figure A.1: A screen shot of the sheet one of the output file, showing the format required by the MSD calculator 
macro to process the co-ordinate data output by both Volocity and View5D. The track IDs are required to find the 
correct co-ordinate information. 
 
Both Volocity and View5D export a large list of all nanoparticle co-ordinates tracked in the 
movie. These lists are imported into and saved as excel spreadsheets. Before mean squared 
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displacement calculations can be performed, these large co-ordinate lists must be separated 
into the co-ordinate lists of each individual nanoparticle. This pre-processing, and the eventual 
mean squared displacement calculations are performed by MSDcalculator, which was 
developed specifically for this project. MSDcalculator uses the first sheet to calculate the 
number of required nanoparticle co-ordinate lists in this data file and creates an array of Track 
IDs of the required trajectories. 
  
The macro creates an output file and for each Track ID, creates a new excel sheet, named with 
the Track ID and then sifts through the large co-ordinate list in Sheet2 to find the 
corresponding co-ordinate list which it copies into columns B and C of the output file, as 
shown in Figure A.2. At this stage the centre of mass of the nanoparticle population must be 
calculated in order to correct for any effects of convection that may occur within the sample 
during experimentation, as discussed in Section 5.4.3. For the purpose of centre of mass 
calculations, after pasting the co-ordinate list, the macro stores the co-ordinates in an array of 
values. There are two arrays, one for the x-co-ordinate values and one for the y-co-ordinate 
values. As subsequent co-ordinate lists are copied, over the co-ordinate values for each time 
frame are added to the value stored in the array. This is done to calculate the centre of mass, 
which is done by adding the x co-ordinate values for each nanoparticle for a single time point 
together and dividing by the total number of nanoparticles, under the assumption that all 
nanoparticles have the same mass. The same is also done for the y co-ordinates. After all the 
nanoparticle co-ordinates have been separated and copied into the output file and accumulated 
in the array, the macro divides the x-array and y-array values by the total number of 
nanoparticles. The array is stored for centre of mass correction as described in Section 5.4.3. 
The macro then works through each sheet subsequently to perform the necessary mean 
squared displacement calculations. 
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Figure A.2: A screen shot showing the sheets created for each nanoparticle track in the output file by the 
MSDcalculator macro. The particle trajectory co-ordinates for the relevant particles must be found in the large list 
of co-ordinates output by View5D. 
 
MSDcalculator first displays the centre of mass co-ordinates in columns G and H and the 
centre of mass adjusted co-ordinate values in columns K and L. The mean squared 
displacement values are then calculated and displayed in column D for the original co-
ordinate list and column M for the centre of mass corrected co-ordinate list, as shown in 
Figure A.3. If there are no drift or convection effects, both sets of mean squared displacement 
values should be the same.    
 
 
Figure A.3: A screen shot showing the completed sheets created for each nanoparticle track by the MSDcalculator 
macro. The mean squared displacement is calculated for both the original and centre of mass corrected co-
ordinates. 
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Figure A.4: A schematic showing how the mean squared displacement algorithm works through the co-ordinate 
arrays of a  nanoparticle‟s trajectory co-ordinates to calculated each mean squared displacement value. 
 
A.1  Mean Squared Displacement Calculation Algorithm 
An algorithm was developed to calculate the mean squared displacement values for a given 
list of nanoparticle co-ordinates. This algorithm could then be applied to any list of co-
ordinates, including the centre of mass corrected co-ordinates. The x and y co-ordinates of 
each nanoparticle trajectory are stored in separate arrays. The mean squared displacement 
algorithm takes the x and y coordinates from these arrays and calculates the nanoparticle 
displacements using the following equation:  
 
)()( 1212 xxyyMSD   
 
In the first pass, the algorithm calculates all displacements of the nanoparticle relative to its 
position in the first frame. The displacement is calculated between the second and first frame, 
the third and first frame, the fourth and first frame and so on. The second pass then calculates 
all displacements of the nanoparticle relative to its position in the second frame. 
  
The displacement values are saved in a separate „displacement‟ array in which the first cell 
stores the displacements between subsequent frames, the second cell stores displacements 
between every second frame, the third cell stores the displacements between every third 
frame, and so forth. Each time the algorithm, Figure A.5, passes through the co-ordinate array, 
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it adds the calculated displacements to the corresponding values in the displacement array. 
Once all cells in the co-ordinate arrays have been worked through, the algorithm goes through 
the displacement array, and averages the values by dividing by the number of displacements 
for each time interval. If n is the number of frames in the movie clip, there are n-1 
displacements values for subsequent frames, n-2 displacement values for every second frame, 
n-3 displacements for every third frame and so on. 
 
Figure A.5: The algorithm for mean squared displacement calculation used in the MSDcalculator software. 
 
 
A.2  Centre of Mass Correction 
 
During preliminary experiments, drag effects could be seen in the nanoparticle trajectories. 
These effects can be seen when all nanoparticles in a given movie appear to be moving 
randomly, but with an overall motion in one direction. This can be the case if the environment 
within which the nanoparticles are diffusing is itself moving, or if there are convection effects 
due to temperature gradients in the incubation chamber of the microscope system. Much effort 
was made to reduce these drag effects, by running the experiments at room temperature, and 
leaving the sample to equilibrate for extended periods of time so that any residual motion 
from the mixing of the sample and the transfer from the vial to the sample holder could 
diminish. Unfortunately in some cases, residual drag effects were still apparent. These effects 
Input:   1D array of x co-ordinates x[n] with n co-ordinate values 
  1D array of y co-ordinates y[n] with n co-ordinate values 
 
Output:   1D array of average displacement values d[n] with n co-ordinate values 
 
for a=0 to a=n-2 
 for b=a+1 to b=n-1 
   
  d[b] = d[b] + ((x[b]-x[a])+(y[b]-y[a])) 
 
for c=0 to c=n-1 
  
 d[c] = d[c] ÷ n-a 
 
return d 
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can, however, easily be corrected by calculating the nanoparticle displacements relative to the 
centre of mass, rather than relative to the origin. 
 
 
 
Figure A.6: A diagram showing a) the centre of mass of three nanoparticles. If there are drag effect due to motion 
of the environment, the centre of mass moves with the particles in the direction of the drag, b). 
 
The centre of mass of n nanoparticles is the average of their x and y co-ordinates, Figure 
A.6.a. If all the nanoparticles have an overall motion in one direction due to drag effects, the 
centre of mass will also move and change with the nanoparticles as shown in Figure A.6.b. 
The MSDcalculator macro therefore calculates the nanoparticles‟ centre of mass values as the 
x and y co-ordinates are copied from the raw data to the output file. The macro then calculates 
the nanoparticle x and y co-ordinates relative to the centre of mass rather than the origin. Each 
time this is done, the macro also plots the nanoparticle trajectory before and after centre of 
mass correction, for verification, Figure A.7. When the nanoparticle motion is subject to 
convection or drag forces the overall trajectory of the nanoparticle can be seen to move in one 
direction. As in Figure A.7.a, the overall motion on the nanoparticle from the bottom left to 
the top right can be seen. For Brownian motion, the nanoparticle‟s trajectory should be 
random, with the nanoparticle moving in all directions with equal probability. 
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Figure A.7: A diagram showing the effect of centre of mass correction on the trajectory of a) a nanoparticle which 
has been subject to drag effects. MSDcalculator algorithm removes the overall drag effect to leave the trajectory of 
b)  a randomly diffusing particles.  
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APPENDIX B: Code for MSDcalculator Macro 
 
Sub test1234() 
 
    Dim LookUpIndex As Long 
    Dim FromIndex As Long 
    Dim ToIndex As Long 
    Dim TrackId As Long 
    Dim LoopIndex As Double 
    Dim Xdrift As Double 
    Dim Ydrift As Double 
    Dim CoArrayx(2000) As Double 
    Dim CoArrayy(2000) As Double 
    Dim DataLength As Long 
    Dim ShortLength As Double 
    Dim link As Double 
    Dim FileName As Variant 
    Dim Out_FileName As Variant 
    Dim NumIDS As Long 
     
    x = MsgBox("Open the raw data file", vbApplicationModal, "Where is raw data?") 
     
    dlgAnswer = Application.Dialogs(xlDialogOpen).Show 
    FileName = ActiveWorkbook.Name 
     
    Set OutWork = Workbooks.Add 
    Do 
        fname = "MSD-COM-PD-2D-R-D160809-" + FileName 
    Loop Until fname <> False 
    OutWork.SaveAs FileName:=fname 
         
    Out_FileName = ActiveWorkbook.Name 
     
    Workbooks(FileName).Activate 
    Worksheets("Sheet1").Activate 
     
    Range("A1").Select 
    Cells.Find(What:="Track ID", After:=ActiveCell, LookIn:=xlValues, LookAt _ 
        :=xlPart, SearchOrder:=xlByColumns, SearchDirection:=xlNext, MatchCase:= _ 
        False, SearchFormat:=False).Select 
    Range(Selection, Selection.End(xlDown)).Select 
    NumIDS = Range(Selection, Selection.End(xlDown)).count 
     
    Columns("C:C").Select 
    Selection.NumberFormat = "0" 
    Cells(NumIDS + 2, 3).Select 
    Selection.ClearContents 
     
    Dim sheetNames(100) As Variant 
     
     
    LookUpIndex = 3 
     
    For LoopIndex = 0 To 2000 Step 1 
        CoArrayx(LoopIndex) = 0 
        CoArrayy(LoopIndex) = 0 
    Next 
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    ShortLength = 2000 
     
      
    While (Not Cells(LookUpIndex, 3).Value = 0) 
        Workbooks(FileName).Activate 
        Worksheets("Sheet1").Activate 
        TrackId = Cells(LookUpIndex, 2).Value 
        Worksheets("Sheet2").Activate 
        sheetNames(LookUpIndex - 3) = TrackId 
         
         
        FromIndex = 3 
        While (Not Cells(FromIndex, 1) = TrackId) 
            FromIndex = FromIndex + 1 
        Wend 
         
        ToIndex = FromIndex 
        While (Cells(ToIndex, 1) = TrackId) 
            ToIndex = ToIndex + 1 
        Wend 
         
        Range(Cells(FromIndex, 3), Cells(ToIndex - 1, 4)).Select 
        Selection.Copy 
        DataLength = (ToIndex - FromIndex) - 1 
         
        If (DataLength < ShortLength) Then 
            ShortLength = DataLength 
         
        End If 
         
        Workbooks(Out_FileName).Activate 
        Set NewSheet = Worksheets.Add 
        NewSheet.Name = TrackId 
        Cells(1, 1).Value = "Track ID" 
        Cells(1, 2).Value = "X Co-ord" 
        Cells(1, 3).Value = "Y-Co-ord" 
         
        Cells(1, 4).Value = "Start Index" 
        Cells(1, 6).Value = "End Index" 
        Cells(1, 8).Value = "No Obs" 
        Cells(1, 5).Value = FromIndex 
        Cells(1, 7).Value = ToIndex 
        Cells(1, 9).Value = DataLength 
        Cells(2, 1).Value = "NumIDS" 
        Cells(2, 2).Value = NumIDS 
         
         
        Range("B5").Select 
        ActiveSheet.Paste 
         
        For LoopIndex = 0 To DataLength - 1 Step 1 
            CoArrayx(LoopIndex) = CoArrayx(LoopIndex) + Cells(5 + LoopIndex, 2).Value 
            CoArrayy(LoopIndex) = CoArrayy(LoopIndex) + Cells(5 + LoopIndex, 3).Value 
        Next 
         
        Workbooks(FileName).Activate 
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        Range(Cells(FromIndex, 2), Cells(ToIndex - 1, 2)).Select 
        Selection.Copy 
        Workbooks(Out_FileName).Activate 
        Range("A5").Select 
        ActiveSheet.Paste 
         
        FromIndex = ToIndex 
        LookUpIndex = LookUpIndex + 1 
        Workbooks(FileName).Activate 
        Worksheets("Sheet1").Activate 
                
    Wend 
     
    For LoopIndex = 0 To ShortLength - 1 Step 1 
            CoArrayx(LoopIndex) = CoArrayx(LoopIndex) / (NumIDS - 1) 
            CoArrayy(LoopIndex) = CoArrayy(LoopIndex) / (NumIDS - 1) 
    Next 
     
    For LoopIndex = ShortLength To DataLength - 1 Step 1 
            CoArrayx(LoopIndex) = 0 
            CoArrayy(LoopIndex) = 0 
    Next 
     
     
     
    f = 1 
    Call paste_formulae(strN:=Out_FileName, driftx:=CoArrayx, drifty:=CoArrayy, Length:=ShortLength) 
     
End Sub 
 
Sub paste_formulae(strN As Variant, driftx() As Double, drifty() As Double, Length As Double) 
 
 
    Dim basefile As Variant 
    basefile = strN 
     
    Dim nObs As Long 
    Dim alpha As Double 
    Dim beta As Double 
    Dim count As Double 
    Dim Farray(2000) As Double 
    Dim Farray2(2000) As Double 
    Dim Farrayt1(2000) As Double 
    Dim Farrayt2(2000) As Double 
    Dim Farrayt3(2000) As Double 
    Dim Farrayt4(2000) As Double 
    Dim Farrayt7(2000) As Double 
    Dim Farrayt32(2000) As Double 
    Dim Farrayt57(2000) As Double 
    Dim Farrayt64(2000) As Double 
    Dim Farrayt114(2000) As Double 
    Dim Farrayt160(2000) As Double 
    Dim Farrayt286(3000) As Double 
    Dim Farrayt320(3000) As Double 
    Dim Farrayt480(3000) As Double 
    Dim Farrayt570(3000) As Double 
    Dim Farrayt857(3000) As Double 
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    Dim coord As Double 
    Dim top As Double 
    Dim topsq As Double 
    Dim bot As Double 
    Dim botsq As Double 
    Dim total As Double 
    Dim top2 As Double 
    Dim topsq2 As Double 
    Dim bot2 As Double 
    Dim botsq2 As Double 
    Dim total2 As Double 
    Dim d1 As Double 
    Dim d2 As Double 
     
    Dim driftxArray(2000) As Double 
    Dim driftyArray(2000) As Double 
    For alpha = 0 To Length Step 1 
    driftxArray(alpha) = driftx(alpha) 
    driftyArray(alpha) = drifty(alpha) 
 
    Next 
    
    Dim extra As Double 
    Dim trans1 As Double 
    Dim trans2 As Double 
    Dim transx As Double 
    Dim transy As Double 
         
    Windows(basefile).Activate 
    count = 1 
     
    For Each ws In Worksheets 
        If (Not ws.Name = "Sheet1") And (Not ws.Name = "Sheet2") And (Not ws.Name = "Sheet3") Then 
            For alpha = 0 To 2000 Step 1 
                Farray(alpha) = 0 
                Farray2(alpha) = 0 
                Farrayt160(alpha) = 0 
                Farrayt114(alpha) = 0 
                Farrayt64(alpha) = 0 
                Farrayt57(alpha) = 0 
                Farrayt32(alpha) = 0 
                Farrayt7(alpha) = 0 
                Farrayt4(alpha) = 0 
                Farrayt3(alpha) = 0 
                Farrayt2(alpha) = 0 
                Farrayt1(alpha) = 0 
            Next 
            For alpha = 0 To 3000 Step 1 
             
            Farrayt286(alpha) = 0 
            Farrayt320(alpha) = 0 
            Farrayt480(alpha) = 0 
            Farrayt570(alpha) = 0 
            Farrayt857(alpha) = 0 
            Next 
             
            ws.Activate 
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            nObs = Cells(1, 9).Value 
             
            Cells(1, 10).Value = "Length" 
            Cells(1, 11).Value = Length 
             
             
             For alpha = 0 To Length - 1 Step 1 
                Cells(5 + alpha, 7).Value = driftxArray(alpha) 
                transx = Cells(5 + alpha, 2).Value - driftxArray(alpha) 
                trans1 = transx * transx 
                Cells(5 + alpha, 11).Value = Sqr(trans1) 
                Cells(5 + alpha, 8).Value = driftyArray(alpha) 
                transy = Cells(5 + alpha, 3).Value - driftyArray(alpha) 
                trans2 = transy * transy 
                Cells(5 + alpha, 12).Value = Sqr(trans2) 
                Cells(5 + alpha, 2).Value = 0.154 * Cells(5 + alpha, 2).Value 
                Cells(5 + alpha, 3).Value = 0.154 * Cells(5 + alpha, 3).Value 
                Cells(5 + alpha, 11).Value = 0.154 * Cells(5 + alpha, 11).Value 
                Cells(5 + alpha, 12).Value = 0.154 * Cells(5 + alpha, 12).Value 
                 
            Next 
                   
            Charts.Add 
                ActiveChart.ChartType = xlXYScatterLinesNoMarkers 
                ActiveChart.SetSourceData Source:=Sheets(ws.Name).Range("B5:C400"), PlotBy:=xlColumns 
                ActiveChart.Location Where:=xlLocationAsNewSheet 
             
            With ActiveChart 
                .HasTitle = True 
                .ChartTitle.Characters.Text = "before" 
                .Axes(xlCategory, xlPrimary).HasTitle = False 
                .Axes(xlValue, xlPrimary).HasTitle = False 
            End With 
            With ActiveChart.Axes(xlCategory) 
                .HasMajorGridlines = False 
                .HasMinorGridlines = False 
            End With 
            With ActiveChart.Axes(xlValue) 
                .HasMajorGridlines = False 
                .HasMinorGridlines = False 
            End With 
            ActiveChart.HasLegend = False 
                   
             
                   
            Charts.Add 
                ActiveChart.ChartType = xlXYScatterLinesNoMarkers 
                ActiveChart.SetSourceData Source:=Sheets(ws.Name).Range("K5:L400"), PlotBy:=xlColumns 
                ActiveChart.Location Where:=xlLocationAsNewSheet 
             
            With ActiveChart 
                .HasTitle = True 
                .ChartTitle.Characters.Text = ws.Name 
                .Axes(xlCategory, xlPrimary).HasTitle = False 
                .Axes(xlValue, xlPrimary).HasTitle = False 
            End With 
            With ActiveChart.Axes(xlCategory) 
                .HasMajorGridlines = False 
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                .HasMinorGridlines = False 
            End With 
            With ActiveChart.Axes(xlValue) 
                .HasMajorGridlines = False 
                .HasMinorGridlines = False 
            End With 
            ActiveChart.HasLegend = False 
                                          
            ws.Activate 
            nObs = Cells(1, 9).Value 
            For alpha = 0 To Length - 1 Step 1 
                For beta = 1 To Length - 1 - alpha Step 1 
                    coord = beta + alpha 
                    top = Cells(5 + coord, 11).Value - Cells(5 + alpha, 11).Value 
                    topsq = top * top 
                    bot = Cells(5 + coord, 12).Value - Cells(5 + alpha, 12).Value 
                    botsq = bot * bot 
                    total = topsq + botsq 
                     
                     
                    Farray(beta) = Farray(beta) + total 
                     
                    top2 = Cells(5 + coord, 2).Value - Cells(5 + alpha, 2).Value 
                    topsq2 = top2 * top2 
                    bot2 = Cells(5 + coord, 3).Value - Cells(5 + alpha, 3).Value 
                    botsq2 = bot2 * bot2 
                    total2 = topsq2 + botsq2 
                     
                     
                    Farray2(beta) = Farray2(beta) + total2 
                     
                     
                Next 
            Next 
             
            For alpha = 0 To Length - 2 Step 1 
                    top = Cells(6 + alpha, 2).Value - driftx(1 + alpha) 
                    topsq = top * top 
                    top2 = Cells(6 + alpha, 3).Value - drifty(1 + alpha) 
                    topsq2 = top2 * top2 
                    d2 = Sqr(topsq + topsq2) 
                    bot = Cells(5 + alpha, 2).Value - driftx(alpha) 
                    botsq = bot * bot 
                    bot2 = Cells(5 + alpha, 3).Value - drifty(alpha) 
                    botsq2 = bot2 * bot2 
                    d1 = Sqr(botsq + botsq2) 
                    Farrayt1(alpha) = d2 - d1 
            Next 
                         
            For alpha = 1 To Length - 2 Step 1 
                    top = Cells(6 + alpha, 2).Value - driftx(1 + alpha) 
                    topsq = top * top 
                    top2 = Cells(6 + alpha, 3).Value - drifty(1 + alpha) 
                    topsq2 = top2 * top2 
                    d2 = Sqr(topsq + topsq2) 
                    bot = Cells(4 + alpha, 2).Value - driftx(alpha - 1) 
                    botsq = bot * bot 
                    bot2 = Cells(4 + alpha, 3).Value - drifty(alpha - 1) 
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                    botsq2 = bot2 * bot2 
                    d1 = Sqr(botsq + botsq2) 
                    Farrayt2(alpha - 1) = d2 - d1 
             
            Next 
             
            For alpha = 2 To Length - 2 Step 1 
                    top = Cells(6 + alpha, 2).Value - driftx(1 + alpha) 
                    topsq = top * top 
                    top2 = Cells(6 + alpha, 3).Value - drifty(1 + alpha) 
                    topsq2 = top2 * top2 
                    d2 = Sqr(topsq + topsq2) 
                    bot = Cells(3 + alpha, 2).Value - driftx(alpha - 2) 
                    botsq = bot * bot 
                    bot2 = Cells(3 + alpha, 3).Value - drifty(alpha - 2) 
                    botsq2 = bot2 * bot2 
                    d1 = Sqr(botsq + botsq2) 
                    Farrayt3(alpha - 2) = d2 - d1 
                             
            Next 
             
            For alpha = 3 To Length - 2 Step 1 
                    top = Cells(6 + alpha, 2).Value - driftx(1 + alpha) 
                    topsq = top * top 
                    top2 = Cells(6 + alpha, 3).Value - drifty(1 + alpha) 
                    topsq2 = top2 * top2 
                    d2 = Sqr(topsq + topsq2) 
                    bot = Cells(2 + alpha, 2).Value - driftx(alpha - 3) 
                    botsq = bot * bot 
                    bot2 = Cells(2 + alpha, 3).Value - drifty(alpha - 3) 
                    botsq2 = bot2 * bot2 
                    d1 = Sqr(botsq + botsq2) 
                    Farrayt4(alpha - 3) = d2 - d1 
                      
            Next 
             
            For alpha = 6 To Length - 2 Step 1 
                    top = Cells(6 + alpha, 2).Value - driftx(1 + alpha) 
                    topsq = top * top 
                    top2 = Cells(6 + alpha, 3).Value - drifty(1 + alpha) 
                    topsq2 = top2 * top2 
                    d2 = Sqr(topsq + topsq2) 
                    bot = Cells(alpha - 1, 2).Value - driftx(alpha - 6) 
                    botsq = bot * bot 
                    bot2 = Cells(alpha - 1, 3).Value - drifty(alpha - 6) 
                    botsq2 = bot2 * bot2 
                    d1 = Sqr(botsq + botsq2) 
                    Farrayt7(alpha - 6) = d2 - d1 
             
            Next 
           
            For alpha = 31 To Length - 2 Step 1 
                    top = Cells(6 + alpha, 2).Value - driftx(1 + alpha) 
                    topsq = top * top 
                    top2 = Cells(6 + alpha, 3).Value - drifty(1 + alpha) 
                    topsq2 = top2 * top2 
                    d2 = Sqr(topsq + topsq2) 
                    bot = Cells(alpha - 26, 2).Value - driftx(alpha - 31) 
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                    botsq = bot * bot 
                    bot2 = Cells(alpha - 26, 3).Value - drifty(alpha - 31) 
                    botsq2 = bot2 * bot2 
                    d1 = Sqr(botsq + botsq2) 
                    Farrayt32(alpha - 31) = d2 - d1 
             
            Next 
             
            For alpha = 56 To Length - 2 Step 1 
                    top = Cells(6 + alpha, 2).Value - driftx(1 + alpha) 
                    topsq = top * top 
                    top2 = Cells(6 + alpha, 3).Value - drifty(1 + alpha) 
                    topsq2 = top2 * top2 
                    d2 = Sqr(topsq + topsq2) 
                    bot = Cells(alpha - 51, 2).Value - driftx(alpha - 56) 
                    botsq = bot * bot 
                    bot2 = Cells(alpha - 51, 3).Value - drifty(alpha - 56) 
                    botsq2 = bot2 * bot2 
                    d1 = Sqr(botsq + botsq2) 
                    Farrayt57(alpha - 56) = d2 - d1 
             
            Next 
            For alpha = 63 To Length - 2 Step 1 
                    top = Cells(6 + alpha, 2).Value - driftx(1 + alpha) 
                    topsq = top * top 
                    top2 = Cells(6 + alpha, 3).Value - drifty(1 + alpha) 
                    topsq2 = top2 * top2 
                    d2 = Sqr(topsq + topsq2) 
                    bot = Cells(alpha - 58, 2).Value - driftx(alpha - 63) 
                    botsq = bot * bot 
                    bot2 = Cells(alpha - 58, 3).Value - drifty(alpha - 63) 
                    botsq2 = bot2 * bot2 
                    d1 = Sqr(botsq + botsq2) 
                    Farrayt64(alpha - 63) = d2 - d1 
             
            Next 
            For alpha = 113 To Length - 2 Step 1 
                    top = Cells(6 + alpha, 2).Value - driftx(1 + alpha) 
                    topsq = top * top 
                    top2 = Cells(6 + alpha, 3).Value - drifty(1 + alpha) 
                    topsq2 = top2 * top2 
                    d2 = Sqr(topsq + topsq2) 
                    bot = Cells(alpha - 108, 2).Value - driftx(alpha - 113) 
                    botsq = bot * bot 
                    bot2 = Cells(alpha - 108, 3).Value - drifty(alpha - 113) 
                    botsq2 = bot2 * bot2 
                    d1 = Sqr(botsq + botsq2) 
                    Farrayt114(alpha - 113) = d2 - d1 
             
            Next 
            For alpha = 159 To Length - 2 Step 1 
                    top = Cells(6 + alpha, 2).Value - driftx(1 + alpha) 
                    topsq = top * top 
                    top2 = Cells(6 + alpha, 3).Value - drifty(1 + alpha) 
                    topsq2 = top2 * top2 
                    d2 = Sqr(topsq + topsq2) 
                    bot = Cells(alpha - 154, 2).Value - driftx(alpha - 159) 
                    botsq = bot * bot 
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                    bot2 = Cells(alpha - 154, 3).Value - drifty(alpha - 159) 
                    botsq2 = bot2 * bot2 
                    d1 = Sqr(botsq + botsq2) 
                    Farrayt160(alpha - 159) = d2 - d1 
             
            Next 
             
            If Length > 320 Then 
            For alpha = 285 To Length - 2 Step 1 
                    top = Cells(6 + alpha, 2).Value - driftx(1 + alpha) 
                    topsq = top * top 
                    top2 = Cells(6 + alpha, 3).Value - drifty(1 + alpha) 
                    topsq2 = top2 * top2 
                    d2 = Sqr(topsq + topsq2) 
                    bot = Cells(alpha - 280, 2).Value - driftx(alpha - 285) 
                    botsq = bot * bot 
                    bot2 = Cells(alpha - 280, 3).Value - drifty(alpha - 285) 
                    botsq2 = bot2 * bot2 
                    d1 = Sqr(botsq + botsq2) 
                    Farrayt286(alpha - 285) = d2 - d1 
             
            Next 
            End If 
             
            If Length > 400 Then 
            For alpha = 319 To Length - 2 Step 1 
                    top = Cells(6 + alpha, 2).Value - driftx(1 + alpha) 
                    topsq = top * top 
                    top2 = Cells(6 + alpha, 3).Value - drifty(1 + alpha) 
                    topsq2 = top2 * top2 
                    d2 = Sqr(topsq + topsq2) 
                    bot = Cells(alpha - 314, 2).Value - driftx(alpha - 319) 
                    botsq = bot * bot 
                    bot2 = Cells(alpha - 314, 3).Value - drifty(alpha - 319) 
                    botsq2 = bot2 * bot2 
                    d1 = Sqr(botsq + botsq2) 
                    Farrayt320(alpha - 319) = d2 - d1 
                 
            Next 
            End If 
             
            If Length > 500 Then 
            For alpha = 479 To Length - 2 Step 1 
                    top = Cells(6 + alpha, 2).Value - driftx(1 + alpha) 
                    topsq = top * top 
                    top2 = Cells(6 + alpha, 3).Value - drifty(1 + alpha) 
                    topsq2 = top2 * top2 
                    d2 = Sqr(topsq + topsq2) 
                    bot = Cells(alpha - 474, 2).Value - driftx(alpha - 479) 
                    botsq = bot * bot 
                    bot2 = Cells(alpha - 474, 3).Value - drifty(alpha - 479) 
                    botsq2 = bot2 * bot2 
                    d1 = Sqr(botsq + botsq2) 
                    Farrayt480(alpha - 479) = d2 - d1 
             
            Next 
            End If 
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            If Length > 600 Then 
            For alpha = 569 To Length - 2 Step 1 
                    top = Cells(6 + alpha, 2).Value - driftx(1 + alpha) 
                    topsq = top * top 
                    top2 = Cells(6 + alpha, 3).Value - drifty(1 + alpha) 
                    topsq2 = top2 * top2 
                    d2 = Sqr(topsq + topsq2) 
                    bot = Cells(alpha - 564, 2).Value - driftx(alpha - 569) 
                    botsq = bot * bot 
                    bot2 = Cells(alpha - 564, 3).Value - drifty(alpha - 569) 
                    botsq2 = bot2 * bot2 
                    d1 = Sqr(botsq + botsq2) 
                    Farrayt570(alpha - 569) = d2 - d1 
             
            Next 
            End If 
             
            If Length > 900 Then 
            For alpha = 856 To Length - 2 Step 1 
                    top = Cells(6 + alpha, 2).Value - driftx(1 + alpha) 
                    topsq = top * top 
                    top2 = Cells(6 + alpha, 3).Value - drifty(1 + alpha) 
                    topsq2 = top2 * top2 
                    d2 = Sqr(topsq + topsq2) 
                    bot = Cells(alpha - 851, 2).Value - driftx(alpha - 856) 
                    botsq = bot * bot 
                    bot2 = Cells(alpha - 851, 3).Value - drifty(alpha - 856) 
                    botsq2 = bot2 * bot2 
                    d1 = Sqr(botsq + botsq2) 
                    Farrayt857(alpha - 856) = d2 - d1 
             
            Next 
            End If 
          
            ws.Activate 
 
            For alpha = 1 To Length - 1 Step 1 
                Cells(5 + alpha, 4).Value = Farray2(alpha) / (Length - alpha) 
                Cells(5 + alpha, 13).Value = Farray(alpha) / (Length - alpha) 
                 
            Next 
             
            Worksheets("Sheet1").Activate 
            Range("A1").Select 
            Cells(1, 1) = "COM calculated" 
            For alpha = 1 To Length - 1 Step 1 
                Cells(3, count) = "Averages" 
                Cells(5 + alpha, count).Value = Farray(alpha) / (Length - alpha) 
                 
            Next 
             
            Worksheets("Sheet2").Activate 
            Range("A1").Select 
            For alpha = 1 To Length - 1 Step 1 
                Cells(3, count) = "Averages" 
                Cells(5 + alpha, count).Value = Farray2(alpha) / (Length - alpha) 
                 
            Next 
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            Worksheets("Sheet3").Activate 
            Range("A1").Select 
            Cells(1, 1) = "2D displacements" 
            For alpha = 0 To Length - 2 Step 1 
                Cells(3, count) = ws.Name 
                Cells(5 + alpha, count).Value = Farrayt1(alpha) 
                Cells(2005 + alpha, count).Value = Farrayt2(alpha) 
                Cells(4005 + alpha, count).Value = Farrayt3(alpha) 
                Cells(6005 + alpha, count).Value = Farrayt4(alpha) 
                Cells(8005 + alpha, count).Value = Farrayt7(alpha) 
                Cells(10005 + alpha, count).Value = Farrayt32(alpha) 
                Cells(12005 + alpha, count).Value = Farrayt57(alpha) 
                Cells(14005 + alpha, count).Value = Farrayt64(alpha) 
                Cells(16005 + alpha, count).Value = Farrayt114(alpha) 
                Cells(18005 + alpha, count).Value = Farrayt160(alpha) 
                Cells(20005 + alpha, count).Value = Farrayt286(alpha) 
                Cells(22005 + alpha, count).Value = Farrayt320(alpha) 
                Cells(24005 + alpha, count).Value = Farrayt480(alpha) 
                Cells(26005 + alpha, count).Value = Farrayt570(alpha) 
                Cells(28005 + alpha, count).Value = Farrayt857(alpha) 
                 
            Next 
             
            count = count + 1 
         
        End If 
         
        Next 
    End 
      
    Exit Sub 
   
End Sub 
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APPENDIX C: Excitation and Emission Spectra for Polystyrene Nanoparticles Used 
 
These excitation and emission spectra are as supplied by Invitrogen for the carboxylate-modified, 
polystyrene nanoparticles purchased from them 
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